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Pregnane X Receptor (PXR, NR1I2) is a member of the nuclear receptor (NR) 
superfamily of ligand-activated transcription factors.  Expression levels of PXR are highest in the 
liver and intestine.  The activation of PXR can be achieved by exposure to a myriad of 
xenobiotic compounds and prescription drugs to regulate the expression of genes that encode key 
enzymes and membrane transporter proteins.  Collectively, these PXR-target genes encode gene 
products that function in a coordinate manner and comprise a vital xenobiotic detoxification 
pathway in these tissues. In this way, PXR activation by these compounds functions as a ‘xeno-
sensor’ of foreign substances in our body to positively regulate the transcription of genes such as 
cytochrome P450 (CYP) 3A4, and the drug efflux transporter multiple drug resistant protein 1 
(MDR1/P-gp), as well as other drug metabolizing enzymes and drug transporter proteins.  
Xenobiotic-mediated activation of PXR in humans also represents the molecular mechanism of 
CYP3A4-triggered adverse drug-drug interactions in which the induction of the expression of 
this broadly selective drug-metabolizing enzyme increases the metabolism of many other co-
administered substrates.  Activation of PXR also appears to be involved at some level in the 
MDR1-mediated acquired resistance to chemotherapeutic agents in multiple cancer types. 
Beyond the canonical physiology of ligand-mediated PXR activation in the regulation of 
drug metabolism, accumulating evidence clearly indicates that PXR exerts a trans-repressive 
activity towards the inflammatory response in both the liver and intestine in humans.  A broad 
spectrum of evidence suggests the involvement of post-translational modifications (PTMs) in the 
regulation of the trans-repressive transcriptional effects of many liver-enriched NR proteins.  
Previous studies in our laboratory have revealed that PXR is the molecular target of several 




modification (SUMOylation).  Moreover, our research shows that PTMs that target PXR likely 
regulate its biological activity through sophisticated system of networking or ‘crosstalk’.  
Crosstalk in this sense is defined as how various PTMs interact with each other on a given 
protein target to produce a specific biological outcome.  The current study is focused on the 
mechanism of crosstalk between the PTMs and their effect upon the regulation of PXR-mediated 
trans-repression phenomenon. 
 In the first chapter of this dissertation I provide an introduction to the topic of NR 
signaling in general, followed by an explanation of canonical PXR signaling in detail.  In 
Chapter 2, the role of crosstalk between the SUMOylation and ubiquitination pathways is 
examined and its effect upon the regulation of PXR biology in primary hepatocytes is discussed.  
Tumor necrosis factor-alpha (TNFα)-triggered SUMO(1)ylation of PXR is well-known to inhibit 
the expression of inflammatory genes in liver and intestine.  I show in this dissertation that 
treatment with the PXR activators, such as Rifampicin (Rif), promotes the SUMO3-modification 
of PXR.  Further, I show that the SUMO(3)ylation of PXR subsequently increases the 
ubiquitination of PXR, likely to promote proteasomal degradation of this important transcription 
factor.  In Chapter 3, the crosstalk between SUMOylation and acetylation was investigated.  I 
found that pharmacological inhibition of histone deacetylase 3 (HDAC3) activity in cell line-
based assays significantly promotes the SUMOylation of PXR, which subsequently impairs the 
ability of PXR to interact with its canonical corepressor multi-protein complex HDAC3/SMRT 
(silencing mediator for retinoid or thyroid–hormone receptor).  Taken together, the results 
presented in this dissertation provide novel insight into the likely molecular mechanisms that 
regulate the clinically observed PXR-mediated trans-repression phenomenon.  Specifically, my 




which PXR acetylation marks PXR as competent for its subsequent SUMOylation, given the 
correct physiological extracellular condition, namely inflammation.  In Chapter 4, the molecular 
details of the role of phosphorylation in the regulation of PXR-initiated transcription, and its 
effect upon the interaction with PXR accessory proteins were examined.  Utilizing a liquid 
chromatography tandem mass spectrometry (LC-MS/MS)-based proteomic approach, two 
phosphorylation sites (T135 and S221) in PXR were identified in primary mouse hepatocytes.  
Phosphorylation at identified sites inhibits the trans-activation capacity of PXR through 
interrupting PXR-RXRα hetero-dimerization and PXR association with coactivator proteins.  In 
conclusion, PTMs modulate different aspects of PXR biological activity in the liver and is 
especially essential for PXR-originated trans-repression of the inflammatory response in liver 
and intestine.  Collectively, the data presented in this dissertation sheds new light upon the 
molecular mechanisms governing PXR-mediated suppression of inflammation, and could be 
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Chapter 1: Introduction 
 
1.1 NUCLEAR RECEPTORS 
1.1.1 General Remarks 
 Three decades ago, the successful cloning of receptors for glucocorticoid, estrogen, and 
thyroid led to rapid recognition of the nuclear receptor (NR) superfamily that composed of 48 
members in the human genome(1-3).  Historically, the discovery of the action of NRs in the field 
of endocrinology was initially uncovered during studies of metabolism, development, and 
reproduction(4).  All NR family members share an evolutionary conserved structural template 
and possess similar functional features.  The principle function of NR is sensing hormones to 
exert direct regulation of tissue-specific gene expression.  The hormone that binds to the NR and 
activates NR-specific transcriptional event is commonly called ligand.  Typical ligands include 
steroidal molecules (progesterones, estrogens, androgens, glucocorticoids, and 
mineralocorticoids), vitamin D3, thyroid hormone, retinoids, as well as other newly discovered 
hormones, including bile acids, dietary lipids, and xenobiotic compounds. 
 According to their cognate ligands, NRs can be classified in three groups.  The first class 
(Class I) of NRs were identified and named after their tissue-specific ligands, the traditional 
hormones.  Glucocorticoid receptor (GR), mineralocorticoid receptor (MR), progesterone 
receptor (PR), androgen receptor (AR), estrogen receptors (ERs), retinoic acid receptors (RARs), 
thyroid receptors (TRs), and vitamin D receptor (VDR) all fall into the Class I NRs.  After the 
identification of Class I NRs, a group of evolutionarily related proteins were discovered while 
their high-affinity endogenous ligands were unknown.  These related proteins have thus acquired 




xenobiotic compounds, were then discovered to bind to specific orphan NRs with high affinity. 
These ‘adopted’ orphan NRs include retinoic x receptors (RXRs), peroxisome proliferator-
activated receptors (PPARs), farnesoid x receptor (FXR), liver x receptor (LXR), pregnane x 
receptor (PXR), and constitutive androstane receptor (CAR).  While ‘adopted’ orphan NRs are 
termed Class II NRs, the rest of the orphan NRs sort into the third class of NRs. 
 The NR initiated transcription activation and repression require two prerequisite actions, 
DNA binding and recruitment of coregulator proteins.  As transcription factors, NRs depend on 
sequence-specific DNA binding to initiate the trans-activation of target genes.  In response to 
ligand stimulation, Class I NRs bind to response elements as homodimers, whereas Class II NRs 
bind to DNA as half of a heterodimer with their preferred counterpart RXR(5-11).  Besides DNA 
binding, NR-mediated transcription activities require coordinate interactions with a group of 
coregulator proteins, which are responsible for converting the NR from a silent state to an active 
state.  Despite the fact that NRs share high-levels of homology among members, they exert 
varies modes of actions towards the regulation of transcription.  For instance, NRs can either 
directly bind to DNA or through interaction with other types of transcription factors to regulate 
gene activation in a ligand-dependent manner.  Additionally, several NRs suppress gene 
expression in response to ligand activation by binding to negative response elements or by 
antagonizing the transcription activity of other transcription factors(12-14). 
1.1.2 Structure of Nuclear Receptors 
 The NR superfamily members share a conserved overall structure, which consists of five 
homologous domains (Figure 1-1).  From N-terminus to C-terminus, the functional domains 
include an N-terminal activation function domain 1 (AF-1), a zinc-finger-type DNA binding 




(LBD), and a C-terminal activation function domain 2 (AF-2).  The AF-1 domain is a ligand-
independent function domain that can be modified by phosphorylation and other types of post-
translational modifications (PTMs).  The DBD of NRs is the most conserved domain, and its 
core function is to recognize and bind specific sequence in the DNA.  Specifically, the two zinc 
fingers buried in DBD intercalate into the major groove of DNA in a sequence-specific manner.  
The flexible hinge domain forms as a bridge to connect DBD and the multifunctional LBD.  The 
hinge region is considered essential for the ligand-mediated conformational change of NRs.  
Also, growing evidence demonstrated that the hinge region contains motifs important for the 
subcellular localization of NRs(15-19).  LBD of NRs contains the ligand-binding pocket, the 
homo- and heterodimerization interfaces, and a co-regulator binding region.  The primary role of 
LBD is to act as a molecular switch by deciphering the ligand structure into conformational 
changes, which transforms the NR into a transcription activator or repressor(20).  The AF-2 
domain is buried in the LBD at the C-terminal region, serves as a scaffold for ligand-dependent 
recruitment of coactivator proteins(21).  The structure and function of AF-2 domain remains 
mysterious due to its high variability.  Mutagenesis and functional studies suggest the activity of 









1.1.3 Nuclear Receptors Dimerization 
 The first and most critical step in the NR-mediated transcription regulation is the 
dimerization.  In response to ligand activation, the Class I steroid NRs (GR, PR, AR, and ER) 
form homodimers to bind to response elements constituted as palindromes composed of two 
hexad nucleotide sequences separated by three base pairs(5).  However, non-steroid NRs (RAR, 
VDR, and TR) tend to bind to response elements configured as tandem repeats of two hexad 
half-sites sequences(22-24).  Another type of dimerization that is strikingly distinct from the 
homodimerization of Class I NRs is the heterodimerization of class II non-steroid NR with a 
common partner RXR(6-11).  The paradigm of RXR heterodimerization is a universal feature in 
most of the orphan NRs that include PPARs, LXRs, FXR, PXR, and CAR.  Three highly 
conserved and functionally identical isoforms of RXR have been discovered, RXRα, RXRβ, and 
RXRγ, and at least one of them is expressed in every tissue type(17).  Thus, the joint 
heterodimerization with RXR offers a simple but elegant mechanism to the evolution of target 
gene specificity.   
1.1.4 The Nuclear Receptor Coregulator Proteins 
 It is currently well known that accessory coregulator proteins are recruited to NR family 
members to both suppress and enhance gene activation.  In general, NR coregulator proteins 
include two small gene families of coactivator and corepressor proteins termed nuclear receptor 
coactivator proteins (NCoA) and NR corepressor proteins (NCoR), respectively. Based on their 
literal meaning, NCoA proteins are the accessory proteins in the nucleus that interact with 
ligand-activated NRs to help produce target gene activation, whereas NCoR proteins are 
accessory factors that interact with non-liganded or antagonist-suppressed NRs to lower the level 




together with NCoR in the absence of ligand or signal; and this multi-protein complex obscures 
interaction with basal transcription machinery, thereby lowering target gene expression(26).  In 
order to suppress gene expression, the NR-NCoR complex requires the involvement of histone 
deacetylase (HDAC) enzymes(27). Therefore, the NR-NCoR complex maintains the repressive 
state of NR mediated transcription(28).  Once the NRs are stimulated by ligand or kinase-
mediated signaling pathways, NCoR proteins will detach following a conformational shift to 
allow NCoA proteins to interact with the liganded receptor to initiate gene activation.  Histone 
acetyltransferase (HAT) enzyme activity appears to be required for liganded NR-mediated gene 
activation(29).  In addition to interaction with NR superfamily members, it is now well 
recognized that NCoRs and NCoAs comprise two small families of structurally conserved 
proteins that are capable of interacting with other signal-dependent transcription factors 
including myocyte enhancer factor-2 (Mef2), c-Jun, c-Fos, cAMP response element-binding 
protein (CREB), and others(25,30,31).  Additional studies revealed that HAT and HDAC 
enzyme activity is associated with coregulator proteins to mediate their functional activity(32-
34).  Histone modifications are therefore intimately involved in gene regulation by NRs and 
other signal-dependent transcription factors(35). 
1.1.4.1 NR Coactivator Proteins 
 Most NR coactivator proteins interact with NRs in a ligand-dependent manner, and this 
interaction directly leads to NR-target gene activation.  The NCoAs typically contain one or 
more “NR box” motifs, LXXLL or FXXLL (where X stands for any amino acid), which forms 
an amphipathic helix that supports interaction with the receptor(36-40).  NCoAs are expressed at 
extremely low levels in most cell types, thus gene activation by one liganded NR effectively 




activation of the second NR than would otherwise be achieved.  This phenomenon is termed the 
“squelching effect”.  In addition, the NCoA proteins not only regulate gene expression, but also 
play key roles in driving alternative mRNA splicing, altered NR subcellular localization, altered 
NR protein stability, and various NR protein post-translational modifications. 
 To date, hundreds of NCoAs have been discovered.  However, the main group is steroid 
receptor coactivator proteins (SRC family), which include SRC1, SRC2, and SRC3, as well as 
their various splice variants.  The SRC family is a group of essential proteins for liganded NRs to 
fulfill their in vivo functions(39).  All three of the SRC family members possess intrinsic HAT 
activity.  Each of the SRC family members exhibit a strong preference for differing NR-binding 
partners.  SRC1 interacts strongly with PR, ER, GR, TR, RXR(41), hepatocyte nuclear factor 4 
(HNF-4)(42), and PPAR(43).  In addition, they can also interact with some other types of 
transcription factors including activator protein 1 (AP-1)(44), serum response factor (SRF)(45), 
nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB)(46), and p53(47).  The 
SRC-2 coactivator protein, alternatively referred to as glucocorticoid receptor-interacting protein 
1 (GRIP1), transcriptional intermediary factor 2 (TIF2), and NCoA-2 in the literature, exhibits 
strong ligand-dependent interaction with RARα, ERs and PXR to stimulate target gene 
activation.  The SRC-3 coactivator protein was the last to be discovered and has a large number 
of splice variants.  The SRC-3 coactivator proteins can broadly activate the largest number of 
liganded NRs including RARα, RXR, TR, GR(48), PR(49) and ER(50).  In addition, SRC-3 
activates other types of signal-dependent transcription factors including the CREB(39) to 
enhance transcription of its target genes. 
 Besides SRC family coactivator proteins for liganded-NR, there are a myriad of other 




CREB-binding protein (CBP) can interact directly with SRC family members to enhance histone 
acetylation by liganded NRs(29).  Moreover, the p300/CBP-associated factor (p/CAF) interacts 
with SRC family members to enhance their transcription efficiency in a similar manner(29,51).  
TR associated proteins/vitamin D receptor-interacting proteins (TRAP/DRIP complex) interact 
with TR/vitamin D receptor (VDR) and many NRs to induce trans-activation on target genes in a 
ligand-dependent fashion(52).  The PPAR binding protein (PBP) that functions as a transcription 
mediator protein, is able to interact with thyroid, retinoid, vitamin D3 receptors and other select 
NRs including PXR in a ligand-dependent manner(53,54). 
1.1.4.2 NR Corepressor Proteins 
 In general, NCoRs interact with non-liganded NRs to maintain the silent state of NR-
target gene activation.  The two family members are termed NCoR1 and silencing mediator for 
retinoic and thyroid hormone receptor (SMRT).  Both NCoR1 and SMRT are unable to interact 
with steroid hormone receptor NR superfamily members in the presence of cognate ligands(55-
58).  The NCoR family members impart a scaffold function to recruit HDAC enzyme activity to 
select NRs in the absence of ligand(59,60).  Specifically, they promote histone deacetylation 
through recruitment of the HDAC3 enzyme to enhance chromatin compaction and subsequent 
target gene repression(61,62).  Similar to coactivator proteins, NCoR proteins also exhibit the 
“squelching effect” due to their relatively low overall cellular expression level.  
 NCoR1 is the first identified NR corepressor protein.  It specifically interacts with TRα, 
RARα, COUP-TF1 (Chicken Ovalbumin Upstream Promoter-Transcription Factor 1), RevErb 
(NR1D1 and NR1D2), and DAX-1 (Dosage-sensitive sex reversal, Adrenal hypoplasia critical 
region, on chromosome X, gene 1), but not RXR, VDR, ER or GR.  Since NCoR1 regulates non-




paramount.  High serum glucose levels and the resulting increase in insulin produce elevation on 
NCoR1 expression level.  In contrast, low glucose level and high fatty acid levels inhibit the 
expression of NCoR1(63).  Signal-dependent activation of NRs increases the PTMs of NCoR1 
and decreases their recruitment and exports corepressor proteins out of nucleus.  Such PTMs of 
NCoR1 include phosphorylation, ubiquitination and SUMOylation(59,60). 
 SMRT was originally identified by its ability to interact with RAR and TR, the two well-
known NRs that mediate strong non-liganded active suppression of target genes.  SMRT 
interacts with RAR and TR in a ligand-reversible manner.  However, SMRT interaction with 
RXR is not ligand-reversible(4,64,65).  The ligand activation of most NRs accelerates the 
dissociation of SMRT from both RAR and TR.  In contrast, reports show that the ability of 
SMRT to associate with RXR-PXR heterodimers is constitutive; in other words, it never leaves 
the heterodimer(65).  TRAC1 (T3 receptor-associating cofactor 1), which is a truncated SMRT 
splice variant, functions as a dominant negative suppressor of SMRT.  It is noteworthy that 
SMRT does not always impart a repressive function, as it can interact with negative thyroid 
response elements (nTREs) to induce trans-activation of select target genes(66).  Like NCoR1 
and SRC family members, SMRT also interacts with various signal-dependent transcription 
factors(67). 
 While NCoR and SMRT share a similar structure, their respective biological functions 
differ in several key aspects, and they each exhibit specific and strong NR-binding preferences.  
For instance, one orphan NR called DAX-1 can only interact with NCoR1, but is unable to 
interact with SMRT(68).  In a similar manner, PXR apparently exhibits a preference for SMRT 
on its prototypical target gene CYP3A(69).  Like the SRC family members, NCoR1 and SMRT 




factors such as NF-κB, AP-1, and SRF to mediate gene repression.  Moreover, gene knockout 
studies indicate that both NCoR1 and SMRT are involved in cell development, metabolic 
homeostasis, inflammation, and cancer(70-72). 
 
1.2 PREGNANE X RECEPTOR 
1.2.1 Overview of PXR 
 PXR (NR1I2) belongs to the Class II NR superfamily and particularly activated by a 
broad spectrum of xenobiotic substances, including drug metabolizing enzymes and transporters.  
PXR is predominantly expressed in the liver and intestines and is also expressed in other tissues 
include kidney, stomach, brain, bone, lung, uterus, heart, adrenal glands, bone marrow, skeletal 
muscle, and testis to a lesser extent.  As a direct regulator of drug metabolism and efflux, PXR is 
essential for the hepatic detoxification system that protects organisms against potential harmful 
xenobiotic and endobiotic chemicals(73-75).  On a structural perspective, PXR comprises a large 
and flexible binding cavity in the LBD allowing PXR to bind to a variety of structurally diverse 
ligands, which is distinct from other NRs.  Ligands for PXR range from endobiotics, such as 
steroid hormone metabolites, vitamins, and bile acids, to xenobiotic molecules, those include 
herbals, macrolide antibiotics, antifungals, and environmental pollutants(76,77).  It is worth 
noting that PXR exhibits various ligand activation profiles across species which is primarily due 
to its relatively low homology (50 - 75% identity) in LBDs(78), which is very different from the 
high level of homology in the DBDs (approximately 95%).  This sequence diversity accounts for 
the major pharmacological differences across species. 
 PXR-mediated transcription activation is initiated by binding to a regulatory DNA 




(XREM).  XREM is composed of two distal NR-interacting motifs (-7836 ~ -7617 on CYP3A4 
gene), DR-3 (direct repeat separated by 3 nucleotides) and ER-6 (everted repeat separated by 6 
nucleotides), respectively.  Both of these binding sites are indispensable for PXR to exert full 
regulation of transcription activity.  In addition, PXR can bind to a proximal response element 
(prPXRE)(79,80).  The sequence of prPXRE varies in different PXR target genes, which can be 
either DR-3 or ER-6.  Upon ligand activation, the PXR-RXRα heterodimer can bind to all three 
sites and thus capable of responding to divergent but overlapping groups of xenobiotic 
compounds. 
 It is well established that the coregulator protein exchange is critical for the activation 
and the termination of PXR activities.  Unliganded PXR rests in a silent state via association 
with NCoR (NCoR1, SMRT).  The NCoR functions as a scaffold protein for PXR to interact 
with histone deacetylase proteins (HDACs).  In response to ligand stimulation, PXR dissociates 
from preoccupied corepressor protein complex and simultaneously recruits coactivator proteins.  
SRC family members (SRC1, SRC2/GRIP1, SRC3) and the transcription mediator PBP interacts 
with liganded PXR and promotes the recruitment of transcription machinery at the promoter of 
target genes by decondensing the chromatin structure(81).  Through the regulation of coregulator 
protein exchange, physiological and pathophysiological signals define the outcome of PXR-
mediated transcription events.  Moreover, PTMs, such as phosphorylation, acetylation, and 
SUMOylation, are expected to contribute to the signal-dependent PXR-mediated transcription 
activities. 
1.2.2 PXR in the Regulation of Drug Metabolism 
 Emerging evidence suggests the association of PXR in many human diseases such as 




cancer types. The canonical mechanism of action of PXR is to directly regulate the expression of 
genes encoding the drug metabolizing enzymes (phase I, phase II, and phase III).  In humans, 
PXR directly activates the expression of cytochrome protein 450 (CYP) 3A4, CYP2B6 and 
UGT1A1 (UDP glucuronosyltransferase 1 family, polypeptide A1), which together are 
responsible for the metabolism of approximately 80% of FDA approved drugs.  Induction of 
these drug-metabolizing enzymes results in increased drug turnover, which leads to clinically 
important drug-drug interactions.  Of note, PXR-mediated adverse drug-drug interactions 
account for 10-17% of medical symptoms for hospital admissions for senior patients(82).  In 
particular, PXR activation can lead to antagonistic effect on co-administrated drugs, such as anti-
HIV protease inhibitors, oral contraceptive, thiazolidinediones, and benzodiazepines(83).  PXR-
activation induced drug-drug interactions can also lead to liver toxicity(84-87).  Constitutive 
activation of PXR affects cholesterol metabolism and thus becomes a driving force of hepatic 
steatosis(77,88,89).  Another aspect of PXR-caused clinical outcomes is drug resistance.  PXR 
directly regulates the gene expression of multiple drug resistance gene 1 (MDR1), which 
functioned as a drug efflux pump for xenobiotic compounds.  Overexpression of the MDR1-
encoding p-glycoprotein (P-gp) leads to drug resistance and tumor progression in many tissue 
types.  For instance, PXR activation promotes the growth of cancerous cells by inducing the 
expression of fibroblast growth factor 19, which results in subsequent colon cancer 
progression(90).  The exact outcome of PXR activation in different cancer types can be tissue-
specific.  Activation of PXR accelerates drug clearance together with increased 
chemotherapeutic drugs resistance in colon cancer and prostate cancer, whereas PXR activation 
inhibits the progression of breast cancer(86,90,91).  Taken together, PXR is a great therapeutic 




1.2.3 PXR in the Regulation of Inflammatory Response 
  Another significant aspect of PXR biology is its ability to regulate an inflammatory 
response in the liver and intestines.  The clinical relevance of this effect is that patients suffering 
from chronic inflammation in the liver and intestines exhibit impaired drug metabolizing 
capability, which leads to increased cytotoxicity in these organs.  Intensive studies on this topic 
indicate that a mutual trans-repression exhibited in drug metabolism and inflammation in the 
liver and intestines where PXR is the interface regulator.  NF-κB is a fundamental transcription 
factor that mainly regulates innate and adaptive immune responses.  The target genes of NF-κB 
consist of pro-inflammation cytokines and anti-inflammation cytokines.  A precise and balanced 
regulation of the cytokines with opposing purposes is the major function of NF-κB.  
Dysregulation of NF-κB often contributes to a variety of human disease states including 
inflammatory diseases, autoimmune and metabolic disorders(94-97).  Accumulating evidence 
indicates that activation of PXR exerted suppressive effects on NF-κB signaling and relieves the 
dextran sulfate sodium (DSS)-induced IBD symptoms in mice(98,99).  These discoveries suggest 
the therapeutic potential of targeting PXR in the treatment of IBD, which is the fifth most 
prevalent gastrointestinal disease in the United States(100).  Additionally, PXR activation has 
emerged as having a role in many inflammatory-related liver diseases that include cholestasis, 
hepatic steatosis, and non-alcoholic fatty liver disease.  PXR agonists exhibit therapeutic 
potential in the treatment of cholestasis regarding a detected association between PXR activation 
and hepatoprotective effect(101).  Moreover, PXR activation prevents the progression of liver 
fibrosis through suppression of the profibrogenic cytokine transforming growth factor β 
(TGFβ)(102).  In summary, activation of PXR ameliorates NF-κB signaling-mediated chronic 




1.2.4 Post-Translational Modifications of PXR 
 PTMs are well-known cellular events involved in the regulation of NRs.  PTM is a 
signal-dependent functional modification that affects NR-mediated transcription event through 
altering the biological activities of NR.  PTMs establish a pivotal mechanism for crosstalk 
between signaling pathways.  Recent efforts revealed a clear role of PTMs in modulating PXR-
mediated transcriptional events.  Known PTMs of PXR include phosphorylation, acetylation, 
SUMOylation, and ubiquitination. 
 Phosphorylation is one of the best-characterized PTM of PXR.  It is now well established 
that site-specific phosphorylation of PXR offers a sophisticated mechanism for PXR-initiated 
transcription events.  Phosphorylation of PXR impedes multiple aspects of PXR biological 
functions, which include subcellular localization, DNA-binding, and coregulator 
interactions(103-108).  The characterized kinases for PXR phosphorylation are protein kinase C 
(PKC)(103,106), protein kinase A (PKA)(104,106,107), cyclin-dependent kinase 1 
(CDK1)(107), CDK2(109-111), CDK5(112), casine kinase 2 (CK2)(107), p70 
S6K(106,108,113), and glycogen synthase kinase 3 (GSK3)(107).  In the context of PXR, direct 
phosphorylation often causes repression towards PXR-mediated transcription activity.  In 
particular, both the PKA and PKC signaling pathway can be activated by inflammation.  The 
initiation of PKA/PKC-mediated PXR phosphorylation results in inhibition of transcriptional 
activation of drug metabolizing enzymes.  Therefore, site-specific phosphorylation may be the 
essential mechanism for PXR-mediated trans-repression towards inflammatory responses. 
 An increasing body of evidence suggests that dynamic acetylation/deacetylation 
constitutes another PTM that regulates the biological functions of NRs in a context-specific 




suppressing FXR-mediated trans-activation(115,116).  According to recent findings, PXR is 
acetylated in vivo and rifampicin-mediated PXR activation stimulates its acetylation(117).  
Sirtuin 1 (SIRT1) is involved in the deacetylation of PXR independent of ligand activation.  
P300 catalyzes the acetylation of PXR at lysine 109 (K109) and subsequently hinders PXR 
transcriptional activity(118).  It is worth noting that a functional crosstalk between acetylation 
and SUMOylation at the level of FXR has been reported(119), which provided innovative 
insights for understanding the complicated and signal-specific PTM regulatory network with 
respect to NR biology. 
 The ubiquitin-proteasome system (UPS) is an essential protein degradation pathway that 
is vital for maintaining protein homeostasis in the organism.  This pathway is considered the 
disposal system that recycles the misfolded proteins and promotes amino acids turnover.  
Ubiquitination is a three-step enzymatic process that is catalyzed by E1 activating enzyme, E2 
conjugation enzyme, and E3 ligase.  Ubiquitination is a dynamic process that can be reversed by 
deubiquitinating enzymes (DUBs).  The physiological function of ubiquitination is to target its 
substrate proteins and to generate poly ubiquitin-chains for further degradation of target proteins.  
According to the specific form of poly ubiquitin chain, target protein will be directed to different 
degradation pathways.  In particular, lysine 48 (K48)-linked poly ubiquitin chain formation 
directs its target protein into the proteasomal degradation pathway, whereas K63-linked poly 
ubiquitin chain formation directs its target protein into the lysosomal degradation pathway.  
Recent studies from our lab have demonstrated that PXR is ubiquitinated in primary mouse 
hepatocytes.  Inhibition of the proteasome with a pharmacological agent MG132 increased 
ubiquitination of PXR(120).  Furthermore, ubiquitination targets multiple sites on PXR protein 




subsequent proteasomal degradation(121).  Therefore, ubiquitination of PXR is required for 
maintaining appropriate physiological functions of PXR in the liver. 
 SUMO is a member of the ubiquitin like protein family.  SUMOylation has very broad 
functional implications in terms of modulating the target protein’s biochemical function, 
subcellular localization, and stability.  To date, four isoforms of SUMO have been identified in 
mammals and are termed SUMO1, SUMO2, SUMO3, and SUMO4(122-125).  Because SUMO2 
and SUMO3 share 98% of amino acid sequence homology, they are frequently referred as 
SUMO2/3. The function of SUMO4 is still unclear, as it is likely a pseudogene and also due to 
the presence of a proline residue (Pro90) that renders it non-activatable(126).  It is also 
noteworthy that SUMO2/3 itself can be SUMOylated forming long chains that resemble those 
found during ubiquitination.  Much like the process of ubiquitination, the SUMOylation pathway 
is comprised of a cascade of enzymatic reactions that catalyze three separate reactions and are 
termed SUMO activating enzyme (E1), conjugating enzyme (E2), and SUMO ligase (E3).  The 
E1 enzyme is composed of a heterodimer of proteins called SAE1 (SUMO activating enzyme 1) 
and SAE2.  The second enzyme in the pathway is called Ubc9 (E2) (homologous to yeast UBC9) 
and is the only E2 that has been identified to this point.  In mammals, multiple SUMO E3 ligases 
facilitate SUMOylation in a substrate and sub-cellular compartment specific manner.  Three 
different groups of E3 ligase enzymes have been classified to date.  The family of protein 
inhibitor of activated STAT (PIAS), which consists of PIAS1, PIAS2, PIASxα, PIASxβ, and 
PIASy, is the largest group of SUMO E3 ligases. Ran binding protein 2 (RanBP2) and HDAC4 
are characterized as the other two types of E3 ligase enzymes(127-129).  While the E1, E2 and 
E3 enzymes control the SUMOylation cascade; dual function sentrin-specific proteases (SENPs) 




There are six SENP members in mammals (SENP1, 2, 3, 5, 6, 7), whereas two have been 
characterized in yeast (ubiquitin-like protein-specific protease 1 and 2, Ubl1 and Ubl2) to 
date(130).  Basically, SENP1 and SENP2 carry out both functions as endopeptidase and 
isopeptidase, whereas SENP3, 5, 6, and 7 can only function as isopeptidase by de-conjugating 
SUMO2/3 from their substrates, as well as functioning to selectively remove the SUMO2/3 
chains formation from target proteins (so-called chain editing function).  The SUMOylation 
pathway plays an important and required regulatory role in many cellular processes including 
mitosis, cell development, cell differentiation, senescence, and apoptosis(131-133).  A growing 
body of evidence has demonstrated that SUMOylation stimulates a plethora of cellular events 
that determine the biological fate of targeted NRs that include GR(134-138), LXR(139,140), 
FXR(119,141), HNF4(142), RXR(143-145), and PXR(146).  Of particular importance, 
SUMOylation has emerged as a fundamental mechanism that converts NRs from a transcription 
activator to a transcription repressor in a signal-specific fashion.  Our lab has previously reported 
that activation of inflammatory response increases the SUMOylation of PXR, and elevated PXR 
SUMOylation feedback suppresses the inflammatory response in hepatocytes(146).  This novel 
observation suggests a potential mechanism by which SUMOylation negatively regulates 
inflammatory response through altering the biological fate of PXR in the liver. 
 
1.3 DISSERTATION HYPOTHESIS 
 Despite the wealth of knowledge that has been collected on the canonical mechanism of 
PXR in regulating drug metabolism, the molecular details of PXR-mediated trans-repression of 
the inflammatory response remains unclear.  While it is now well accepted that post-translational 




transcription activation (trans-activation) and transcriptional repression (trans-repression), the 
precise and sophisticated regulation of PTMs in response to physiological or pathophysiological 
conditions is, in my view, key to understanding the precise molecular interactions that occur 
between the pathways mediating endocrine/drug homeostasis and the inflammatory signaling 
pathway.  In the specific case of PXR, accumulating evidence suggests that it is a promising 
therapeutic target for chronic inflammatory diseases in liver and intestinal tissues.  This study is 
focused on the molecular details that regulate the clinically observed mutual trans-repression that 
occurs between PXR-activated xenobiotic response and NF-κB-mediated inflammatory response 
in the liver.  We hypothesize that post-translational modifications including phosphorylation, 
acetylation, SUMOylation, and ubiquitination fine-tune the PXR-mediated trans-repression of 
the inflammatory response (Figure 1-2).  The role of each listed PTMs in regulating PXR 
biology was tested and is discussed in detail in the following chapters.  In particular, how the 
crosstalk between PTMs modulates PXR-mediated trans-activation capacity is the primary 







Figure 1-2. Working hypothesis.  PTMs, including phosphorylation, acetylation, 
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Chapter 2: SUMOylation and Ubiquitination Circuitry Controls Pregnane X 
Receptor Biology in Hepatocytes 
 
ABSTRACT 
 Several nuclear receptor (NR) superfamily members are known to be the molecular target 
of either the SUMO- or ubiquitin-signaling pathways.  However, little is currently known 
regarding how these two post-translational modifications interact to control NR biology.  We 
show that the SUMO and ubiquitin circuitry coordinately modifies Pregnane X Receptor (PXR, 
NR1I2) to play a key role in regulating PXR protein stability, trans-activation capacity, and 
transcriptional repression.  The SUMOylation and ubiquitination of PXR is increased in a ligand- 
and tumor necrosis factor-alpha (TNFα)-dependent manner in hepatocytes.  The SUMO-E3 
ligase enzymes PIAS1 and PIASy drive high levels of PXR SUMOylation.  Expression of PIAS1 
selectively increases SUMO(3)ylation, as well as PXR-mediated induction of CYP3A and the 
xenobiotic response.  The PIASy-mediated SUMO(1)ylation imparts a transcriptionally 
repressive function by ameliorating interaction of PXR with co-activator protein peroxisome 
proliferator-activated receptor gamma coactivator-1-alpha (PGC-1α).  The SUMO-modification 
of PXR is effectively antagonized by the sentrin/SUMO-specific protease 2 (SENP2), whereas 
SENP3 and SENP6 proteases are highly active in removal of SUMO2/3-chains.  The PIASy-
mediated SUMO(1)ylation of PXR inhibits ubiquitin-mediated degradation of this important 
liver-enriched NR by the 26S proteasome.  Our data reveal a working model that delineates the 
interactive role that these two post-translational modifications play in reconciling PXR-mediated 
gene activation of the xenobiotic response -versus- transcriptional repression of the pro-




and ubiquitination of PXR interface in a fundamental manner to direct its biological function in 
liver in response to xenobiotic or inflammatory stress. 
 
2.1 INTRODUCTION 
Ligand-dependent activation of Pregnane X Receptor (PXR, NR1I2) is associated with 
increased metabolism and clearance of a myriad of potentially toxic compounds from the body, 
and is thus thought of as a master-regulator of the protective xenobiotic response.  However, 
clinical treatment with PXR activators can also lead to the repression or attenuation of other 
biochemical pathways including the inflammatory response in liver and intestine (1).  It is now 
well-accepted that activation of PXR is associated with general suppression of the inflammatory 
response in these tissues (2-6).   
Post-translational modification with the small-ubiquitin related modifier (SUMO) plays a 
key role in determining the biological fate and function of a myriad of transcription factors, 
including several liver-enriched NR superfamily members to alter inflammatory signaling 
pathways (7).  There are a number of different SUMO-E3 ligase enzymes, and the best 
characterized family is the protein inhibitors of activated STAT (PIAS) family (8).  
SUMOylation is a reversible process through the action of a family sentrin proteases (SENPs) 
that function as isopeptidases to deconjugate SUMO from substrates (9).   
The SUMO- and ubiquitin-signaling pathways share a high degree of commonality (10).    
A recent thrust of research indicates that these two signaling pathways not only share structural 
similarity, but they also share a multitude of functional interrelations.  These interactions include 
two discreet and distinct modes.  The first mode of interaction is characterized by a stress-




second mode of interaction is characterized by a stress-induced formation of SUMOylation-
dependent ubiquitin chains on unique lysine residues in close proximity in a given target protein 
(11-13).  The first mode of competitive interaction between SUMO and ubiquitin occurs on 
lysine residues within the inhibitor of transcription factor NF-κB-alpha, also known as IκBα, as 
well as within the proliferating cell nuclear antigen protein, also called PCNA (14,15).  An 
example of the second mode of stress-induced SUMOylation-dependent ubiquitination is 
exemplified by arsenic inducing PML-RARα SUMOylation and its subsequent 
ubiquitination/K48-linked chain-mediated degradation by the proteasome (16).  Another example 
of a protein that undergoes SUMO-dependent ubiquitination is NF-κB essential modulator 
(NEMO), which is activated by consecutive modifications with SUMO and ubiquitin that 
initiates K48-linked degradation by the proteasome following genotoxic stress (17).  In each 
case, the interaction between these two post-translational modifications determines the biological 
function and molecular fate of the resulting modified protein. 
Our laboratory has previously demonstrated that PXR is SUMOylated to suppress the 
expression of tumor necrosis factor alpha (TNFα)-inducible interleukin 1 beta (IL1β) gene 
expression in hepatocytes (18).  We and others have also previously shown PXR to be a target 
for the ubiquitin signaling pathway (19-21) and it is well-known that ubiquitination is an integral 
part of canonical NR-mediated gene expression (22).  Several studies have shown that 
phosphorylation controls PXR biological function as well (23-29).  Moreover, PXR has been 
shown to be a target for acetylation (30).  While these respective post-translational modifications 
of PXR have been observed and characterized in isolation, there has been no examination of the 
potential biological role of the interaction between these key signaling pathways at the level of 




de-SUMOylation of PXR.  Using primary cultures of hepatocytes and cell line-based assays to 
demonstrate that the molecular consequence of SUMO-ubiquitin interaction at the level of PXR 
defines its role in mediating canonical activation of the xenobiotic response, contrasted with 
PXR-mediated repression of the pro-inflammatory response. 
 
2.2 MATERIALS AND METHODS 
2.2.1 Plasmids and Chemicals. 
 The full-length human PXR expression vectors were previously described (31,32).  To 
construct the FLAG-tagged human PXR expression vector the cDNA encoding human PXR was 
excised from pSG5-PXR expression vector using EcoRI and SalI sites and was inserted into 
pCMV-Tag 2B (Agilent) using EcoRI and SalI restriction sites.  Expression vectors encoding 
(His)6-tagged SUMO1, SUMO2 and SUMO3 were a kind gift of Dr. Ronald T. Hay and were 
previously described (33).  Expression vectors encoding protein inhibitor of activated stat (PIAS) 
proteins were a kind gift from Dr. Ke Shuai (34) and were obtained from Addgene (plasmid 
numbers- 15206, FLAG-PIAS1; 15209, FLAG-PIASxα; 15210, FLAG-PIASxβ; 15207, FLAG-
PIAS3; 15208, FLAG-PIASy). The expression vectors encoding the respective SENPs and the 
corresponding catalytically deficient mutant SENPs were a kind gift from Dr. Ed Yeh (35) and 
were obtained from Addgene (plasmid numbers- 17357, FLAG-SENP1; 17358, FLAG-
SENP1m; 18047, FLAG-SENP2; 18713, FLAG-SENP2m; 18048, RGS-SENP3; 18714, RGS-
SENP3m; 18053, RGS-SENP5; 18715, RGS-SENP5m; 18065, FLAG-SENP6; 18716, FLAG-
SENP6m; 42886, 3XFLAG-SENP7).  Expression vectors encoding HA-tagged wild type and 
K48R mutant ubiquitin constructs were previously described (36).  Inserts encoding wild type 




inserted into the EcoRI and NotI sites in pCDNA4-HisMax-A to create (His)6-tagged forms of 
wild type and K48R (His)6-ubiquitin. The single mutant (His)6-K63R and double mutant (His)6-
K48,63R expression vectors were created using the primers listed in Table 2-1 in a QuickChange 
site-directed mutagenesis  reaction per manufacturer instructions (Agilent).  The reporter plasmid 
(ER-6)3-tk-Luc was generated by insertion of three copies of the double-stranded annealed 
oligonucleotide primers listed in Table 2-1 into the Bgl II site of pGL3-Basic.  The FLAG-
tagged PIAS1 adenoviral expression vector was constructed using PCR primers listed in Table 2-
1 to introduce an Xho I site and was inserted into the pShuttle IRES-hrGFP expression vector 
(Agilent).  The SUMO3 adenoviral expression vector was constructed using PCR primers listed 
in Table 2-1 to insert Spe I and Xho I restriction sites into the 5’ and 3’ end of the open reading 
frame of (His)6-SUMO3, respectively, and was inserted into pShuttle IRES-hrGFP expression 
vector (Agilent).   The human PXR adenoviral expression vector was constructed using PCR 
primers to remove the STOP codon in PXR and introduce EcoRV and Xho I restriction sites into 
the open reading frame of PXR using (His)6-tagged PXR as a template.  The resulting PCR 
amplimer was inserted into the multiple cloning site in the pShuttle IRES-hrGFP expression 
vector and adenovirus was generated as described (37). 
2.2.2 Cell-based Cobalt-Bead Affinity Pull-down Assay. 
 The Hepa1-6 cell line was utilized due to its proven utility in studies of hepatic gene 
expression and liver biochemistry (38).  The general strategy for enrichment of SUMO- and 





Table 2-1. PCR Primers used in Cloning and Site-Directed Mutagenesis. 
 
  
Ubiquitin K63R Left Primer 5' gCT gTC TgA TTA CAA CAT TCA gAg ggA gTC CAC CCT 3’ 
  Right Primer 5’ Agg gTg gAC TCC CTC TgA ATg TTg TAA TCA gAC AgC 3’ 
CYP3A4-ER6-
PXRE 
Sense Primer 5’ gAT CAA TAT gAA CTC AAA ggA ggT CAg Tg 3’ 
  Antisense 
Primer 
5’ gAT CCA CTg ACC TCC TTT gAg TTC ATA TT 3’ 
FLAG-tagged 
PIAS1  
Left Primer 5’ gAC ggC CTC gAg ACC ATG GAC TAC AAG GAC GAC 3’ 
  Right Primer 5’ gAC ggC CTC gAg TCA gTC CAA TgA gAT AAT gTC Tgg 3’ 
SUMO3 Left Primer 5’ gAC ggC ACT AgT Cgg ACg gCC TCC gAA ACC ATG g 3’ 
  Right Primer 5’ gAC ggC CTC gAg CTA ACC TCC CgT CTg CTg CCg g 3’ 
(His)-tagged-PXR Left Primer 5’ gAC ggC gAT ATC TTA ATA CgA CTC ACT ATA ggg Ag 3’ 
  Right Primer 5’ gAC ggC CTC gAg GCT ACC TGT GAT GCC GAA CAA CTC C 
3’ 
PXR-K108R Left Primer 5' CTg gAg AgC ggC ATg Agg AAg gAg ATg ATC ATg 3'  
  Right Primer 5’ CAT gAT CAT CTC CTT CCT CAT gCC gCT CTC CAg  3’  
PXR-K128R Left Primer 5' CTT gAT CAA gCg gAA gAg AAg TgA ACg gAC Agg gA 3' 
  Right Primer 5' TCC CTg TCC gTT CAC TTC TCT TCC gCT TgA TCA Ag 3'  
PXR-K160R Left Primer 5' gAT ggA CgC TCA gAT gAg AAC CTT TgA CAC TAC CT 3'  
  Right Primer 5' Agg TAg TgT CAA Agg TTC TCA TCT gAg CgT CCA TC 3'  
PXR-K170R Left Primer 5' TAC CTT CTC CCA TTT CAg gAA TTT CCg gCT gCC Ag 3'  




2.2.3 Isolation and Culturing of Primary Hepatocytes. 
 PXR knockout (PXR-KO) mice were generated as previously described (39).  
Hepatocytes were isolated from congenic (C57BL6) wild type and PXR-KO mice aged 6-10 
weeks using a standard collagenase perfusion method as described previously (40).  Hepatocytes 
isolated from either male or female mice were used throughout this study in order to identify any 
potential sex difference.  Identical results were obtained in both sexes.  The results shown are 
from the male mice.  The hepatocytes were allowed to attach to the plate for 4 hours and the 
medium was then replaced with serum-free Williams E medium as described previously (40). 
2.2.4 Total RNA Isolation, Reverse Transcription, and Real-Time Quantitative-
Polymerase Chain Reaction Analysis. 
 Real time quantitative Polymerase Chain Reaction was performed as described (41). 
2.2.5 Western Blot Analysis. 
 Western blot analysis was performed as described previously (42).  Antibodies used 
include anti-PXR antibody (Santa Cruz, H-11), anti-SUMO1 antibody (Cell Signaling, C9H1), 
anti-SUMO2/3 antibody (Cell Signaling, 18H8), anti-Ubiquitin (Cell Signaling, P4D1), and an 
anti-β-actin (Chemicon, MAb1501). 
2.2.6 LC-MS/MS Analysis. 
 LC/MS experiments were performed essentially as described (43). Data were processed 
using Thermo Proteome Discoverer software (Thermo Fisher Scientific, version 1.4) which 
workflow combined two complementary search engines, Sequest (44) and Mascot (Matrix 
Science, London, UK; version 2.5).  The search parameters covered fragment ion mass tolerance 
of 0.8 Da, parent ion tolerance of 20 PPM, and cysteine carbamidomethylation as a fixed 




attachment to lysine, was included into the search.  Protein fasta database was composed from all 
murinae entries of Uniprot (http://www.uniprot.org/).  Search results were imported into the 
Scaffold software (version 4.4, Proteome Software Inc., Portland, OR) for further validation of 
MS/MS based peptide and protein identifications.  Peptide identifications were accepted if they 
could be established at greater than 90.0% probability as specified by the Peptide Prophet 
algorithm (45).  
2.2.7 Statistical Analysis. 
 Where appropriate the statistical differences among an experimental group were 
determined using a one-way analysis of variance followed by the Duncan's multiple range post 




2.3.1 PXR is the Molecular Target of Both the SUMO- and Ubiquitin-Signaling Pathways 
in Primary Hepatocytes.   
Several type II liver-enriched NR superfamily members are SUMOylated to modify their 
trans-activation capacity.  In most cases, the protein inhibitor of activated STAT-1 (PIAS1) 
functions as an E3 SUMO-ligase to enhance their modification (46-48).  Previous research from 
our laboratory indicated that endogenous hepatic PXR was the molecular target of SUMO-
signaling pathway (18).  However, the specific SUMO-E3 ligase(s) that performed this function 
was not investigated.  We therefore constructed several adenoviral expression vectors to examine 
whether PIAS1 could function as a SUMO-E3 ligase to enhance PXR-SUMO(3)ylation in 




SUMO3 in hepatocytes produced robust SUMO3-modification of this NR family member, as 
detected using anti-PXR antibody in western blot analysis following metal affinity (cobalt beads) 
methods as described (21) (Figure 2-1B).   
A recent report indicated that hepatocyte nuclear factor 4-alpha is the simultaneous target 
of SUMO2/3 and ubiquitin to regulate its stability and biological function (49).  We therefore 
sought to determine the extent to which the endogenous SUMO- and ubiquitin-signaling 
pathways converge at the level of the PXR protein in hepatocytes.  Wild type mouse hepatocytes 
were transduced with the blank virus (Ad-GFP) or the virus encoding a (His)6-tagged form of 
PXR (Ad-PXR).  Twenty-four hours post-transduction, cells were treated with rifampicin 
(10μM), a potent and efficacious human PXR ligand, for 24 hours.  Following rifampicin 
treatment, hepatocytes were treated for an additional three hours with TNFα (10 ng/mL) alone, 
or were co-treated with rifampicin and TNFα together as indicated. Total PXR protein was 
enriched from whole cell lysates.  Protein aliquots were resolved using SDS-PAGE, and 
subsequent western blot analysis was performed to detect PXR, SUMO1-, SUMO2/3-, ubiquitin-
modified forms of PXR, and β-actin as a loading control (Figure 2-1C).  The SUMO- and 
ubiquitin-signaling pathways modified the exogenously added PXR protein, with ligand- and 
TNFα-treatment both increasing the levels of detectable non-modified PXR, as well as the 
SUMO- and ubiquitin-modified forms of PXR.  We note here that SUMO(1)ylation of PXR was 
observed with comparatively low stoichiometry when compared with SUMO(2/3)ylation and 
ubiquitination, as judged by their respective sensitivity in western blot analysis.  These data 
reveal that PXR is the simultaneous target of both the SUMO- and ubiquitin-signaling pathways, 
and that it is targeted in both a ligand- and TNFα-dependent manner.  It is likely that the 




observed for hepatocyte nuclear factor 4-alpha (49), and further suggest that these two post 
translational modifications somehow alter PXR protein-stability, likely through regulating its 













Figure 2-1. Adenoviral-Mediated Approach to Examine PXR Post-Translational 
Modifications.  (A) Depiction of adenoviral constructs including Ad-PIAS1, Ad-PXR, and Ad-
SUMO3.  Note the use of FLAG epitope and (His)6-affinity tags that increase the apparent 
molecular weight of the exogenously expressed proteins.  (B) Primary hepatocytes isolated from 
wid type (C57Bl6) mice were left non-transduced or were transduced as indicated in the figure.  
Hepatocytes were lysed using strong denaturing conditions as described in Materials and 
Methods.  Cell lysates were subjected to enrichment using cobalt beads and captured proteins 
were washed sequentially using guanidine-HCl and urea-based wash buffers.  Proteins were 
eluted using 2X-Laemmli buffer and resolved using 10 % SDS-PAGE.  Western blot analysis 
was performed with an anti-PXR antibody that detects all modified forms of the protein (Santa 
Cruz, H-11 monoclonal Ab).  (C) Primary hepatocytes isolated from wid type (C57Bl6) mice 
were left non-transduced, or were transduced with either blank virus (Ad-GFP) or Ad-PXR.  
Hepatocytes were lysed using strong denaturing conditions, and western blot analysis was 
performed with an anti-PXR antibody (Santa Cruz, H-11 monoclonal Ab), anti-SUMO1 antibody 
(Cell Signaling, C9H1), anti-SUMO2/3 antibody (Cell Signaling, 18H8), anti-Ubiquitin (Cell 





2.3.2 Expression of PIAS1 Modulates PXR Activity in Primary Mouse Hepatocytes. 
We next examined whether expression of PIAS1 altered PXR activity in liver cells.  
Primary hepatocytes were isolated from 8-week old male pxr-nullizygous (PXR-KO) mice and 
cultured overnight.  The next day hepatocytes were transduced with purified adenoviral vectors 
encoding human PXR, PIAS1, or were co-transduced with both adenoviral expression vectors 
together.  Forty-eight hours post-transduction, hepatocytes were treated with rifampicin (10 μM), 
a potent and efficacious human PXR ligand, for and additional twenty-four hours.  Following 
rifampicin treatment, hepatocytes were treated as indicated with TNFα (10 ng/mL) alone, or 
were co-treated with rifampicin and TNFα together for an additional three hours as indicated.  
Total RNA was isolated and rt-QPCR analysis was performed to determine expression levels of 
PXR-target genes.  As expected, induction of the well-known PXR-target gene, Cyp3a11, was 
absent following rifampicin treatment in both non-transduced as well as PIAS1 transduced PXR-
KO hepatocytes (Figure 2-2A).  In contrast, rifampicin treatment produced an approximately 
fourteen-fold induction of Cyp3a11 gene expression levels in PXR-KO mouse hepatocytes 
expressing human PXR.  Treatment of hepatocytes expressing of both PXR and PIAS1 with 
rifampicin produced an approximately thirty five-fold increase in Cyp3a11 gene expression 
levels, indicating that PIAS1 has a co-activator effect on PXR with respect to the Cyp3a11 
promoter.  Co-treatment of PXR-transduced hepatocytes, as well as PXR- and PIAS1-co-
transduced hepatocytes, with rifampicin and TNFα produced significant repression of Cyp3a11 
expression when compared with rifampicin treatment alone.  There was no modulation of 
Cyp3a11 expression in PXR-KO hepatocytes by any treatment when the addition of exogenous 
PXR was omitted.  Taken together, these data indicate that PIAS1 activity can enhance PXR 




suggest that PXR is required for TNFα-mediated repression of Cyp3a11 expression levels in 
hepatocytes. 
Previous research from our laboratory and others indicates that PXR activation can 
suppress the cytokine-inducible expression of TNFα and IL-6 in liver and intestine 
(3,5,6,18,50,51).  We therefore examined the role of PIAS1 in promoting this effect in a PXR-
dependent manner in liver.  Primary hepatocytes isolated from PXR-KO mice were transduced 
with PIAS1 alone, human PXR alone, or both PIAS1 and PXR together for twenty-four hours.  
Hepatocyte cultures were treated with either vehicle, rifampicin, TNFα, or with rifampicin and 
TNFα together as indicated.  The expression levels of pro-inflammatory cytokines TNFα and IL-
6 were subsequently examined (Figure 2-2B and 2-2C).  As expected, in non-transduced PXR-
KO hepatocytes, treatment with TNFα (10 ng/mL) for three hours increased the expression of 
TNFα messenger RNA approximately 16-fold.  In contrast, co-treatment of non-transduced 
PXR-KO cells with rifampicin and TNFα together, or treatment with rifampicin alone had no 
significant effect on TNFα messenger RNA levels.  Similarly, expression of PIAS1 alone did not 
modify the TNFα-inducible expression of TNFα messenger RNA.  Expression of exogenous 
PXR significantly increased the basal levels of TNFα messenger RNA by approximately 8-fold 
when compared with vehicle treated non-transduced PXR-KO hepatocytes.  This is consistent 
with our previous publication that indicates that hepatocytes lacking PXR exhibit a diminished 
capacity to mount a robust immune response following challenge with lipopolysaccharide (6).  
Hepatocytes expressing exogenous PXR that were co-treated with TNFα and rifampicin together 
exhibited significant repression of TNFα-inducible TNFα messenger RNA expression.  The co-
expression of PIAS1 and PXR further suppressed TNFα-inducible TNFα expression in a PXR-




TNFα expression in hepatocytes.  A similar effect was noted when expression levels of IL-6 
messenger RNA were examined as well (Figure 2-2C).  Taken together, the data presented in 
Figure 2-2 indicate that PXR is required for production of full and robust TNFα-inducible pro-
inflammatory cytokines (TNFα and IL-6), and that PIAS1 participates in this PXR-dependent 















Figure 2-2. PIAS1-mediated Modulation of the Xenobiotic Response and Inflammatory 
Response in Hepatocytes.  Primary hepatocytes isolated from pxr nullizygous (PXR-KO) mice 
were transduced as indicated.  Following treatments, total RNA was isolated and the relative 
expression level of (A) Cyp3a11, (B) TNF, and (C) IL-6 were determined.  All data are 
normalized to β-actin levels and are presented as fold regulation.  Asterisks indicate a statistical 





2.3.3 Detection of the SUMOylation Machinery in Primary Hepatocytes. 
To characterize the levels of SUMO and its associated enzymes in mouse liver, we first 
examined the expression levels of SUMO1, SUMO2/3, Sae1, Sae2, Ubc9, PIAS1, PIAS2, 
PIAS3, PIASy, SENP1, SENP2, SENP3, SENP5, SENP6, and SENP7 using cDNA generated 
using RNA isolated from primary cultures of wild type C57BL6 hepatocytes isolated from male 
animals aged 6-10 weeks.  Initial studies using standard rt-PCR analysis revealed that all genes 
examined were expressed at detectable levels in mouse hepatocytes (Figure 2-3), except for 
Sentrin protease 3 (SENP3) (Figure 2-3, Arrow Lane 12).  Subsequent real-time quantitative 
PCR (rt-QPCR) analysis determined that twenty-four hour treatment with PXR ligand, 
pregnenolone 16α-carbonitrile (10μM), or three hour treatment with TNFα (10ng/mL) had no 
effect on expression levels of the genes encoding these enzymes (data not shown).  These data 
indicate that primary hepatocytes express most of the key genes involved in regulating the 
SUMOylation of target proteins, and that neither PXR ligand nor pro-inflammatory cytokine 








Figure 2-3. Detection of SUMO1, SUMO2/3, and SUMO-Associated Enzymes at the 
Level of Gene Expression in Hepatocytes.  Primary hepatocytes isolated from wid type 
(C57Bl6) mice were isolated and cultured as described in Materials and Methods.  Total RNA 
was isolated and the expression of indicated genes was determined using standard non-
quantitative reverse transcriptase-PCR and agarose gel (2%) electrophoresis methods.  The arrow 





2.3.4 Identification of the SUMO-E3 Ligase Enzymes Important for SUMO-Modification 
of PXR. 
To determine which PIAS family members could function as the most effective SUMO-
E3 ligase towards PXR, the murine hepatoma-derived cell Hepa1-6 cells was used (38).   
Cultured cells were co-transfected with expression vectors encoding FLAG-tagged PXR together 
with either (His)6-SUMO1 or (His)6-SUMO3.  An additional expression vector encoding a 
specific PIAS- family member was added as indicated (Figure 2-4A).  The expression levels of 
all five PIAS proteins examined in this assay were roughly equivalent (data not shown).  In the 
presence of PIASy, modification of PXR by SUMO1 was supported at least two sites as 
determined using western blot analysis with an anti-PXR antibody following enrichment with 
cobalt beads (Figure 2-4A, asterisks Lane 7).  The other four PIAS family members examined 
(PIAS1, PIASxα, PIASxβ, and PIAS3) promoted more modest SUMO1-modification of PXR.  
When (His)6-SUMO3 was used in the assay, more robust SUMO-chain formation was observed 
with PIASy promoting robust SUMO(3)ylation of PXR (Figure 2-4A, Bracket Lanes 8, 11, and 
12).  While both PIAS1 and PIAS3 promoted SUMO(3)ylation of PXR with high efficiency,  
PIASy was the most effective SUMO-E3 ligase examined with respect to SUMO(3)ylation of 
PXR.  Of note, the intensity of the primary non-modified PXR band was increased in direct 
proportion to the level of SUMO-modified PXR (Figure 4A, arrow Lanes 7, 8, 11, and 12).    
Taken together, the data presented in Figures 2-3 and 2-4A indicate that PIASy is the most 
effective SUMO-E3 ligase towards the PXR protein in this cell line-based assay.  It is worth 
noting here that PIASy, PIAS1, and PIAS3 potentially play differential roles in SUMO-




2.3.5 Identification of the Sentrin Protease Enzymes Important for De-SUMOylation of 
PXR.   
There is increasing recognition that de-SUMOylation of SUMO-substrates by sentrin 
protease enzymes, or SENPs, represents a key regulatory step in the SUMO-signaling pathway 
(52,53).  Similar to SUMO-E3 ligase enzymes, the specific SENP(s) that remove SUMO from 
PXR are currently unknown.  We therefore sought to identify the specific SENPs capable of de-
SUMOylating PXR using a variation of our transient transfection cell line-based assay.  
Expression vectors encoding FLAG-PXR, PIASy, and (His)6-SUMO1 were introduced into 
Hepa1-6 cells together with selected SENPs as indicated (Figure 2-4B).  Where available, the 
catalytically deficient mutant forms of each SENP (ΔSP1, ΔSP2, ΔSP3, ΔSP5, AND ΔSP6) were 
used as negative controls as indicated.  Expression of SENP2 completely abolished 
SUMOylation of PXR, whereas, the catalytically deficient form of SENP2 (ΔSP2) was 
ineffective.  While expression of SENP1 and SENP6 promoted de-SUMOylation of PXR to 
some extent, the removal was incomplete.  It is noteworthy that the 52 kDa immunoreactive band 
that corresponds to non-modified PXR decreases in direct proportion to the level of PXR de-
SUMOylation (Figure 2-4B, arrow).  These data suggest that PIASy-mediated SUMOylation of 
PXR may stabilize the protein or inhibit its proteasome-mediated degradation.  Identical 
experiments using SUMO3 indicate that the SENP1, SENP3, and SENP6 de-SUMOylating 
enzymes selectively remove SUMO-chains, while SENP2 is the most effective at removing all 
SUMO moieties from PXR (Figure 2-4C).   These data suggest that SENP2 is the key de-
SUMOylating enzyme for PXR, and also raise the possibility that other SENPs (SENP1, SENP3, 
and SENP6) may have differential effects on removal of SUMO chains or site-specific de-














Figure 2-4. Characterization of SUMO E3-Ligases and SENPs Associated with PXR 
SUMOylation and De-SUMOylation.  (A) Indicated expression vectors were transfected into 
Hepa1-6 cells.  Forty-eight hr post-transfection cells were harvested and SUMOylated proteins 
were gathered. Proteins were subjected to SDS-PAGE and subsequent western blot analysis 
using an anti-PXR antibody.  Asterisks (*) indicate modified forms of PXR and the arrow () 
indicates non-modified PXR protein.  (B and C) Expression vectors encoding SENPs, control 
mutant catalytically deficient SENPs (ΔSP’X’) were transfected into Hepa1-6 cells in 
combination with either SUMO1 or SUMO3, together with PXR and PIASy as indicated.  Forty-
eight hr post-transfection cells were harvested in denaturing buffer and SUMOylated proteins 
were captured.  Proteins were subjected to SDS–PAGE and subsequent western blot analysis 
using anti-PXR antibody.  Asterisks (*) indicate SUMO-modified forms of PXR and the arrow 
() indicates non-modified PXR protein.  The brackets in (A) and (C) represent the formation of 





2.3.6 PGC-1α-Mediated Trans-activation of PXR Is Regulated by PIASy-mediated 
SUMOylation. 
Interaction of peroxisome proliferator-activated receptor gamma coactivator 1-alpha 
(PGC-1α) with liver X receptor-beta is attenuated by increased SUMO-signaling (54,55).  The 
PXR NR family member also strongly interacts with, and is co-activated by PGC-1α (56).  We 
therefore sought to determine the extent to which PGC-1α-mediated trans-activation of PXR is 
modulated by the SUMO1 or SUMO2/3-signaling pathways.  To accomplish this we constructed 
a multimerized (3X) PXR-dependent (ER-6 PXR-enhancer) luciferase reporter gene [(ER-6)3-tk-
Luc] as described in Materials and Methods.  Treatment of PXR-transfected CV-1 cells with 
rifampicin induced expression of this PXR-dependent reporter gene approximately 2.7-fold 
(Figure 2-5).  The addition of PGC-1α significantly increased reporter gene activity in a PXR-
dependent manner, while the addition of SUMO1 and PIASy together significantly inhibited 
PGC-1α-mediated trans-activation of PXR.  Importantly, the de-SUMOylating enzyme SENP2 
significantly restored the SUMO1/PIASy-mediated suppression of PXR/PGC-1α reporter gene 
activity when compared with cells expressing only PIASy and SUMO1, while SENP6 was less 
effective in this regard.  When SUMO3 was used in place of SUMO1 in identical experiments 
the PIASy-mediated suppression of PXR activity was absent, suggesting a differential role for 
SUMO(1)ylation versus SUMO(3)ylation.  However, addition of SENP2 had a significant 
positive effect upon both basal- and rifampicin-dependent PGC-1α-mediated trans-activation of 
PXR-dependent reporter gene activity in this case.  It is interesting to note that SENP6, which 
has strong SUMO-chain editing activity and is ineffective at complete removal of SUMO3 from 




face of SUMO3 and PIASy.  These data suggest that strong de-SUMOylation signaling pathways 




Figure 2-5. PIASy and SUMO1 Abrogate Association of PXR with PGC-1α to Attenuate 
Its Trans-activation Capacity.  CV-1 cells were transfected with a PXR-dependent luciferase 
reporter gene (ER6)3-tk-Luc and expression vectors encoding PXR, PGC-1α, PIASy, SUMO1, 
SUMO3, SENP2, or SENP6 as indicated.  Twenty-four hours post-transfection cells were treated 
with vehicle (0.1% DMSO) or Rif (10μM) for an additional 24 hr.  Luciferase activity was 
normalized to β-gal controls and data are presented as fold induction + SEM.  Asterisks indicate 





2.3.7 The SUMO- and Ubiquitin-signaling Pathways Interface at the Level of PXR. 
Ubiquitination of PXR has previously been demonstrated by our group and others (19-
21), and pharmacological inhibition of the 26S proteasome in cells inhibits PXR function (21).  
However, the precise molecular nature of the ubiquitin chain formation, the specific lysine 
residue on PXR that is the target of ubiquitin and the biological significance of ubiquitin- SUMO 
interaction at the level of PXR are not currently well defined.  The novel ubiquitin expression 
vector we constructed adds approximately 17 kDa to the size of the PXR protein due to the 
presence of an extended N-terminus (Figure 2-6A).  We engineered several key features into the 
N-terminus of ubiquitin including a (His)6-metal-affinity tag for bead-based enrichment, as well 
as both an Xpress-epitope tag and an HA-epitope antibody tag for enrichment and western blot 
strategies.  We have termed this expression vector His-Ub.  The His-Ub expression vector was 
used as a template to create expression constructs that contain mutations at key lysine residues 
including  (1) lysine 48 mutated to arginine (His-K48R), (2) lysine 63 mutated to arginine (His-
K63R), and (3) both lysine 48 and lysine 63 mutated to arginine (His-K48R,K63R).  Using His-
Ub and the mutant ubiquitin expression vectors in our cell line-based assay together with a 
plasmid encoding FLAG-PXR (52 kDa) in transfection-based experiments, we detect heavily 
mono-ubiquitinated PXR at the predicted 69 kDa molecular weight (Figure 2-6B, lanes 3, 4, 5, 
and 6).  When His-K48R was used co-expressed with PXR, chain formation was dramatically 
reduced.  In contrast, when the His-K63R mutant was co-expressed with PXR, chain formation 
was completely intact.  When the double mutant His-K48,K63R construct was used in the assay, 
ubiquitin chain formation was completely lacking.  Taken together, these data suggest that lysine 





To directly examine the nature of ubiquitin chains and site of PXR ubiquitination using 
LC-MS/MS-based methods, we took advantage of our adenoviral expression vector encoding 
(His)6 -tagged human PXR to achieve high level of expression and relative ease of purification.  
Primary hepatocytes were transduced with an appropriate amount of PXR virus.  Forty-eight 
hours post-transduction, cells were treated with either vehicle (0.1% DMSO) or rifampicin for an 
additional twenty-four hours.  Hepatocytes were lysed using denaturing conditions, and total 
PXR was isolated using cobalt-bead affinity methods (21).  Following SDS-PAGE of PXR-
enriched protein lysates, LC-MS/MS methods were used to probe the site of PXR-ubiquitination 
(Figure 2-6C), and the precise nature of observed ubiquitin chains (Figure 2-6D).  This analysis 
detected lysine 170 (K170) as the site of PXR ubiquitination, and also confirmed our previous 
analysis indicating a high level of K48-linked ubiquitin chains.  It is widely recognized that 
ubiquitin-chain formation linked through K48 that is anchored to a single lysine in the substrate 
is a canonical signal for targeting proteins for proteasome-mediated degradation (57).  These data 
confirm that PXR is the target of the ubiquitin-signaling pathway, and further confirm the precise 
site (K170) and nature of PXR ubiquitination (K48-linked ubiquitin chains).  Taken together, 
these data indicate that PXR post-translational modification by ubiquitin is highly implicated in 

















Figure 2-6. K48-Linked Ubiquitin chain formation on a Single Lysine Residue (K170) 
within PXR. (A) Single letter amino acid representation of the open reading frame of (His)6-
tagged wid type ubiquitin. (B) Hepa1-6 cells were transfected with expression vectors encoding 
PXR alone, or the wild type and indicated mutant forms of ubiquitin together with PXR as 
shown.  Cells were lysed and total (His)6-tagged ubiquitinated proteins were captured using 
cobalt beads.  Captured proteins were subjected to SDS-PAGE and subsequent western blot 
analysis was performed using an anti-PXR antibody.  Asterisks (*) indicate ubiquitin-modified 
forms of PXR and the arrow () indicates non-modified PXR protein. The bracket and asterisks 
indicate poly-ubiquitinated forms of PXR. (C) Lysine residue (K170) in PXR was identified 
based on assignment of multiple product ions (b and y ions) in the MS/MS scan of the precursor 
ion at M/z 587.95 to the PXR tryptic peptide sequence with a mass addition of 114 at the lysine 
residue (ubiquitin di-glycine post-tryptic digestion).  (D) MS/MS spectrum assigned to ubiquitin 
tryptic peptide sequence showed lysine residue (K48) carried a modification with a mass of 114 




We next sought to determine whether promoting SUMO(1)ylation of PXR in cells can 
affect its modification by ubiquitin.  Transfection of Hepa1-6 cells with expression vectors 
encoding His-Ub and PXR produces detectable forms of ubiquitinated PXR, both in the absence 
and presence of the PXR ligand (Figure 2-7, lanes 3 and 4).  Co-expression of PIASy and PXR 
in the absence of His-Ub produces increased levels of unmodified PXR (Figure 2-7, lanes 5 and 
6).  When His-Ub was co-expressed with PIASy and SUMO1 together, the modification of PXR 
by ubiquitin was dramatically increased (Figure 2-7, lanes 3 and 4 versus lanes 7 and 8).  These 
data indicate that PIASy-mediated SUMO(1)ylation of PXR stabilizes the protein, likely through 







Figure 2-7. PIASy Increases Levels of Ubiquitinated PXR.  Hepa1-6 cells were transfected 
with expression vectors as indicated.  Ubiquitinated proteins were captured using cobalt-linked 
agarose beads.  Captured proteins were subjected to SDS-PAGE and the blots were probed for 





2.3.8 Identification of Site 1 and Site 2 as the Primary Sites of SUMO-Modification. 
The PXR protein contains several lysine residues that are predicted to serve as acceptor 
sites for SUMOylation (18).  Among the four sites (labeled Site1, Site 2, Site 3, and Site 4) is 
one ‘high probability’ type I consensus site (Ψ-K-x-D/E; where Ψ=hydrophobic residue) at 
lysine 108 (Site 1, K108) (Figure 2-8A).  The other three predicted sites have a lower probability 
to serve as SUMO-acceptor sites.  We created a series of mutant PXR expression vectors as 
indicated at these four potential sites of SUMOylation shown in Figure 2-8B.  Co-transfection of 
Hepa1-6 cells with (His)6 -SUMO1, PIASy, and PXR together produced two clear sites of 
modification following enrichment and western-blot with an anti-PXR antibody (Figure 2-8B, 
asterisks).  Consistently, wherever mutation of Site 1 appears (K108R, lanes 4, 5, 6, and 8), the 
upper band disappears.  No other lysine to arginine mutation examined in Site 2, 3, or 4 appeared 
to support SUMO(1)ylation in this analysis.  When (His)6 -SUMO3 was used in place of (His)6 -
SUMO1, both Site 1 and Site 2 in PXR appeared to support SUMO(3)ylation and SUMO-chain 
formation in a cooperative manner, with adjacent lysine residues 128 and 129 serving as a likely 
sites of further SUMO(3)ylation.  It is interesting to note that both Site 1 (-MKKE-) and Site 2 (-
KKSE-) contain di-lysine residues (-KK-) embedded within the predicted SUMO-acceptor sites.  
These data indicate that both Site 1 and Site 2 contribute differentially to SUMO-modification of 
PXR, and further suggest that SUMO1 may modify PXR in a manner that is distinct from that 














Figure 2-8. Site-Directed Mutagenesis Study of Potential Sites of SUMOylation of PXR. 
(A) Four probable sites of SUMO modification were identified using SUMOplot 
(http://www.abgent.com/sumoplot)  and SUMPsp (http://sumosp.biocuckoo.org/) prediction 
analysis servers.  (B) Site-directed mutagenesis was performed and the indicated mutant PXR 
proteins were transfected together with PIASy and (C) SUMO1 or (C) SUMO3.  SUMOylated 
proteins were captured using cobalt-linked agarose beads.  Captured proteins were subjected to 
SDS-PAGE and the blots were probed for PXR immunoreactivity.  Asterisks (*) and brackets 






SUMO proteins are transcribed as immature precursor molecules with an extended C-
terminus that first need to be cleaved by a SENP to expose the C-terminal di-glycine motif (58).  
Following cleavage of SUMO at its C-terminus by SENPs, the SUMO-E1 activating enzyme 
heterodimeric protein (SAE1/SAE2) utilizes an ATP-dependent process to activate the SUMO 
for entry into the SUMO-signaling pathway.  Next, the activated SUMO is transferred to the 
catalytic Cys residue (C93) of the E2 enzyme Ubc9 to form a thioester-linkage at the C-terminal 
di-glycine motif of SUMO.  The E2-SUMO activated complex is conjugated to a specific lysine 
residue in the substrate by a SUMO-E3 ligase enzyme that catalyzes the transfer of SUMO from 
E2 to its specific substrate. Like protein ubiquitination, protein SUMOylation is regulated by two 
opposing reactions.  The first reaction is conjugation, which is carried out by a three-step cascade 
of enzymes that activate SUMO and selectively couple it to its target substrate proteins.  The 
second reaction is deconjugation, which is carried out by a specialized family of SUMO-protease 
enzymes called SENPs (53,58).   
While the SUMOylation of liver-enriched NR family members is strongly associated 
with suppression of the acute phase response, there are important molecular differences 
governing their anti-inflammatory effect.  One key distinction is evident with respect to ligand-
dependence of the SUMOylation reaction.  On the one hand, SUMOylation of farnesoid x 
receptor, liver receptor homologue-1, and liver x receptor-β are all enhanced by ligand 
(Balasubramaniyan et al., 2013; Venteclef et al., 2010), whereas the SUMOylation of 
peroxisome proliferator activated receptor-α is decreased by ligand (Pourcet et al., 2010).  
Additional differences exist in whether NRs are modified by SUMO1 or SUMO2/3. Most NRs 




of PXR was observed with both SUMO1 and SUMO2/3.  The modification of PXR was 
stimulated by ligand and pro-inflammatory signaling.  We also found that multiple PIAS family 
members are capable of promoting SUMO-modification of PXR, and may thus play distinct roles 
in modulating its function.  Further, we found that different SENPs have differing activity with 
respect to the deSUMOylation of PXR.  Hence, our data indicate that it is likely that SUMO1 
and SUMO2/3 play differing roles in regulating PXR biological function.  It is also worth noting 
that inflammatory mediators increase SUMOylation of RXR α, a critical heterodimeric partner of 
PXR (59,60).  This is particularly interesting in light of the fact that not only can RXRα function 
as a partner for the xenobiotic sensor PXR, but it also functions as an obligate heterodimeric 
partner for many other NR family members including those for retinoic acid, thyroid hormone, 
vitamin D, prostanoids, oxysterols, and bile acids.  
Protein modification by SUMO was historically thought of as a post-translational 
modification that largely regulates the biological function and subcellular localization of many 
cellular proteins (61).  Recent evidence indicates that SUMOylation is often a prerequisite for, or 
a competitor of shared substrate protein ubiquitination (12).  Hence, SUMOylation was proposed 
as a post-translational modification that can possibly influence the degradation of shared SUMO-
ubiquitin substrate proteins.  More recently, SUMO2/3-dependent ubiquitin-proteasome 
proteolysis has been clearly demonstrated to play a critical role in the regulation of the biological 
function and fate of key tumor suppressor proteins involved in the development of Fanconi’s 
anemia and other yet to be identified proteins (11-13).   
In this study we identified a key role for interaction between SUMOylation and 
ubiquitination post-translational modifications of PXR that likely play a crucial role in the 




protein is SUMOylated by SUMO1 and SUMO2/3 and ubiquitinated in both primary 
hepatocytes, as well as in cell line-based assays.  We found SUMO1, SUMO2/3 and all of the 
SUMO-E3-ligase and key SENP enzymes to be highly expressed in mouse liver.  Using novel 
expression and affinity purification methods combined with western blot analysis we revealed 
that both SUMOylation and ubiquitination of PXR was increased in a ligand-dependent fashion 
in cultured primary hepatocytes.  Expression of PIAS1, an effective PXR-dependent SUMO-E3 
ligase enzyme, and PXR in PXR-KO hepatocytes revealed that PIAS1 increases ligand-
dependent expression of the prototypical xenobiotic response gene- Cyp3a11.  In contrast, 
expression of PIAS1 and PXR endowed hepatocytes with rifampicin-dependent suppression of 
TNFα-inducible pro-inflammatory cytokine gene expression.  In cell line-based assays, both 
PIAS1 and PIASy functioned as SUMO-E3 ligase enzymes to modify PXR, with PIASy 
promoting effective modification of PXR by either SUMO1 or SUMO2/3.  In contrast, the 
PIAS1 promoted strong SUMO(1)ylation of PXR.  These data raise the intriguing possibility that 
PIASy and PIAS1 may play differing respective roles in regulating PXR biology through the 
selective promotion of SUMO2/3 versus SUMO1 modification of this NR family member.  The 
SENP2 SUMO-protease effectively removed all SUMO-modification from PXR, whereas 
expression of SENP1, SENP3, and SENP6 reduced the SUMO2/3-chain formation on this 
SUMO-substrate.  Interaction of PXR with the strong co-activator protein PGC-1α was 
completely abrogated by PIASy-mediated SUMO(1)ylation, and this effect was reversed by co-
expression of the SENP2 and SENP6 PXR-de-SUMOylase enzymes. This repressive effect was 
largely absent when PIASy-driven SUMO(3)ylation of PXR was examined in cell line-based 




PXR) increased co-activation of PXR by PGC-1α as determined using a multimerized PXR-
response element (ER-6). 
Four potential sites SUMO- and ubiquitin-modification of PXR were identified (Site 1, 
Site 2, Site 3, and Site 4), and were examined using site-directed mutagenesis and cell line-based 
assays.  Using LC-MS/MS and cell-based assays we identified Site 4 (K170) as a primary site of 
ubiquitination of PXR.  Our LC-MS/MS analysis combined with ubiquitin mutant expression 
vectors revealed the formation of K48-linked ubiquitin chains on the PXR protein through a 
single lysine residue (K170).  These data indicate a likely role for ubiquitination of PXR in 
regulating its degradation by the 26S proteasome, as K48-linked ubiquitin chains on a single 
substrate lysine comprises the canonical signal for marking proteins for proteasome-mediated 
degradation (57).  In addition, PIASy-mediated SUMO(1)ylation of PXR strongly increased the 
presence of both ubiquitinated and non-modified forms of this NR, suggesting a key interaction 
between these two post-translational modifications at the level of PXR.  Mutation of the well-
conserved type I (-Ψ-K-x-D/E-) SUMOylation consensus site at lysine 108 (Site 1- MKKE-) 
abolished a discrete form of PXR SUMO(1)ylation.  In contrast, modification of PXR by 
SUMO2/3 and subsequent chain formation on PXR required mutation at both Site 1 and Site 2.  
Mutation of Site 2 alone had no effect on PXR SUMOylation, whereas mutation of all four sites 
strongly reduced the capacity of PXR to support chain formation.  These data suggest that 
SUMO2/3-modification at Site 1 and Site 2 affect ubiquitination at Site 4, likely through the 
formation of mixed SUMO-ubiquitin chains or SUMO-dependent ubiquitination at Site 4 to 
promote proteasome-mediated degradation of the PXR protein (Figure 9).  Taken together, these 




SUMO2/3, and ubiquitin to regulate its degradation during the xenobiotic response, and to 
mediate PXR-dependent repression of the pro-inflammatory response. 
An increasing number of proteins have been shown to bind SUMO or SUMOylated 
proteins non-covalently through SUMO-interacting motifs (SIM).  The PXR protein also 
contains a SIM consensus amino acid sequence, but how this contributes to SUMO-dependent 
PXR biological function is yet to be determined.  Regardless, there are multiple proteins for 
which SUMOylation is dependent on the presence of a SIM in the substrate (62,63).  The current 
thought is that SUMO binding to the SIM domain comprises the initial association with its target 
protein, which precedes SUMO conjugation to the SUMO consensus motif.   Another possibility 
is that the SIM allows modified proteins to interact with new and novel protein partners, or 
allows SUMO-substrates to interact with themselves following SUMO-modification.  
Alternatively, there are many transcription factors and co-activator proteins such as PGC-1α 
involved with PXR trans-activation that are also subject to SUMOylation, thereby allowing the 
formation of SUMO-dependent multi-protein complexes.  Our data indicate that it is likely that 
PXR interacts with PGC-1α and that modification by SUMO1, but not SUMO2/3, prevents this 
protein-protein interaction.  The functional significance of this and other complex regulatory 
networks will require additional studies.  
In vivo, SUMOylation can influence single or multiple properties of a target protein 
including its stability, localization, or activity.  In most cases SUMO1 modification inhibits 
transcriptional activity of a NR, as we have now shown here with PXR towards the inflammatory 
response.  Synergistic or antagonistic cross-talk among different types of post-translational 
modifications can occur, and our data clearly show that PXR modification by SUMO2/3 likely 




thereby facilitates another round of messenger RNA production.  These data are consistent with 
the ubiquitin-mediated ‘promoter clearance’ hypothesis put forth by Dennis and O’Malley (22).  
However, our data indicate that PXR is likely ubiquitinated in a SUMO2/3-dependent manner, 
and that SUMO(1)ylated PXR is refractory to this phenomenon.  More importantly, our data 
suggest that a very low stoichiometric amount of PXR is in fact modified by SUMO1 in ligand- 
and TNFα-stimulated primary cultures of hepatocytes, furthermore, that this particular post-
translational modification results in PXR-mediated repression of the pro-inflammatory response 
in a ligand-dependent manner.  Unraveling the details of how phosphorylation and acetylation, or 
other post-translational modifications on PXR and associated protein cofactors, influence PXR 
biology in the context of SUMOylation and ubiquitination will undoubtedly require further 







Figure 2-9. Working Model and Hypothesis of the Role of Ubiquitin- and SUMO-
Signaling in Regulation of PXR Biology.  A schematic representation of the molecular basis of 
the interface between canonical PXR activation and the xenobiotic response (Left Half of 
Diagram), and the molecular basis of the role of SUMO-PXR in suppression of the pro-
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Chapter 3: A SUMO-Acetyl Switch in PXR Biology 
 
ABSTRACT 
Post-translational modification (PTM) of nuclear receptor superfamily members regulates 
various aspects of their biology to include sub-cellular localization, the repertoire of protein-
binding partners, as well as their stability and mode of degradation.  The nuclear receptor 
Pregnane X Receptor (PXR, NR1I2) is a master-regulator of the drug-inducible gene expression 
in liver and intestine.  The PXR-mediated gene activation program is primarily recognized to 
increase drug metabolism, drug transport, and drug efflux pathways in these tissues.  The 
activation of PXR also has important implications in significant human diseases including 
inflammatory bowel disease and cancer.  Our recent investigations reveal that PXR is modified 
by multiple PTMs to include phosphorylation, SUMOylation, and ubiquitination.  Using both 
primary cultures of hepatocytes and cell line-based assays, we show here that PXR is modified 
through acetylation on lysine residues.  Further, we show that increased acetylation of PXR 
stimulates its increased SUMO-modification to support active transcriptional suppression.  
Pharmacologic inhibition of lysine de-acetylation using trichostatin A (TSA) alters the sub-
cellular localization of PXR in cultured hepatocytes, and also has a profound impact upon PXR 
trans-activation capacity.  Both the acetylation and SUMOylation status of PXR is affected by its 
ability to associate with the lysine de-acetylating enzyme histone de-acetylase (HDAC) 3 in a 
complex with silencing mediator of retinoic acid and thyroid hormone receptor (SMRT).  Taken 
together, our data support a model in which a SUMO-acetyl ‘switch’ occurs such that acetylation 
of PXR likely stimulates SUMO-modification of PXR to promote the active repression of PXR-





Pregnane X Receptor (PXR, NR1I2) was initially described as a master-regulator of 
drug-inducible xenobiotic detoxification pathways in the enterohepatic system [1, 2].  However, 
there is increasing recognition that PXR activation has a multiplicity of ‘non-canonical’ roles.  
For example, recent evidence indicates that PXR activation in liver impacts regulation of glucose 
and lipid metabolism [3, 4], and may affect the development of multi-drug resistance in certain 
solid tumor types [5].  Moreover, a fundamental role for PXR activation in ameliorating pro-
inflammatory signals and loss of intestinal barrier permeability in the inflamed condition has 
been identified [6, 7].   
Numerous studies reveal that acetylation of transcriptional regulatory proteins blends 
together with phosphorylation, ubiquitination, SUMOylation to form complex programs of gene 
activation [8].  More recently, attention has been given to the notion that a complex interplay 
between post-translational modifications (PTMs) occurs to allow alterations of PXR biology 
depending upon the physiological context [9, 10].  It is abundantly clear that different PTMs 
form a complex regulatory network with interactions and integrated features that resemble a 
refined language.  We feel that such a complex and interwoven regulatory program of gene 
expression is likely to play a pivotal role in disease pathogenesis and progression.  The discovery 
of the repertoire of PTMs that target the PXR protein and how they interact with each other is 
thus an important and newly emerging field of research.   
Our recent efforts combined with that of others indicate that phosphorylation, 
ubiquitination, and SUMOylation of PXR play a pivotal and likely interactive role in regulating 
the biological function of this nuclear receptor protein [11-18].   However, where the PTMs 




complex biology in liver and intestine is only beginning to be understood.  There is a clear 
recognition that both SUMOylation and acetylation of numerous transcriptional regulatory 
proteins and histone proteins occurs in a coordinated and unified manner [8, 19, 20].  We 
therefore sought to investigate whether SUMOylation and acetylation have the ability to 
determine aspects of PXR biology, and whether they might interact with each other to affect 
PXR activity in hepatocytes. 
Using an immunoprecipitation approach, we detect acetylation of PXR in primary 
hepatocytes and this is reduced by treatment with the PXR ligand rifampicin (Rif).  The 
acetylation of PXR is increased in hepatocytes following treatment with the class I and class II 
de-acetylation inhibitor TSA.  Further, we identify the lysine/histone deacetylase HDAC3-SMRT 
co-repressor multi-protein complex as a likely regulator of ligand-dependent PXR acetylation.  
The co-expression of fluorescently tagged HDAC3 and PXR proteins in hepatocytes indicate that 
PXR and HDAC3 co-localize in mouse hepatocytes, and that the increased acetylation of PXR 
produced by treatment with TSA alters their sub-cellular localization.  Treatment of transfected 
cells with TSA produces synergistic trans-activation of a PXR-dependent reporter gene when 
combined with Rif.   Enzymatic de-acetylation of PXR with the HDAC3-SMRT co-repressor 
complex inhibits SUMO-modification of PXR, while pharmacological promotion of acetylation 
with TSA promotes high levels of SUMO-modification of PXR.  The acetylated and 
SUMOylated forms of PXR differentially associate with the HDAC3-SMRT co-repressor 
complex.  The covalent attachment of SUMO proteins to PXR produces a strong repressive 
function that is functionally separate from its interaction with the HDAC3-SMRT co-repressor 




‘switch’ occurs at the level of PXR, such that acetylation is prerequisite to promote SUMO-
modification of PXR to support active repression of PXR-target gene expression. 
 
3.2 MATERIALS AND METHODS 
3.2.1 Chemicals and Plasmids 
Rifampicin (Rif), Trichostatin A (TSA), and Pregnenolone-16α-carbonitrile (PCN) were 
purchased from Sigma-Aldrich.  All other reagents including culture medium for primary 
hepatocytes and mammalian cell lines were purchased from standard sources.  The expression 
vectors encoding FLAG-tagged full length human PXR, (His)6-tagged SUMO3, and protein 
inhibitor of activated STAT-1 (PIAS1) were as previously described (Cui et al., 2015).  The 
expression vector encoding FLAG-tagged HDAC3 is a kind gift from Dr. Eric Verdin and 
purchased from Addgene (plasmid #13819) [21].  The expression vector encoding HDAC3-GFP 
was a kind gift of Dr. Eric Olson [22].  The expression vector encoding full length SMRT was a 
kind gift of Dr. J.D. Chen [23].  The RFP-PXR expression vector was constructed by using the 
following primers to amplify human PXR to add a HindIII site: Left Primer- 5’ 
GACGGCCAAGCTTCGATGGAGGTGAGACCCAAAG 3’; Right Primer: 5’ 
GACGGCAAGCTTTCAGCTACCTGTGATGCCG 3’.  The resulting amplimer was inserted 
into the pM-Cherry-C1 expression vector using the HindIII site (ClonTech).  To generate (His)6-
PXR-SUMO1 and  (His)6-PXR-SUMO3 linear fusion construct, we used the following PCR 
primers that introduce XhoI restriction sites and both adds a STOP codon and removes one C-
terminal glycine from the SUMO1 and SUMO3: SUMO1- left primer- 5’ 
GACGGCCTCGAGGCCATGTCTGACCAGGAGGCAAAA 3’; SUMO1- right primer- 5’ 




GACGGCCTCGAGCCATGTCCGAGGAGAAGCCCAAG 3’; SUMO3- right primer 5’ 
GACGGCCTCGAGCTATCCCGTCTGCTGCTGGAACAC 3’.  The modified SUMO1 and 
SUMO3 sequences were amplified and then sub-cloned into pShuttle-(His)6-PXR-(FLAG)3 
expression vector using the XhoI restriction site that exists in between the last amino acid of 
PXR and the triple FLAG tag in this expression vector [11].  The FLAG-SUMO3-PXR construct 
was generated using the following PCR primers to introduce EcoRI restriction sites and removes 
the STOP codon and one glycine residue from SUMO3:  SUMO3- left primer- 5’ 
GACGGCGAATTCATGTCCGAGGAGAAGCCCAAG 3’; SUMO3- right primer- 5’ 
GACGGCGAATTCTCCCGTCTGCTGCTGGAACAC 3’.  The resulting amplimer was 
digested with EcoRI and inserted into the EcoRI site that exists between the FLAG epitope and 
PXR in the previously described pCMV-Tag human PXR expression construct [11].  All 
expression vectors were sequenced on both strands to ensure the integrity of the resulting open-
reading frames. 
3.2.2 Isolation and Culturing of Primary Mouse Hepatocytes 
Primary hepatocytes were isolated from C57BL6 mice at age 6-10 weeks with a classic 
collagenase perfusion procedure as previously described (Staudinger, 2003).  Potential sex 
differences were determined throughout the study, and identical results were acquired from both 
male and female mice.  The representative results were obtained from male mice. 
3.2.3 Total RNA Isolation, Reverse Transcription, and Real-Time Quantitative-
Polymerase Chain Reaction Analysis 
Real-time (RT) quantitative polymerase chain reaction (qPCR) was executed as 
previously described (Ding, 2005). 




Primary hepatocytes or Hepa1-6 cells cultured in 10 cm dishes and were harvested in 1 
mL of a Lysis Buffer containing 150 mM NaCl, 50 mM Tris-Cl (pH 8.0), 1% Triton X-100, 20 
mM N-Ethylmaleimide (NEM), and 1% Halt™ Protease and Phosphatase Inhibitor Cocktail 
(Thermo Scientific).  Samples were disrupted through sonication and subsequently centrifuged at 
18,000 x g for 10 minutes to remove the insoluble substances.  A fraction of the supernatant 
(5%) was saved as a loading control for western blot analysis, while the rest of sample was 
subjected to pre-clearing with 5% Protein A/G Sepharose beads at 4 °C.  The pre-cleared cell 
lysates were separated from beads by centrifugation and then incubated with the appropriate 
antibody.  The anti-acetylated lysine antibody cocktail was previously described and consisted of 
equal masses of four separate monoclonal antibodies from Novus Biologicals-15G10, Santa 
Cruz-AKL5C1, Cell Signaling-Ac-K-103, and Thermo Scientific-1C6 [24].  An equal amount of 
each antibody was added to the mixture, and the final antibody concentration was 4 μg per 1 mL 
of total cell lysate.  The antibody cocktail was mixed together with a 5% volume of Protein A/G 
Sepharose beads and was applied to cell lysates for immunoprecipitation of acetylated proteins 
overnight at 4 °C with shaking.  FLAG-tagged-HDAC3 and associated proteins were 
immunoprecipitated using antibody-agarose conjugated beads (Anti-FLAG M2 Affinity Gel, 
Sigma Aldrich, A2220).  Subsequently, the beads were pelleted gently and were washed 3 times 
with Lysis Buffer containing 20 mM NEM, and 1% Halt™ Protease and Phosphatase Inhibitor 
Cocktail.  Immunoprecipitated proteins were eluted in 30 μL 2X-Laemmli buffer and heated at 
95 °C for 10 minutes for western blot analysis. 
3.2.5 Cell-Based Immobilized Metal Affinity Pull-Down Assay 
SUMO-modified proteins were enriched with cobalt beads using a modification of a 




hepatocytes or Hepa1-6 cells were harvested using 1 mL of a strong denaturing lysis buffer 6M 
Guanidine-Cl (pH 8) according to specified experimental treatment.   The whole cell lysates 
were then applied to 30 μL of cobalt beads and incubated on a rotor at room temperature for two 
hours with shaking.  The gathered proteins were collected via centrifugation and washed twice 
with lysis buffer, three times with 8M Urea buffer (pH 6.5), and once with 1 x PBS.  Proteins 
were removed from the beads using 30 μL of 2 x Laemmli buffer and heated at 95 °C for 10 
minutes for subsequent western blot analysis. 
3.2.6 Fluorescence Microscopy 
Primary cultured mouse hepatocytes were transfected using Lipofecamine 2000 
(Invitrogen) and maintained in William’s E Media prior to image analysis.  Twenty-four hours 
post-transfection, hepatocytes were washed once with 1x PBS and subsequently stained with 
Hoechst 33432 for an additional 30 minutes.  To visualize, mouse hepatocytes were washed three 
times with 1x PBS and then maintained in Opti-MEM® I Reduced Serum Media during 
fluorescence protein image analysis.  Fluorescent proteins were imaged with a 30x air objective, 
and excited at either 400 nm (GFP) or 561 nm (RFP).  The nuclei were visualized using Hoechst 
33432 staining under ultraviolet light. 
3.2.7 Luciferase Reporter Gene Assay 
CV-1 cells were seeded at 1 x 104 cells per well (n=8) in 96-well plate and transfected 
using lipofectamine 2000.  Twenty-four hours post-transfection, cells were treated with either 10 
μM rifampicin (Rif), 0.5 μM trichostatin A (TSA), or both for an additional 24 hours. Cells were 
lysed using standard conditions at 32 μL per well of lysis buffer (100 mM KPO4, pH 7.8; 0.2% 
Triton X-100; 1 mM DTT) and subjected to luciferase activity analysis (12 μL) using a standard 




activity of β-galactosidase (20 μL).  Fold change among experimental groups were normalized to 
control group with relative luciferase units/ β-galactosidase readouts. 
3.2.8 Western Blot Analysis 
Western blot analysis was conducted as described previously (Xu et al., 2009).  
Purchased antibodies include the mouse monoclonal anti-PXR antibody (H-11, Santa Cruz), 
rabbit monoclonal anti-SUMO1 (C9H1, Cell Signaling) and anti-SUMO2/3 antibodies (18H8, 
Cell Signaling).  The mouse monoclonal anti-acetylated lysine antibody cocktail consisted of 
Cat# 15G10 from Novus Biologicals, Cat# AKL5C1 from Santa Cruz, Cat # Ac-K-103 from Cell 
Signaling, and Cat # 1C6 from Thermo Scientific. 
3.2.9 Liquid Chromatography-Tandem Mass Spectrometry Analysis 
The LC-MS/MS analysis for identification of PXR post-translational modification was 
performed as described previously (Cui et al., 2015). 
3.2.10 Statistical Analysis 
The statistical analysis was executed wherever required.  Statistical differences among 
one experimental group were determined using a one-way ANOVA followed by the Duncan’s 
multiple range post hoc test.  Moreover, statistical differences between experimental groups were 
determined using the Student’s t test. 
 
3.3 RESULTS 
3.3.1 The Interface between PXR Acetylation and SUMOylation. 
A study involving the farnesoid X receptor, a close relative of PXR, revealed the 
existence of a SUMO-acetyl ‘switch’ [20].  PXR has previously been identified as a likely 




Furthermore, a recent study indicates that PXR physically associates with the lysine/histone de-
acetylating enzyme HDAC3 in cell line-based assays, and it has been suggested that this enzyme 
can de-acetylate PXR [17].  In vivo, HDAC3 forms an obligate and stable complex with the 
well-known nuclear receptor co-repressor protein SMRT, and the SMRT-HDAC3 co-repressor 
complex exhibits strong lysine de-acetylase activity [28, 29].  An additional study indicates that 
the SMRT protein is the preferred co-repressor protein-partner of PXR [23].  Therefore, we 
sought to determine the extent to which potential de-acetylation of PXR by HDAC3-SMRT co-
repressor complex affects the SUMOylation level of PXR in cells.  The murine hepatoma cell 
line, Hepa1-6, can support high levels of PXR SUMO-modification [11].  Cultures were 
therefore transfected with expression plasmids encoding PXR, (His)6-SUMO3, the SUMO-E3 
ligase enzyme- PIAS1, HDAC3, and SMRT as indicated (Figure 3-1A).  Forty-eight hours post-
transfection, total SUMOylated proteins were gathered using strong denaturing conditions in an 
immobilized metal affinity pull-down assay [25].  The level of SUMOylated PXR was 
determined using western blotting analysis.  Forced over-expression of the HDAC3-SMRT 
lysine de-acetylase enzyme complex strongly reduced the overall SUMOylation level of PXR.   
To investigate whether increased acetylation of PXR alters its SUMOylation status we 
used TSA, a pharmacological inhibitor of the class I and II mammalian HDAC enzymes.  
Cultures of Hepa1-6 cells were co-transduced with adenoviral vectors encoding Ad-(His)6-PXR, 
Ad-(His)6-SUMO3, and Ad-PIAS1 (Figure 3-1B). Twenty-four hours post-transduction, cells 
were treated with vehicle (0.1% DMSO), 10 μM Rif, or 0.5 μM TSA for an additional 24 hours.  
SUMO-modified PXR proteins were enriched and the level of SUMO-modified PXR protein was 
determined using western blotting.  Inhibition of lysine de-acetylase activity with TSA promoted 




exhibited comparatively low levels of SUMO-modified PXR.  Taken together, the data in Figure 
3-1 suggests that acetylation and SUMOylation interface with each other at the level of the PXR 
protein and that acetylation of PXR likely promotes its subsequent SUMOylation in a 













Figure 3-1. The Interface between Acetylation and SUMOylation of PXR.  (A) Hepa1-6 
cells were transfected with the indicated plasmid-based expression vectors.  Cell lysates were 
produced using strong denaturing conditions to inhibit de-SUMOylation enzymes.  SUMOylated 
proteins were enriched using cobalt beads and were washed sequentially using both guanidine-
HCl and urea-based wash buffers.  Proteins were eluted using 2X-Laemmli buffer and were then 
resolved using 10% SDS-PAGE.  Western blot analysis was performed with an anti-PXR 
antibody that detects all modified forms of the protein (Santa Cruz, H-11 monoclonal Ab).  (B) 
Hepa1-6 cells were transduced with the indicated adenoviral expression vectors.  Twenty-four hr 
post-transduction, cells were treated with vehicle (0.1% DMSO) rifampicin (Rif, 10 μM) or 
Trichostatin A (TSA, 0.5 μM) for an additional eighteen hr.  SUMOylated proteins were 






3.3.2 Acetylation of PXR is altered during the Trans-activation Process in Hepatocytes.   
To examine the extent to which PXR acetylation status is altered in liver in response to 
ligand activation, we transduced hepatocytes isolated from wild type C57BL/6 mice with an 
adenoviral expression vector encoding a (His)6-tagged form of human PXR [Ad-(His)6-PXR].  
Twenty-four hours post-transduction, hepatocytes were treated with vehicle (0.1% DMSO), 10 
μM Rif, 0.5 μM TSA, or were co-treated with Rif and TSA together for an additional 24 hours.  
Acetylated proteins were immuno-purified from the respective cell extracts using a cocktail 
consisting of four commercially available anti-acetylated lysine monoclonal antibodies as 
described in Materials and Methods.  A non-immune mouse IgG antibody was used as a negative 
control.  Acetylated human PXR protein was detected in the acetylated lysine-enriched protein 
extracts by western blot analysis (Figure 3-2A).  Note the slight decrease in electrophoretic 
mobility that is typical of acetylated nuclear receptor proteins.  Treatment with TSA produced a 
significant increase in the level of PXR acetylation.  In contrast, ligand activation of PXR by Rif 
tempered the TSA-induced acetylation of PXR when compared with the vehicle treated cells 
(Figure 3-2B).  These results reveal that PXR is the molecular target of the acetylation signaling 
pathway in hepatocytes, and suggest that PXR trans-activation capacity is inversely correlated 









Figure 3-2. Acetylation of PXR is Altered during Trans-activation by Ligand.  (A) 
Primary hepatocytes isolated from wild type C57BL/6 mice were isolated and transduced with an 
adenoviral expression vector encoding a FLAG-tagged form of human PXR (Left Panel). Total 
acetylated proteins were immunoprecipitated from cell extracts using a cocktail of four anti-
acetylated lysine monoclonal antibodies as described in Materials and Methods.  A non-immune 
antibody was also used as a negative control (IgG).  Acetylated PXR was identified by western 
blotting with anti-PXR polyclonal antibody.  (B) Western Blot images were quantitated by 
densitometric scanning of the X-ray films with the UVP Biodoc-It 220 image analysis system 
and 1D Gel Analysis Software.  The numbers represent the relative densitometric image intensity 
of acetylated PXR divided by the image intensity of input levels of PXR, where vehicle treated 
control group was set to equal 1.  Asterisks indicate a statistical difference from vehicle-treated 




3.3.3 The Trans-activation Capacity of PXR is modified by the Acetylation Signaling 
Pathway in Hepatocytes.   
We next sought to examine the functional consequence of increased acetylation upon 
drug-inducible PXR activity.  Primary hepatocytes isolated from wild type C57BL/6 mice were 
cultured overnight.  The cultures were then treated for 24 hours with either vehicle (0.1% 
DMSO), 10 μM, PCN, 0.5 μM TSA, or were co-treated with PCN and TSA.  Total RNA was 
isolated and the expression of the prototypical PXR-target gene Cyp3a11 was measured using 
real-time quantitative PCR analysis (Figure 3-3).  As expected, significant induction of Cyp3a11 
was observed following treatment with PCN.  Treatment with TSA by itself did not produce 
significant alterations in Cyp3a11 gene expression.  In contrast, the co-treatment of PCN 
together with TSA significantly diminished PCN-inducible Cyp3a11 gene expression levels 
when compared with the PCN alone treatment group.  These data indicate that the canonical 







Figure 3-3. PXR Trans-activation Capacity is the Molecular Target of Acetylation in 
Hepatocytes.  Primary hepatocytes isolated from C57BL/6 mice were cultured overnight.  
Following twenty-four hr treatment with pregnenolone 16α-carbonitrile (PCN, 10 μM), 
trichostatin A (TSA, 0.5 μM), or both together, total RNA was isolated and the relative 
expression level of the Cyp3a11 gene was determined.  Data are normalized to β-actin levels and 
are presented as fold induction.  Letters different from each other indicate a statistical difference 





3.3.4 Acetylation Affects the Sub-cellular Localization of PXR in Hepatocytes.   
Like other nuclear receptors, PXR can shuttle between the cytoplasmic and nuclear 
compartment to modulate its transcriptional activity in response to different cellular signaling 
pathways [30].  The translocation of PXR to the nucleus is thought to be tightly regulated by 
various PTMs [31].  We first determined whether the engineered fusion between the red 
fluorescent protein and PXR (RFP-PXR) is able to undergo SUMO-modification, and whether 
RFP-PXR SUMOylation is subject to regulation by the HDAC3-SMRT lysine de-acetylase co-
repressor complex.  Cultured hepatoma cells were transfected with expression vectors encoding 
RFP-PXR, (His)6-SUMO3, PIAS1, HDAC3, and SMRT as indicated (Figure 3-4A).  Forty-eight 
hours post-transfection, SUMOylated proteins were gathered and SUMOylated RFP-PXR 
proteins were detected by western blotting.  The RFP-PXR fusion protein indeed retained its 
ability to be targeted by SUMO, and like wild type PXR, the HDAC3-SMRT co-repressor de-
acetylation complex significantly inhibited SUMO-modification of RFP-PXR.   
We next sought to investigate the extent to which acetylation might alter the sub-cellular 
localization of PXR.  Primary hepatocytes were transfected with expression vectors that encode 
RFP-PXR and green fluorescent-tagged HDAC3 (HDAC3-GFP) proteins, respectively (Figure 
3-4B).  Twenty-four hours post-transfection, cultures were treated with vehicle (0.1% DMSO), 
10 μM Rif, 0.5 μM TSA, or both together for an additional 24 hours.  Fluorescence image 
analysis was performed as described in Materials and Methods.  Hoechst 33342 (3μM) was used 
to visualize the nucleus by staining for 30 minutes immediately prior to imaging.  Under vehicle-
treated conditions, PXR was distributed roughly equally between the nuclear periphery and 
cytoplasmic compartments, and also exhibited strong co-localization with HDAC3-GFP.  




produced much less co-localization with HDAC3-GFP, save for some low levels of punctate sub-
nuclear localization.  Treatment with produced a high level of RFP-PXR localization to the 
aforementioned punctate sub-nuclear architecture.  Interestingly, additional co-localization of 
RFP-PXR and HDAC3-GFP was observed at the cell periphery following TSA treatment.  Co-
treatment with Rif and TSA together produced broad and diffuse RFP-PXR fluorescence in the 
nucleus with a somewhat diminished presence of the punctate nuclear pattern.  In contrast to the 
Rif-treated hepatocytes, the co-treated cells exhibited a significant amount of PXR cytoplasmic 
co-localization with HDAC3-GFP.  These data suggest that acetylation of PXR can likely affect 













Figure 3-4. The HDAC3 Deacetylase Enzyme Affects PXR-SUMOylation and Co-
localizes with PXR in Hepatocytes.  (A) Hepa1-6 cells were transfected with the indicated 
plasmid expression vectors.  SUMOylated proteins were captured using cobalt beads and the 
extent of RFP-PXR modification was analyzed using western blotting with an anti-PXR 
antibody.  (B) Primary cultures of mouse hepatocytes were transfected with RFP-PXR and 
HDAC3-GFP.  Twenty-four hr post-transfection, hepatocytes were treated with rifampicin (10 
μM), trichostatin A (0.5 μM), or both for an additional 18 hr.  Fluorescent cells were imaged as 
described under Materials and Methods.  To facilitate the visualization of the nucleus Hoechst 





3.3.5 Acetylated PXR interacts with HDAC3-SMRT Co-repressor Complex.   
We next investigated the extent of PXR-HDAC3-SMRT protein-protein interactions 
using an immunoprecipitation approach.  Cultures of Hepa1-6 cells were transfected with 
expression vectors encoding PXR, FLAG-HDAC3, SMRT, SUMO3, and PIAS1 as indicated 
(Figure 3-5).  Twenty-four hours post-transfection, cells were treated with vehicle (0.1% 
DMSO), 10 μM Rif, 0.5 μM TSA, or both for an additional 24 hours.  Immunoprecipitation was 
performed using a monoclonal anti-FLAG antibody that recognizes FLAG-tagged HDAC3.  A 
non-immune mouse IgG antibody was used as negative control.  The ability of PXR to associate 
with HDAC3 was determined using western blot analysis.  The PXR protein interacts with 
HDAC3 in Hepa1-6 cell extracts (Lane 3), and over-expression of SMRT further enhanced this 
interaction (Lane 4).  Interestingly, forced over-expression of the SUMO signaling machinery 
abolished interaction between PXR and the HDAC3-SMRT de-acetylation co-repressor complex 
(Lanes 5-7).  In contrast, treatment of cells with TSA restored the interaction of PXR with the 
HDAC3-SMRT co-repressor complex (Lane 8).  As expected, the interaction between PXR and 
the HDAC3-SMRT was reduced by addition of Rif (Lane 9).  These data support the concept 
that acetylated PXR interacts with HDAC3-SMRT while SUMOylated PXR has a greatly 







Figure 3-5. Acetylated PXR Interacts with HDAC3-SMRT Corepressor Complex.  
Hepa1-6 cells were transfected with the indicated expression vectors.  Twenty-four hr post-
transfection, cells were treated with rifampicin (10 μM), trichostatin A, or both for an additional 
24 hr.  Cell extracts were subjected to immunoprecipitation with an antibody that recognizes 
FLAG-HDAC3 (α-FLAG). A non-immune antibody was also used as a negative control (IgG).  
Western blot analysis was conducted using an anti-PXR polyclonal antibody to detect interaction 
between HDAC3-SMRT corepressor protein complex and PXR. The asterisk (*) indicates a non-





3.3.6 Covalent Attachment of SUMO Represses Ligand-dependent Trans-activation 
Capacity.   
It is widely held that SUMOylation of transcriptional factors leads to transcriptional 
repression via alteration of sub-nuclear localization, or perhaps by increasing the interactions 
with transcription co-repressor proteins [32].  However, a recent publication indicates that PXR 
activity is increased following SUMO-modification [15].  We have previously found that co-
expression of the SUMO E3-ligase enzyme PIAS1 modestly increases drug-inducible Cyp3a11 
gene expression in hepatocytes [11].  However, in the same study we also found that PXR is 
required for PIAS1-dependent rifampicin-mediated suppression of pro-inflammatory cytokine 
gene expression.  One strategy utilized to determine whether SUMOylation suppresses trans-
activation capacity has been to utilize a gene fusion approach [33].  Thus, to more precisely 
determine how SUMO-modification of PXR affects its ability to activate gene expression we 
generated a series of expression vectors that encode a variety of linear PXR-SUMO fusion 
proteins as depicted in Figure 3-6A.  The relative protein expression level of the five forms of 
PXR was roughly equal as verified using antibodies that recognize PXR, SUMO1, and SUMO3 
in western blot analysis (Figure 3-6B).  We next examined the effect of covalent attachment of 
SUMO on regulating drug-inducible PXR-dependent trans-activation capacity using a reporter 
gene derived from the CYP3A4 promoter to drive luciferase activity (XREM-Luc ) in cell based 
assays [34].  Twenty-four hours post-transfection, CV-1 cells were treated with Rif for an 
additional 24 hours.  Treatment of cells expressing wid type PXR (construct number 1) with 
Rif increased reporter gene activity by approximately 50-fold.  To determine if covalently 
attaching additional protein sequences to the N-terminus or C-terminus of PXR had non-specific 




N-terminus and the triple FLAG-tag [(FLAG)3] to the C-terminus of PXR, respectively, as 
shown in construct number 2.  Cells expressing this form of PXR did not significantly alter its 
Rif-inducible trans-activation capacity.  In contrast, cells expressing either the PXR-SUMO1 
(construct number 3), the PXR-SUMO3 (construct number 4), or the SUMO3-PXR 
(construct number 5) exhibited significantly diminished Rif-inducible reporter gene activity 
(Figure 3-6C).  These data indicate that covalent attachment of SUMO to PXR, even in the 
absence of isopeptide linkage and irrespective of the location of SUMO at the N- or C-terminus, 















Figure 3-6. Linear SUMO-fusion Proteins are Deficient in Trans-activation Capacity.  
(A) A series of expression vectors were constructed (Left Panel) encoding various forms of PXR, 
with some fused to SUMO proteins, as described in Materials and Methods.  (B) Western blot 
analysis was performed using the indicated antibodies that recognize PXR, SUMO1, and 
SUMO3 using cell extracts from CV-1 cells that were transfected with the plasmid-based 
expression vectors as indicated.  (C) CV-1 cells were transfected with the XREM-Luc reporter 
gene together with the indicated construct.  The reporter gene alone was used as a negative 
control (Reporter Only).  Twenty-four hr post-transfection, cells were treated with either vehicle 
(0.1% DMSO) or rifampicin (Rif, 10 μM) for an additional 24 hours. Luciferase activity was 
normalized to β-galactosidase controls and data are presented as fold induction + SEM.  Letters 






3.3.7 SUMOylation of PXR is Dominant over HDAC3-mediated Inhibition of PXR 
Activity. 
Under normal conditions, the co-repressor protein SMRT is required for the lysine-
deacetylase activity of HDAC3 in vivo [28, 29].  The SMRT co-repressor also serves as a 
molecular scaffold for additional regulatory proteins to modulate metabolic and inflammatory 
processes in liver [35].  Using a multimerized PXR-response element driving the luciferase 
reporter gene [(ER6)3-Luc] we sought to determine the extent to which HDAC3-SMRT co-
repressor complex contributes to the repression of PXR trans-activation capacity following 
SUMO-modification.  We chose the multimerized PXR-response element reporter gene because 
it lacks the additional complex and over-lapping enhancer elements associated with the 
CYP3A4-derived XREM-Luc reporter gene [34], and it likely represents a more direct readout of 
PXR trans-activation capacity in cell line-based assays versus the XREM-Luc reporter gene.  
Treatment of cells with Rif that were transfected with either PXR alone, PXR together with 
HDAC3, or PXR together with HDAC3 and SMRT produced approximately 3-4-fold increase in 
reporter gene activity (Figure 3-7).  Treatment with TSA also produced very modest levels of 
reporter gene activity in these three experimental groups (3-4-fold induction).  In contrast, co-
treatment of PXR-transfected cells with Rif and TSA together produced an approximately 16-
fold increase in reporter gene activity.  The addition of HDAC3 dramatically increased reporter 
gene activity to approximately 36-fold, while the addition of SMRT significantly reduced the 
reporter gene activity to approximately 24-fold.  Similar experiments performed in the absence 
of PXR did not produce synergistic reporter gene activity in the absence of the receptor (data not 
shown).  These data confirm that HDAC3 and SMRT have a profound impact upon ligand-




co-repressor complex activity with TSA produces a synergistic activation of this PXR-dependent 
reporter gene.  When the same experimental groups were used in the presence of expression 
vectors encoding SUMO3 and PIAS1, the overall ligand-dependent synergistic trans-activation 
capacity produced by co-treatment with Rif and TSA was strongly diminished, independent of 
the presence of HDAC3 and SMRT.  These data indicate that SUMOylation likely represses 
PXR trans-activation capacity in a manner that is distinct from that mediated by the HDAC3-






Figure 3-7. SUMOylation of PXR Represses PXR Trans-activation. CV-1 cells were 
transfected with the (ER6)x3-Luc reporter gene together with the indicated expression vectors.  
Twenty-four hr post-transfection, cells were treated with either vehicle (Veh, 0.1% DMSO), 
rifampicin (Rif, 10 μM), trichostatin A (TSA, 0.5 μM), or both together for an additional twenty-
four hours. Luciferase activity was normalized to β-galactosidase controls and data are presented 
as fold induction above vehicle control + SEM.  Asterisks indicate statistically significant 





3.3.8 Ubiquitination of PXR on Lysine 109 in Hepatocytes is TSA-Dependent. 
Many laboratories have identified potential PTMs in PXR through an in vitro approach 
using either LC-MS/MS, or by using a biochemical approach with purified components [12, 13, 
17].  These experimental approaches are encumbered by the relative absence of meaningful 
biology when performed purely in vitro.  In an effort to identify a specific site of acetylation in 
vivo, we took advantage of our adenoviral system to express and purify the (His)6-tagged form of 
PXR from primary cultures of rat hepatocytes following treatment with either vehicle (0.1% 
DMSO) or TSA (0.5 μM).  Using this experimental approach we routinely achieve high 
expression and robust purification of the Ad-PXR protein from cultured hepatocytes as 
demonstrated using coomassie blue staining (Figure 3-8A).  Our overall coverage of the Ad-
PXR protein following digestion with trypsin using LC-MS/MS methods was approximately 
60%, to include fifteen out of twenty-eight total lysine residues contained within the human PXR 
protein.  We failed to detect acetylation on observable lysine residues following trypsin 
digestion.  However, we found that vehicle treated PXR is heavily multi-mono ubiquitinated on 
K109, K160, K170, K198, and K226 (Figure 3-8B-F).  Following treatment with TSA, both 
K160 and K170 were still heavily ubiquitinated.  In contrast, ubiquitin modification at K198 and 
K226 was absent.  Moreover, the PTM-status at the K109 position was ambiguous due to a lack 
of coverage in the spectra of this particular lysine residue within the TSA-treated experimental 
group.  The reason for a lack of coverage at K109 specifically in the TSA-treated group is 





























Figure 3-8. Identification of Ubiquitin-Modified Peptides of PXR Isolated from 
Hepatocytes using LC-MS/MS.  (A) Primary hepatocytes were isolated from a male 14 week 
old rat and were cultured overnight in ten separate 15 cM dishes.  The adenoviral expression 
vector encoding the six-histidine-tagged form of PXR [Ad-(His)6-PXR] was added to 
experimental groups 2 through 5 on the morning of day 2.  On day 3, cultures were treated with 
vehicle (Groups 2 and 3) or 0.5 M TSA (Groups 4 and 5) for an additional 24 hours.  
Following IMAC-enrichment under denaturing conditions (1 lane per 15 cM dish), the bands 
corresponding to PXR and Ub-PXR were excised and in-gel trypsin digestion was performed.   
(B-F) ESI-CID-MS/MS analysis of in-gel digested PXR resulted in a number of spectra that 
were assigned to tryptic peptides carrying covalently bound ubiquitin residues of Gly-Gly 
(ubiquitin di-glycine remnant post-trypsin digestion).   The tryptic peptides of ubiquitin-modified 
PXR were identified with a mass addition of 114 at the lysine residues K109, K160, K170, 
K198, and K226 based on the assignment of multiple product ions (y and b ions) as indicated in 






The notion that lysine-directed PTMs including SUMOylation, ubiquitination, and 
acetylation interact with each other within the context of a given transcriptional regulatory 
complex is gaining wide acceptance [8].  The class I lysine de-acetylase HDAC3 regulates 
metabolism through multiple signalling pathways in the liver, and liver-specific deletion of 
HDAC3 disrupts normal hepatic metabolic homeostasis [36]. A recent article focused on 
farnesoid x receptor acetylation postulates that targeting acetylation of this receptor and its 
transcriptional cofactors may provide a new molecular strategy for development of 
pharmacological agents to treat metabolic disorders [37].  An additional study from the same 
group indicates that a dysregulated SUMO-acetyl switch on farnesoid x receptor that occurs 
during morbid obesity may serve as a general mechanism for diminished anti-inflammatory 
response observed in these patients [20].  Moreover, this group has shown that acetylation of 
farnesoid x receptor is normally regulated by the acetyl transferase  E1A binding protein p300 
and the class III NAD-dependent deacetylase Sirtuin-1 [38].  Similarly, the de-acetylation of 
PXR has been previously suggested to be mediated by both Sirtuin-1 and a TSA-dependent 
lysine de-acetylase [26]. 
Previous studies conducted in our laboratory have revealed that SUMOylation of PXR 
alters its ubiquitination, and likely regulates two distinct facets of PXR biology.  The 
SUMOylation of PXR increases its stability, apparently through protection of this nuclear 
receptor from the proteasome-mediated degradation pathway [11].  Another likely function of 
SUMO-modified PXR is the active suppression of the expression of pro-inflammatory cytokines 
in hepatocytes as well as participation in the resolution of inflammation [27, 39].  While PXR 




of PXR acetylation in this process is not clear.  Two studies have independently detected 
acetylation of PXR by using either biochemical over-expression methods in cultured cell lines 
[26], or by using a western blotting approach in whole-cell protein extracts from rodent liver 
[20].  How acetylation of PXR potentially affects its SUMOylation or ubiquitination was not 
addressed in these studies.  However, it was suggested that in addition to Sirtuin 1, other as yet to 
be identified lysine de-acetylase enzymes likely play an important role in enhancing or assisting 
with de-acetylation upon PXR activation [26], and our current study suggests that HDAC3 is 
intimately involved in PXR de-acetylation. 
Taken together, the data obtained in our current study put forward a working model of the 
role of acetylation, SUMOylation, and ubiquitination in regulating PXR biology (Figure 9).  We 
favor the notion that acetylation and SUMOylation are mutually exclusive events, but that 
acetylation is likely a prerequisite for its subsequent SUMO-modification.  Moreover, it appears 
that ubiquitin migrates to various lysine residues within PXR, likely depending upon the 
repertoire of other PTMs that co-exist on the protein and its state of ligand activation.  The 
ligand-dependent ubiquitination of PXR likely promotes its degradation through the proteasome-
mediated pathway during the canonical response, in the absence of concurrent pathological 
conditions such as inflammatory-related disease states.  In the presence of a pathological 
stimulus, such as inflammation, the acetyl group is removed and a PXR-mediated gene activation 
program is supplanted by active repression of select PXR-target genes by SUMO-modified and 
stabilized PXR.  Our hypothesis agrees with the previous observation that poly-ubiquitination of 
transcription factors on a single lysine residue authorizes their trans-activation capacity by 
linking gene activation to their subsequent destruction [40].  Moreover, mono- or multi-mono-




through the formation of ubiquitin chains [41].  Our data show that PXR is heavily multi-mono-
ubiquitinated in a silent state, and that the formation of poly-ubiquitinated PXR at K160 and 
K170 is stimulated by a more heavily acetylated receptor.  We have previously shown that 
SUMOylation of PXR focuses the formation of K48-linked ubiquitin chains at K170 to support 
degradation of ligand-activated PXR [11]; and that this event is likely required in order for 
additional rounds of transcription to proceed [42].  It therefore appears that acetylation of PXR 
also affects its ubiquitin modification. 
It is worth noting that while acetyl-lysine modification of PXR was readily detected in 
this study using an immunological approach, we were not successful in identifying any 
acetylated lysine residues in PXR using mass spectrometry analysis.  This is likely due to the 
relatively low stoichiometry of the acetyl-modification [43], or perhaps due to the large size of 
the SUMO- and acetyl-modified target peptide(s), or the inherent limitations of the LC-MS/MS 
approach.  Further refinement of our experimental conditions through the use of proteases other 








Figure 3-9. Working model of the Role of the Acetyl-SUMO Switch in PXR Biology.  
Newly synthesized PXR protein is acetylated and poised on canonical PXR-target genes in a 
complex with the HDAC3-SMRT co-repressor multi-protein complex and is transcriptionally 
silent.  Ligand activation promotes hyper-acetylation of the genomic locus, likely through the 
action of canonical histone/lysine acetyltransferase enzymes belonging to the E1A binding 
protein p300/CREB-binding protein coactivator family.  Following one round of transcription the 
PXR-associated multi-protein complex is degraded by the 26S proteasome in an ubiquitin-
dependent manner, and the promoter is thus cleared and poised to receive another round of 
transcriptional machinery. In the presence of specific signals, such an inflammatory stress or 
potentially other extra-cellular stimuli, PXR is de-acetylated and the HDAC3-SMRT co-
repressor multi-protein complex is disassociated.  The resulting signal-dependent action of a 
SUMO E3 ligase enzyme, such as PIAS1, promotes PXR-SUMOylation to inhibit PXR-target 






In conclusion, the acetylation, SUMOylation, and ubiquitination of PXR interface with 
each other to alter PXR biolgical activity.   We show here that PXR is the molecular target of the 
acetylation signal transduction pathway and that the HDAC3-SMRT multi-protein corepressor 
complex is a key component of the PXR de-acetylation pathway.  The promotion of PXR 
acetylation enhances its SUMO-modification, while de-acetylation of PXR by HDAC3-SMRT 
tends to inhibit its SUMOylation in cell line-based assays.  Ligand-mediated activation with 
rifampicin fuels de-acetylation of PXR, while inhibition of HDAC3 activity using 
pharmacological methods mildly suppresses the PXR-mediated gene activation program in 
hepatocytes. Acetylated PXR interacts with HDAC3 and forced over-expression of SMRT 
further increases PXR-HDAC3 interactions.  The SUMOylation of PXR likely forms the 
molecular basis of PXR-mediated active gene repression during pathological disease states.  
However, further research in this area should determine the extent to which these and other 
signaling pathways contribute to this effect.  What is abundantly clear is that the regulation of 
PXR by various PTMs is highly interactive and in a state of constant fluidity.  Giving the fact 
that PXR is a pivatol regultor of drug metabolism and disposition and is heavily involved in the  
pathogenesis of important human diseases, unrevling the molecular and biochemical details of 
how PTMs determine PXR biology should remian an important thust of future research efforts.  
The studies presented here utilize cell line-based and biochemical methods as well as primary 
cultures of rodent hepatocytes; future experiments should include the use of transgenic mouse 
models.  Specifically, mouse models that express mutant forms of the PXR protein refractory to 
modification with SUMO and acetyl groups should greatly aid in furthering the knowledge base 
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Chapter 4: Identification and Mechanistic Analyses of PXR Phosphorylation 
 
ABSTRACT 
 The nuclear receptor Pregnane X Receptor (PXR, NR1I2) is a DNA-binding transcription 
factor that primarily regulates gene expression of enzymes involved in xenobiotic metabolism 
and transport in the liver and intestines.  Upon ligand binding, PXR undergoes a conformational 
change to dissociate from the corepressor protein complex and to simultaneously recruit the 
coactivator protein complex.  Many mechanistic investigations have revealed that post-
translational modifications (PTMs) play a critical role in modulating PXR biological activity.  In 
the current study, we report that phosphorylation regulates the circulation of coregulator protein 
complex at the level of PXR.  We detected PXR phosphorylation at T135 and S221 in primary 
hepatocytes using a novel LC-MS/MS-based proteomic approach.  To investigate the biological 
outcome of PXR phosphorylation at the identified sites, we constructed both phosphomimetic 
and phosphodeficient mutants of PXR.  Phosphorylation at either T135 or S221 suppresses the 
trans-activation capacity of PXR.  We next employed a mammalian two-hybrid system to 
examine whether phosphorylation affects the PXR-coregulator protein-protein interaction.  
Constitutive phosphorylation at either T135 or S221 inhibits PXR heterodimerization with 
retinoid x receptor alpha (RXRα).  Moreover, S221 phosphorylation dramatically induces PXR 
interaction with the nuclear receptor corepressor 1 (NCoR1) while suppressing its interaction 
with coactivator proteins including steroid receptor coactivator 1 (SRC1), glucocorticoid 
receptor-interacting protein 1 (GRIP1), and peroxisome proliferator-activated receptor (PPAR)-
binding protein (PBP).  Interestingly, T135 phosphorylation shows no effect on PXR-NCoR1 




and corepressor NCoR1 in a phosphorylation independent manner.  Furthermore, we 
demonstrate that neither T135 nor S221 phosphorylation affects the ubiquitination of PXR.  In 
conclusion, our results suggest site-specific phosphorylation determines the coordination of 
coregulator protein complexes at the level of PXR.  
 
4.1 INTRODUCTION 
Pregnane X Receptor (PXR, NR1I2) belongs to the nuclear receptor superfamily and is 
enriched in liver and intestine.  The nuclear receptor family members are evolutionarily 
conserved transcription factors that share a similar functional structure comprised of an N-
terminal DNA-binding domain (DBD), a C-terminal ligand-binding domain (LBD) and a flexible 
hinge region between DBD and LBD.  Unlike other classic nuclear receptors, PXR LBD 
possesses a large volume and flexible binding cavity that enables the accommodation of a broad 
spectrum of compounds to trigger PXR transcriptional activity.  Such compounds known as PXR 
ligands are comprised of steroid hormones, bile acids, environmental toxins, and most xenobiotic 
chemicals.  In response to ligand activation, PXR attaches to a DNA promoter region to facilitate 
the activation of genes involved in the regulation of drug metabolism and efflux.  The 
prototypical target genes of PXR include Cytochrome P450 family 3 subfamily A member 4 
(CYP3A4) and multi-drug resistance gene 1 (MDR1).  Studies have shown that CYP3A4 is 
responsible for metabolizing more than 50% of prescribed drugs for humans(1-3), while MDR1, 
encoding p-glycoprotein 1 (P-gp 1), serves as an ATP-dependent efflux pump for xenobiotic 
substances(4,5).  Accumulating evidence indicates that PXR plays a critical role in mediating 
adverse drug-drug interaction, drug toxicity, and drug resistance to cancer chemotherapy in 




evidence show that PXR serves as a negative regulator of the inflammatory response in the 
intestines and liver(12-14).  The clinical observation of patients suffering from inflammatory 
bowel disease (IBD) have impaired drug detoxification response suggests a mutual suppression 
between PXR and NF-κB.  PXR is implicated in numerous human diseases include chronic 
inflammatory liver disease, IBD, diabetes, and many cancer types(14-21).  Therefore, targeting 
PXR has become an attractive therapeutic strategy to combat the chronic inflammatory diseases 
in the liver and intestines. 
PXR-mediated gene activation requires PXR coordination with coregulator proteins.  
PXR initially binds to the corepressor protein complex in the silent state.  Ligand-activated PXR 
protein undergoes a conformational change to dissociate from the corepressor protein complex 
followed by the recruitment of the coactivator protein complex to initiate a full activation of its 
target genes.  The major coactivator proteins involved in PXR-mediated trans-activation are 
ligand-dependent steroid receptor coactivator (SRC) family members SRC1, SRC2 (also known 
as glucocorticoid receptor-interacting protein 1, GRIP1), and transcription mediator PPAR-
interacting protein (PBP).  The nuclear corepressor protein 1 (NCoR1) and the silencing 
mediator for retinoid or thyroid hormone receptors (SMRT) are the two essential corepressor 
proteins for PXR-mediated gene silencing.  Understanding the precise circulation of the 
coregulator protein exchange in a temporal and spatial manner in response to xenobiotic stimulus 
and pathogenic challenges is critical for unraveling the mechanism of PXR-initiated drug-drug 
interaction and drug resistance. 
To the present day, the mechanism by which PXR suppresses the inflammatory response 
in the liver remains unclear.  Intensive research has been conducted to examine the involvement 




30).  Such PTMs include phosphorylation, acetylation, ubiquitination, and SUMOylation.  
Previous studies from our laboratory have demonstrated that cAMP-dependent protein kinase A 
(PKA) and protein kinase C (PKC)-mediated phosphorylation of PXR at predicted sites inhibits 
its trans-activation capacity through modulating PXR heterodimerization with RXRα and its 
association with coregulator proteins(22,31,32).  To date, the specific phosphorylation sites on 
PXR protein in primary hepatocytes remain unknown.  In the current study, we utilized a novel 
LC-MS/MS-based proteomic approach established by our laboratory to identify the 
phosphorylation sites of PXR protein in primary mouse hepatocytes(29).  We identified that PXR 
is phosphorylated at Threonine 135 (T135) and Serine 221 (S221).  To examine the biological 
outcome of the site-specific phosphorylation of PXR, we constructed the phosphomimetic 
mutants T135D and S221D, and the phosphodeficient mutant T135A.  Our results reveal that 
phosphorylation of PXR at both identified sites indeed impairs PXR-mediated transactivity.  The 
heterodimerization of PXR-RXRα, which is considered a critical step for gene activation, is also 
inhibited by PXR phosphorylation at both T135 and S221.  Additionally, S221 phosphorylation 
results in a decreased association with all three of the tested coactivator proteins and a significant 
induction regarding association with corepressor proteins NCoR1 and SMRT.  However, T135 
phosphorylation results in reduced association with coactivator GRIP1 and corepressor NCoR1.  
In summary, we identified novel phosphorylation sites of PXR in primary cultures of mouse 
hepatocytes and our further investigation suggested a site-specific phosphorylation event that 
inhibits PXR transactivation capacity through governing the coregulator protein circulation.  Our 
findings provide novel insights into the mechanism of phosphorylation in the regulation of PXR-
mediated gene repression in the liver. 




4.2.1 Chemicals and Plasmids. 
 Rifampicin and recombinant human TNFα were purchased from Sigma-Aldrich (557303) 
and Thermo Fisher (PHC3015), respectively.  All other reagents including culture medium for 
primary hepatocytes and mammalian cell lines were purchased from standard sources.  Human 
PXR wild type and mutant constructs were fused to the VP16 transcriptional activation domain 
by sub-cloning into the pVP16 expression vector (Clontech, Mountain View, CA) at EcoRI and 
BamHI restriction enzyme sites.  GAL4-SRC1, GAL4-GRIP1, GAL4-PBP, GAL4-NCoR1, and 
GAL4-SMRT expression vectors were generously given by Dr. Barry Forman (City of Hope, 
CA).  These expression vectors were constructed as previously described(33).  To generate the 
GAL4- RXRα expression vector, the cDNA-encoding human RXRα was inserted into the GLA4 
expression vector using BamHI and EcoRI restriction sites.  The pFR-LUC reporter gene, which 
is responsive to GAL4-fusion proteins, is commercially available (BD Biosciences, San Jose, 
CA).  The CYP3A4 reporter plasmid XREM-Luc was previously described(29).  The adenoviral 
expression construct encoding human PXR (Ad-(His)6-PXR) was described previously(29).  
4.2.2 Site-directed Mutagenesis. 
 The identified phosphorylation sites of PXR (T135, S221) were either mutated to an 
aspartic acid as a phosphomimetic mutation or mutated to an alanine as a phosphodeficient 
mutation. The mutant pCMV-FLAG-hPXR expression vectors were generated by site-directed 
mutagenesis with the use of the QuikChange Mutagenesis system (Stratagene, La Jolla, CA). 





Table 4-1. PCR primers used in site-direct mutagenesis 
Amino 
Acid 
Oligos for Mutagenesis to A Oligos for Mutagenesis to D 
T135 Left 
Primer 
































4.2.3 Isolation and Culturing of Primary Hepatocytes. 
 Primary hepatocytes were isolated from C57BL6 mice at the age of 6-10 weeks with a 
standard collagenase perfusion procedure as previously described(34).  Potential sex differences 
were evaluated and identical results were obtained from both male and female mice.  The 
representative results were acquired from male mice. 
4.2.4 Cell-Based Cobalt-bead Affinity Pull-Down Assay. 
 Post-translationally modified PXR was purified and enriched from either primary 
cultured mouse hepatocytes or hepatoma cell line Hepa1-6 cells as previously described(35). 
4.2.5 Western Blot Analysis. 
 Western blot analysis was performed as described previously(36).  Antibodies used 
include the mouse monoclonal anti-PXR antibody (Santa Cruz, H-11), anti-GLA4 (DNA Biding 
domain) monoclonal antibody (Upstate, 06-262), and an anti-actin monoclonal antibody (MP 
Biomedicals, 691002). 




 The LC-MS/MS analysis for identification of PXR phosphorylation was performed as 
described previously(29). 
4.2.7 Luciferase Reporter Gene Assay. 
 The luciferase reporter gene assay was performed as described previously(30).  
4.2.8 Statistical Analysis. 
 Data are presented as mean ± standard error of the mean (SEM) and analyzed with Prism 
7 software (GraphPad, La Jolla, CA).  All data were analyzed by one-way analysis of variance 
(ANOVA) or two-way ANOVA.  Post hoc tests were conducted using Dunnett’s or Turkey’s 
multiple comparison test.  To determine the differences between groups, a value of p<0.05 was 
considered statistically significant. 
 
4.3 RESULTS 
4.3.1 Identification of PXR Phosphorylation Sites Using LC-MS/MS in Primary 
Hepatocytes. 
 It is a well-established notion that site-specific phosphorylation of PXR contributes to the 
PXR-mediated gene activation through modulating a broad range of its biological activities 
including heterodimerization, DNA-binding, and coregulator interactions(22,31,32,37-39).  The 
reported kinases that facilitate such site-specific phosphorylation of PXR include 70-kDa 
ribosomal S6 kinase (p70 S6K)(32,39,40), PKA(22,32,37), PKC(31,32), cyclin-dependent kinase 
2 (CDK2)(24,41-43), and CDK5(44).  Many efforts have been made to detect the sites of PXR 
phosphorylation in vitro or in immortalized cell lines.  To achieve a more relevant biological 
meaning, we sought to identify the sites of PXR phosphorylation in primary cultured mouse 




to achieve a robust protein expression and a convenient protein purification in primary mouse 
hepatocytes.  In general, we transduced primary mouse hepatocytes with the adenoviral construct 
encoding human PXR (Ad-(His)6-PXR) for 48 hours followed by the treatment of either 0.1% 
DMSO (Veh) or 10μM rifampicin (Rif) for an additional 24 hours(29).  This approach has 
yielded abundant expression of human PXR protein in primary mouse hepatocytes as 
demonstrated using Coomassie blue staining (Figure 4-1A).  The corresponding western blot 
indicates the positions of immunoreactive PXR proteins using an anti-PXR monoclonal antibody.  
The overall coverage of the IMAC-enriched tryptic peptides of Ad-(His)6-PXR in LC-MS/MS 
analysis is approximately 60%.  We have identified two phosphorylation sites of human PXR 
protein, which are threonine 135 (T135) and serine 221 (S221) (Figure 4-2B-C).  The mass 
spectrometric parameters for the identification of PXR phosphorylation sites are listed in Table 
4-2.  It is worth noting that while T135 phosphorylation was only present in the lower band of 
PXR protein across treatment, S221 phosphorylation was detected in both bands of PXRs. 
 






























Figure 4-1. Identification of the Phosphorylation Sites of PXR using LC-MS/MS.  (A) 
Primary hepatocytes were isolated from C57Bl6 mice and were subsequently left either non-
transduced or transduced as indicated for 48 hours.  Hepatocytes were treated with 0.1% DMSO 
or 10μM rifampicin 24 hours prior to harvest.  Hepatocytes were lysed in a potent denaturing 
buffer as described in Materials and Methods. Cell lysates were subjected to enrichment and 
purification using cobalt-bead affinity pull-down assay.  Captured unmodified and post-
translational modified PXR protein were eluted using the 2X-Laemmli buffer and resolved in 
10% SDS-PAGE.  Western blot analysis was performed using a monoclonal anti-PXR antibody 
(Santa Cruz, H-11, sc-48340) that detects all modified forms of PXR protein. Arrow (←) 
represents detected phosphorylated PXR protein.  An identical gel has proceeded to Coomassie 
blue staining.  (B) Threonine 135 (T135) phosphorylation on human PXR was identified 
according to the assignment of multiple product ions (b and y ions) in the MS2 scan of the 
precursor ion at m/z 897.44 to the PXR tryptic peptide sequence, with a mass addition of 80 at 
the threonine residue (phosphate group).  (C) Serine 221 (S221) phosphorylation on human PXR 
was identified according to the assignment of multiple product ions (b and y ions) in the MS2 
scan of the precursor ion at m/z 972.42 to the PXR tryptic peptide sequence, with a mass 




4.3.2 Constitutive Phosphorylation Inhibits the Trans-activation Capacity of PXR. 
 To examine the biological outcome of PXR phosphorylation at identified sites, we 
conducted site-direct mutagenesis to construct PXR phosphomimetic mutants T135D, S221D, 
and phosphodeficient mutant T135A in a pCMV-FLAG expression vector.  Unfortunately, we 
were unable to generate the phosphodeficient mutation at S221 due to a technical difficulty to 
modify the guanine-enriched region on DNA.  We first sought to determine whether 
phosphorylation at indicted site alters PXR basal or ligand-inducible transcriptional activity 
using a cell line-based reporter gene assay.  An expression vector encoding wild type or mutant 
PXR was co-transfected with the PXR-dependent CYP3A4 reporter gene XREM-Luc.  Twenty-
four hours post-transfection, cells were treated with either vehicle (0.1% DMSO) or Rifampicin 
(10 μM) for an additional 24 hours.  The transcription activities of XREM-Luc were examined 
using luciferase assay.  Fold induction of each experimental group was compared to the vehicle-
treated wild type PXR group.  Both of the T135D and the S221D mutation on PXR significantly 
impair the ligand-mediated transcriptional activation (p<0.0001, p<0.0001, respectively).  These 
results are along in line with previous findings that PXR phosphorylation leads mostly to a 







Figure 4-2. Constitutive Phosphorylation Inhibits the Trans-activation Capacity of PXR.  
CV-1 cells were transfected with a CYP3A4-derived reporter gene XREM-Luc and expression 
vector encoding FLAG tagged-PXR or its mutant as indicated.  Twenty-four hours post-
transfection, cells were treated with 0.1% DMSO or 10μM rifampicin for an additional 24 hours.  
Luciferase activity was normalized to β-gal readouts.  Data is presented as fold induction ± SEM.  
Two-way ANOVA shows a significant effect of the T135A mutation {F (1, 12)=12.35, p< 0.01}, 
a significant effect of ligand-treatment {F (1, 12)=1248, p<0.0001}, and a significant interaction 
between ligand-treatment and phosphor-deficient mutation on PXR transactivation capacity {F 
(1, 12)=11.26. p< 0.005}.  Tukey’s multiple comparison test indicate n.s., n=4 compared with 
vehicle-treated WT-PXR group; ##, p<0.001, n=4 compared with rifampicin-treated WT-PXR 
group.  Two-way ANOVA shows a significant effect of the T135D mutation {F (1, 12)=7.265, 
p< 0.05}, a significant effect of ligand-treatment {F (1, 12)=1508, p<0.0001}, and a significant 
interaction between ligand-treatment and phosphor-mimetic mutation on PXR transactivation 
capacity {F (1, 12)=5.425, p<0.05}.  Tukey’s multiple comparison test indicate n.s., n=4 
compared with vehicle-treated WT-PXR group; #, p<0.05, n=4 compared with rifampicin-treated 
WT-PXR group.  Two-way ANOVA shows a significant effect of the S221D mutation {F (1, 
12)=61, p< 0.0001}, a significant effect of ligand-treatment {F (1, 12)=1334, p<0.0001}, and a 
significant interaction between ligand-treatment and phosphor-mimetic mutation on PXR 
transactivation capacity {F (1, 12)=41.23, p<0.0001}.  Tukey’s multiple comparison test indicate 
n.s., n=4 compared with vehicle-treated WT-PXR group; ####, p<0.0001, n=4 compared with 




4.3.3 Validation of the Mammalian-Two-Hybrid System. 
 PXR-mediated transcriptional events require the recruitment of a variety of positive and 
negative regulatory proteins, namely coactivator proteins and corepressor proteins. The potential 
mechanism that controls the circulation of the coregulator protein complex at the level of PXR 
has been hypothesized and proven to be post-translational modifications.  As the most studied 
post-translational modification of PXR, phosphorylation is considered as a negative regulator of 
PXR-mediated transcription activation.  Several lines of evidence suggest that phosphorylation at 
certain sites ameliorates PXR heterodimerization with RXRα(23,32).  However, whether 
phosphorylation contributes to the coregulator exchange on PXR is poorly studied.  Therefore, 
we sought to utilize a mammalian two-hybrid system to assess the effect of site-specific 
phosphorylation on PXR-coregulator protein-protein interaction.  We first constructed fusion 
genes by sub-cloning the PXR mutants into a VP16 vector.  All of the VP16-PXR expression 
vectors are expressed in CV-1 cells as the immunoreactivity was detected using a monoclonal 
anti-PXR antibody (Figure 4-3A).  Next, a similar experiment was accomplished for the 
validation of expression vectors encoding GAL4-fused coregulator proteins.  The protein 
expression levels were evaluated by western blot analysis using a monoclonal anti-GAL4-DBD 
antibody (Figure 4-3B).  At last, we conducted mammalian two-hybrid assay to examine the 
capability of VP16-PXR to interact with its dimerization partner RXRα, the coactivator proteins 
SRC1, GRIP1, PBP, and the corepressor proteins NCoR1 and SMRT.  CV-1 cells were co-
transfected with a GAL4-dependent reporter gene pFR-Luc, the expression vector encoding 
VP16-PXR protein, together with GAL4-coregulator fusion proteins as indicated.  Twenty-four 
hours post-transfection, cells were treated either with 0.1% DMSO (Vehicle) or with the ligand 




hours post-transfection.  The VP16-PXR fusion protein efficiently interacts with all tested 
coregulator proteins and its heterodimer partner RXRα.  In addition, ligand activation results in a 
decreased heterodimerization of PXR-RXRα (Figure 4-3C).  As expected, ligand activation 
induces the interaction between PXR and coactivator proteins including SRC1, GRIP1, and PBP, 
while the interactions between PXR and co-repressor proteins namely NCoR1 and SMRT are 











Figure 4-3. Validation of the Mammalian Two-Hybrid System.  (A-B) Indicated 
expression vectors were transfected into CV-1 cells.  Forty-eight hours post-transfection, whole 
cell lysates were collected.  (A) Expression constructs that encoding PXR proteins were 
subjected to 10% SDS-PAGE and subsequent western blot analysis using a monoclonal anti-
PXR antibody (Santa Cruz, H-11, sc-48340).  The arrows () indicate detected PXR proteins.  
The expression vector encoding pSG5-PXR protein (positive control) is approximately 52kDa in 
size (lower arrow).  The expression vectors encoding VP16-PXR proteins are approximately 
100kDa in size (upper arrow).  (B) Expression vectors encoding GAL4-coregulator proteins were 
subjected to 4-20% gradient SDS-PAGE and subsequent western blot analysis using an anti-
GLA4 (DNA Binding domain) monoclonal antibody (Upstate, 06-262). (C) CV-1 cells were co-
transfected with a mammalian two-hybrid reporter gene pFR-Luc, expression vector encoding 
VP16-PXR, and the expression vectors encoding GAL4-RXRα, GAL4-SRC1, GAL4-GRIP1, 
GAL4-PBP, GLA4-NCoR1, or GAL4-SMRT as indicated.  Twenty-four hours post-transfection, 
cells were treated with 0.1% DMSO or 10μM rifampicin for an additional 24 hours.  Luciferase 





4.3.4 Phosphorylation Inhibits the PXR-RXRα Heterodimerization. 
 The heterodimerization of PXR and RXRα is the first wave of action for ligand-mediated 
transcriptional activation.  While sensing the ligand stimulation, PXR and RXRα form a 
heterodimer and subsequently attach to the promoter region to initiate gene activation.  A 
previous study in our laboratory demonstrated that phosphorylation at certain sites on PXR 
impairs the heterodimerization of PXR-RXRα(32).  Therefore, we sought to determine whether 
the T135 and S221 phosphorylation on PXR weakens its heterodimerization with RXRα.  CV-1 
cells were co-transfected with the reporter gene pFR-Luc, the expression vector encoding the 
GAL4-RXRα fusion protein, and the wild type or mutant form of VP16-PXR fusion construct.  
Twenty-four hours post-transfection, cells were treated with 0.1% DMSO (Vehicle) or 
Rifampicin (10μM) for an additional 24 hours.  The luciferase activity was measured to evaluate 
the interaction between PXR and RXRα.  Both T135D and S221D mutations interrupt the ability 
of PXR to dimerization with RXRα (Figure 4-4).  Moreover, the phosphor-deficient mutant 







Figure 4-4. Phosphorylation Inhibits the Heterodimerization of PXR-RXRα.  CV-1 cells 
were co-transfected with a mammalian two-hybrid reporter gene pFR-Luc, expression vector 
encoding GAL4-RXRα, and the expression vectors encoding VP16-PXR as indicated.  Twenty-
four hours post-transfection, cells were treated with 0.1% DMSO or 10μM rifampicin for an 
additional 24 hours.  Luciferase activity was normalized to β-gal readouts.  Data presentation is 
fold induction ± SEM.  Two-way ANOVA shows a significant effect of the T135A mutation {F 
(1, 12)=228.6, p< 0.0001}, a significant effect of ligand-treatment {F (1, 12)=367.1, p<0.0001}, 
and a significant interaction between ligand-treatment and phosphor-deficient mutation on PXR 
transactivation capacity {F (1, 12)=5.837, p<0.05}.  Tukey’s multiple comparison test indicate 
****, p<0.0001, n=4 compared with vehicle-treated WT-PXR group; ####, p<0.0001, n=4 
compared with rifampicin-treated WT-PXR group.  Two-way ANOVA shows a significant effect 
of the T135D mutation {F (1, 12)=16.61, p< 0.01}, a significant effect of ligand-treatment {F (1, 
12)=101.3, p<0.0001}, and no significant interaction between ligand-treatment and phosphor-
mimetic mutation on PXR transactivation capacity {F (1, 12)=0.5963, p=0.4549}.  Tukey’s 
multiple comparison test indicate *, p<0.05, n=4 compared with vehicle-treated WT-PXR group; 
n.s., n=4 compared with rifampicin-treated WT-PXR group.  Two-way ANOVA shows a 
significant effect of the S221D mutation {F (1, 12)=26.37, p< 0.0005}, a significant effect of 
ligand-treatment {F (1, 12)=74.67, p<0.0001}, and a significant interaction between ligand-
treatment and phosphor-mimetic mutation on PXR transactivation capacity {F (1, 12)=41.64, 
p<0.0001}.  Tukey’s multiple comparison test indicate ****, p<0.0001, n=4 compared with 




4.3.5 Site-Specific Phosphorylation Determines PXR Cooperation with Corepressor 
Proteins. 
 To decipher the mechanism regarding phosphorylation-mediated suppression on PXR 
trans-activation capacity, we attempted to evaluate whether phosphorylation at identified sites 
alters PXR cooperation with its corepressor proteins.  Standard mammalian two-hybrid assays 
were conducted and the luciferase activity was measured for quantitative analysis. 
Phosphodeficient mutation at T135 shows no effect on the PXR-NCoR1 protein-protein 
interaction, while the S221D significantly inducing PXR association with NCoR1 by 40 fold 
(p<0.0001) (Figure 4-5A).  It is interesting to note that the phosphomimetic mutant S221D 
exhibits an opposite effect on PXR-SMRT protein-protein interactions compared to wild type 
PXR.  The phosphomimetic mutant T135D significantly reduces PXR interaction with SMRT 
(p<0.0001) while S221D shows no effect on the PXR-SMRT protein-protein interaction (Figure 
4-5B).  Moreover, Ligand activation results in an induction of wild type PXR-SMRT protein-
protein interaction, whereas PXR S221 phosphorylation reduces this ligand-induced PXR-SMRT 
protein-protein interaction as shown in Figure 4-5B.  Interestingly, the PXR-SMRT protein-
protein interaction is significantly inhibited by the phosphodeficient mutation T135A (p < 
0.0001).  One possible theory regarding this phosphorylation-independent suppression is that the 













Figure 4-5. Phosphorylation Alters PXR Association with Different Corepressor 
Proteins.  CV-1 cells were co-transfected with a mammalian two-hybrid reporter gene pFR-Luc, 
expression vector encoding VP16-PXR, and the expression vectors encoding GAL4 fused genes 
as indicated.  Twenty-four hours post-transfection, cells were treated with 0.1% DMSO or 10μM 
rifampicin for an additional 24 hours.  Luciferase activity was normalized to β-gal readouts.  
Data presentation is fold induction ± SEM.  (A) Quantitative evaluation of the PXR-NCoR1 
interaction using mammalian two-hybrid assay.  Two-way ANOVA shows a significant effect of 
the T135A mutation {F (1, 12)=168.1, p< 0.0001}, a significant effect of ligand-treatment {F (1, 
12)=7344, p<0.0001}, and a significant interaction between ligand-treatment and phosphor-
deficient mutation on PXR transactivation capacity {F (1, 12)=35.73, p<0.0001}.  Tukey’s 
multiple comparison test indicate ****, p<0.0001, n=4 compared with vehicle-treated WT-PXR 
group; ##, p<0.01, n=4 compared with rifampicin-treated WT-PXR group.  Two-way ANOVA 
shows no significant effect of the T135D mutation {F (1, 12)=0.5267, p=0.4819}, a significant 
effect of ligand-treatment {F (1, 12)=935.2, p<0.0001}, and no significant interaction between 
ligand-treatment and phosphor-mimetic mutation on PXR transactivation capacity {F (1, 
12)=3.38, p=0.0909}.  Tukey’s multiple comparison test indicate n.s., n=4 compared with 
vehicle-treated WT-PXR group; n.s., n=4 compared with rifampicin-treated WT-PXR group.  
Two-way ANOVA shows a significant effect of the S221D mutation {F (1, 12)=321.5, p< 
0.0001}, a significant effect of ligand-treatment {F (1, 12)=832.1, p<0.0001}, and a significant 
interaction between ligand-treatment and phosphor-mimetic mutation on PXR transactivation 
capacity {F (1, 12)=277.1, p<0.0001}.  Tukey’s multiple comparison test indicate ****, 
p<0.0001, n=4 compared with vehicle-treated WT-PXR group; n.s., n=4 compared with 
rifampicin-treated WT-PXR group.  (B) Quantitative evaluation of the PXR-SMRT interaction 
using mammalian two-hybrid assay.  Two-way ANOVA shows a significant effect of the T135A 
mutation {F (1, 12)=331.4, p< 0.0001}, a significant effect of ligand-treatment {F (1, 12)=10.29, 
p<0.01}, and a significant interaction between ligand-treatment and phosphor-deficient mutation 
on PXR transactivation capacity {F (1, 12)=9.044, p<0.05}.  Tukey’s multiple comparison test 
indicate ****, p<0.0001, n=4 compared with vehicle-treated WT-PXR group; ####, p<0.0001, 
n=4 compared with rifampicin-treated WT-PXR group.  Two-way ANOVA shows a significant 
effect of the T135D mutation {F (1, 12)=459.5, p<0.0001}, a significant effect of ligand-
treatment {F (1, 12)=11.5, p<0.01}, and a significant interaction between ligand-treatment and 
phosphor-mimetic mutation on PXR transactivation capacity {F (1, 12)=8.286, p<0.05}.  
Tukey’s multiple comparison test indicate ****, p<0.0001, n=4 compared with vehicle-treated 
WT-PXR group; ####, p<0.0001, n=4 compared with rifampicin-treated WT-PXR group.  Two-
way ANOVA shows a significant effect of the S221D mutation {F (1, 12)=8.521, p< 0.05}, no 
significant effect of ligand-treatment {F (1, 12)=2.356, p=0.1508}, and a significant interaction 
between ligand-treatment and phosphor-mimetic mutation on PXR transactivation capacity {F 
(1, 12)=50.53, p<0.0001}.  Tukey’s multiple comparison test indicate n.s., n=4 compared with 






4.3.6 Phosphorylation Compromises PXR Association with Coactivator Proteins. 
 Gene repression is a spatial and temporal event that is precisely carried out by the 
circulation of coregulator proteins.  Opposite to ligand-mediated gene activation that is executed 
by the dissociation of corepressor protein complex along with the recruitment of coactivator 
protein complex, termination of gene expression commands the release of coactivator machinery 
accompanied by the physical interaction with corepressor protein complex.  Therefore, we 
examined the extent to which phosphorylation-inhibited PXR transcription activity is carried out 
by accelerated coactivator protein dissociation. Standard mammalian two-hybrid assays were 
conducted for quantitative evaluation of the protein-protein interactions.  Phosphomimetic 
mutant S221D significantly inhibits PXR interaction with coactivator proteins SRC1 (p<0.0001), 
GRIP1 (p<0.05), and PBP (p<0.0001) in the absence of ligand (Figure 4-6).  Furthermore, 
S221D decreases the ligand-induced PXR association with coactivator proteins SRC1 
(p<0.0001), GRIP1 (p<0.0001), and PBP (p<0.0001).  The phosphomimetic mutation at T135D 
hinders PXR ability to interact with coactivator protein SRC1 (p<0.01) and GRIP1 (p<0.05) in 
the presence of ligand.  This T135 phosphorylation-mediated suppression on the ligand-induced 
PXR-coactivator interaction can be abolished by the phosphodeficient mutation.  Notably, the 
constitutive phosphorylation at T135 was unable to interrupt the PXR association with the 














Figure 4-6. Phosphorylation Compromises PXR Association with Coactivator Proteins 
SRC1, GRIP1, and PBP.  CV-1 cells were co-transfected with a mammalian two-hybrid 
reporter gene pFR-Luc, expression vector encoding VP16-PXR, and the expression vectors 
encoding GAL4 fused genes as indicated.  Twenty-four hours post-transfection, cells were 
treated with 0.1% DMSO or 10μM rifampicin for an additional 24 hours.  Luciferase activity was 
normalized to β-gal readouts.  Data presentation is fold induction ± SEM.  (A) Quantitative 
evaluation of the PXR-SRC1 interaction using mammalian two-hybrid assay.  Two-way 
ANOVA shows a significant effect of the T135A mutation {F (1, 12)=14.02, p< 0.01}, a 
significant effect of ligand-treatment {F (1, 12)=23520, p<0.0001}, and a significant interaction 
between ligand-treatment and phosphor-deficient mutation on PXR transactivation capacity {F 
(1, 12)=143.4, p<0.0001}.  Tukey’s multiple comparison test indicate ****, p<0.0001, n=4 
compared with vehicle-treated WT-PXR group; ###, p<0.0005, n=4 compared with rifampicin-
treated WT-PXR group.  Two-way ANOVA shows a significant effect of the T135D mutation {F 
(1, 12)=138, p<0.0001}, a significant effect of ligand-treatment {F (1, 12)=25364, p<0.0001}, 
and a significant interaction between ligand-treatment and phosphor-mimetic mutation on PXR 
transactivation capacity {F (1, 12)=21.77, p<0.005}.  Tukey’s multiple comparison test indicate 
**, p<0.01, n=4 compared with vehicle-treated WT-PXR group; ####, p<0.0001, n=4 compared 
with rifampicin-treated WT-PXR group.  Two-way ANOVA shows a significant effect of the 
S221D mutation {F (1, 12)=7487, p< 0.0001}, a significant effect of ligand-treatment {F (1, 
12)=13695, p<0.0001}, and a significant interaction between ligand-treatment and phosphor-
mimetic mutation on PXR transactivation capacity {F (1, 12)=1402, p<0.0001}.  Tukey’s 
multiple comparison test indicate ****, p<0.0001, n=4 compared with vehicle-treated WT-PXR 




evaluation of the PXR-GRIP1 interaction using mammalian two-hybrid assay.  Two-way 
ANOVA shows a significant effect of the T135A mutation {F (1, 12)=51.61, p<0.0001}, a 
significant effect of ligand-treatment {F (1, 12)=1247, p<0.0001}, and a significant interaction 
between ligand-treatment and phosphor-deficient mutation on PXR transactivation capacity {F 
(1, 12)=39.33, p<0.0001}.  Tukey’s multiple comparison test indicate n.s., n=4 compared with 
vehicle-treated WT-PXR group; ####, p<0.0001, n=4 compared with rifampicin-treated WT-
PXR group.  Two-way ANOVA shows no significant effect of the T135D mutation {F (1, 
12)=3.356, p=0.0919}, a significant effect of ligand-treatment {F (1, 12)=1479, p<0.0001}, and 
a significant interaction between ligand-treatment and phosphor-mimetic mutation on PXR 
transactivation capacity {F (1, 12)=5.674, p<0.05}.  Tukey’s multiple comparison test indicate 
n.s., n=4 compared with vehicle-treated WT-PXR group; #, p<0.05, n=4 compared with 
rifampicin-treated WT-PXR group.  Two-way ANOVA shows a significant effect of the S221D 
mutation {F (1, 12)=75.94, p< 0.0001}, a significant effect of ligand-treatment {F (1, 12)=1191, 
p<0.0001}, and a significant interaction between ligand-treatment and phosphor-mimetic 
mutation on PXR transactivation capacity {F (1, 12)=16.78, p<0.01}.  Tukey’s multiple 
comparison test indicate *, p<0.05, n=4 compared with vehicle-treated WT-PXR group; ####, 
p<0.0001, n=4 compared with rifampicin-treated WT-PXR group.  (C) Quantitative evaluation 
of the PXR-PBP interaction using mammalian two-hybrid assay.  Two-way ANOVA shows no 
significant effect of the T135A mutation {F (1, 12)=1.6, p=0.0387}, a significant effect of 
ligand-treatment {F (1, 12)=426.3, p<0.0001}, and a significant interaction between ligand-
treatment and phosphor-deficient mutation on PXR transactivation capacity {F (1, 12)=5.386, 
p<0.05}.  Tukey’s multiple comparison test indicate n.s., n=4 compared with vehicle-treated 
WT-PXR group; n.s., n=4 compared with rifampicin-treated WT-PXR group.  Two-way 
ANOVA shows no significant effect of the T135D mutation {F (1, 12)=2.529, p=0.1377}, a 
significant effect of ligand-treatment {F (1, 12)=135, p<0.0001}, and no significant interaction 
between ligand-treatment and phosphor-mimetic mutation on PXR transactivation capacity {F 
(1, 12)=0.1968, p=0.6652}.  Two-way ANOVA shows a significant effect of the S221D 
mutation {F (1, 12)=105.2, p< 0.0001}, a significant effect of ligand-treatment {F (1, 12)=208.5, 
p<0.0001}, and a significant interaction between ligand-treatment and phosphor-mimetic 
mutation on PXR transactivation capacity {F (1, 12)=16.61, p<0.01}.  Tukey’s multiple 
comparison test indicate ****, p<0.05, n=4 compared with vehicle-treated WT-PXR group; 





4.3.7 The Effect of T135 and S221 Phosphorylation on the Ubiquitination of PXR. 
 In our previous studies, we have demonstrated that PXR protein is degraded through the 
ubiquitin-proteasomal pathway.  Moreover, SUMO1-modification inhibits the ubiquitin-
mediated proteasomal degradation of PXR.  These findings suggest that post-translational 
modifications crosstalk at the level of PXR to determine its biological fate at the cellular level.  
Therefore, we sought to determine whether the phosphorylation-mediated repression on the PXR 
transactivity is carried out by accelerated ubiquitination-mediated degradation.  We tested the 
ubiquitination status of these aforementioned PXR mutants in a mouse hepatoma cell line.  
Hepa1-6 cells were left non-transfected, or transfected with expression vector encoding (His)6-
tagged ubiquitin (His-Ub) and expression vector encoding wild type or phosphomimetic mutant 
PXR as indicated (Figure 4-7).  Forty-eight hours post-transfection, ubiquitinated PXR was 
enriched and purified using a Cobalt-bead based affinity pull down assay.  The immunoreactivity 
of modified PXR was detected using a monoclonal anti-PXR antibody.  Neither T135 







Figure 4-7. The Phosphomimetic Mutations Exhibit No Effect on Ubiquitination of PXR.  
Hepa1-6 cells were transfected with expression vectors as indicated.  Ubiquitinated proteins were 
enriched using a cobalt bead based-affinity pull down procedure.  Captured proteins were 
subjected to SDS-PAGE, and the blot was probed with a monoclonal anti-PXR antibody (Santa 
Cruz, H-11) for detecting the PXR immunoreactivity.  Arrow (←) indicates the primary form of 






 Utilizing LC-MS/MS-based proteomic approach is a trending strategy to monitor protein 
PTMs.  To overcome the mass spectrometry detection challenge due to the low stoichiometry of 
PTMs, we have developed an innovative adenoviral expression construct to achieve the high 
expression of PXR in primary hepatocytes.  This strategy allows us to detect PTMs of PXR in a 
biological environment, which is particularly beneficial for understanding the mechanism of 
PXR-mediated transcription events in the liver.  We have successfully applied this approach to 
identify various types of PTMs at the level of PXR using LC-MS/MS in our laboratory.  In the 
current study, we have identified two novel phosphorylation sites of PXR at T135 and S221.  
Structurally, these two phosphorylation sites show great potentials in regulating PXR 
transactivity in a site-specific fashion.  On the one hand, T135 is buried in the hinge region that 
connects DBD and LBD of PXR.  The hinge region controls the particular orientation of the 
DBD and LBD upon ligand binding which eventually leads to nuclear localization and 
activation(46,47).  Several lines of evidence suggested that phosphorylation at the hinge region 
of many nuclear receptors contributes to their heterodimerization and transactivity(48,49).  On 
the other hand, S221 locates within the LBD of PXR, which is considered a molecular switch by 
translating the ligand structure into the conformational change which transforms nuclear 
receptors into transcription activators or repressors(50).  Unlike the LBD of a canonical nuclear 
receptor, which is composed of ten α helices and three β strands and forms a three-layer 
sandwich, LBD of PXR has two additional β1 and β1’ strands, which are thought to adapt to bind 
a broad spectrum of ligands of PXR(51-53).  The location of S221 is in the additional β1’ strands 
of PXR LBD.  Therefore, phosphorylation at this particular serine may be involved in the 




 Further investigation employing the phosphomimetic and phosphodeficient mutants of 
PXR indicates PXR phosphorylation at both sites impairs its trans-activation capacity.  PXR-
mediated transcription activity involves a series of protein-protein interaction events.  Such 
protein-protein interaction events include the heterodimerization of PXR-RXRα and the 
circulation of coregulator proteins.  PXR heterodimerization with RXRα is considered the first 
step in response to ligand binding and is essential for subsequent gene activation.  The molecular 
basis for nuclear receptor-regulated transcription activation is ligand binding-triggered 
coregulator protein exchange.  We utilized mammalian two-hybrid assays to examine the 
outcome of phosphorylation as PXR-specific protein-protein interactions. Our results showed 
phosphorylation at both identified sites is capable of inhibiting PXR-mediated CYP3A4 reporter 
gene activation.  Regarding PXR association with coregulator proteins, S221 phosphorylation 
leads to a dissociation of tested coactivator proteins and increased interaction with the 
corepressor proteins NCoR1 and SMRT.  However, phosphorylation at T135 significantly 
interrupts the PXR-SMRT protein-protein interaction while showing no effect on PXR 
association with NCoR1.  Of note, our results show that phosphomimetic mutation at T135 
hampers the ability of ligand-activated PXR to interact with the coactivator SRC1 and GRIP1, as 
well as the corepressor SMRT.  Moreover, phosphorylation at T135 has no effect on the PXR 
interaction with PBP and NCoR1.  Collectively, these finding suggests T135 phosphorylation-
mediated inhibition of PXR transactivity may invloves alternative mechanism without the 
involvement of coregulator circulation. 
 It is now well accepted that phosphorylation suppresses PXR transactivity through 
interrupting its heterodimerization and interactions with coregulator proteins.  To date, kinases 




synthase kinase 3 (GSK3), and casein kinase II (CK2)(24,31,32,40,41,43).  In response to 
specific cellular signals, PXR phosphorylation inhibits its transcription activity through the 
action of reducing the capability to form a heterodimer with RXRα, disrupting the interaction 
between PXR and coactivator proteins, and affecting the translocation of PXR into the nucleus.  
In our current study, we have observed a consistent outcome of PXR phosphorylation at the 
newly identified site S221.  Using an “in silico” bioinformatic approach (GPS 3.0, 
http://gps.biocuckoo.org), the predicted kinase that catalyzes PXR phosphorylation at S221 is the 
mitogen-activated kinase (MAPK)-interacting serine/threonine-protein kinase MNK1/2.  MNK is 
an effector protein kinase downstream of MAPK signaling that directly regulates many cellular 
events including differentiation, apoptosis, and the immune response to cytokine stimulation.  
Therefore, PXR phosphorylation at S221 may be the key step in inflammation-mediated 
inhibition of drug metabolism. 
 Post-translational modifications often regulate the biology of nuclear receptors in a 
collaborative fashion.  Multiple individual studies have clearly observed that the crosstalk 
between PTMs at the level of PXR regulates many aspects of its biological activities.  Our 
previous study demonstrated that SUMOylation of PXR suppresses the inflammatory gene 
activation and subsequently promotes the recognition by ubiquitin for proteasomal 
degradation(29).  To examine the extent to which PXR phosphorylation-mediated trans-
repression involves the cooperation of other PTMs, we monitored the ubiquitination of PXR 
using a biochemical approach.  Phosphomimetic mutation at both identified sites does not affect 
the ubiquitination of PXR, which excludes the possibility of phosphorylation-stimulated protein 
degradation.  In conclusion, our results provide evidence that detecting the onset of PXR 




activity through modulating the coregulator circulations.  Though the specific kinase that 
catalyzes PXR phosphorylation at S221 remains unknown at the present stage, our findings may 
shed new light on developing novel therapeutic strategies to target PXR for the treatment of 
chronic inflammatory diseases in the liver and intestines. 
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Chapter 5: Conclusions and Future Outlook 
 
5.1 CONCLUSIONS AND CRITICAL ANALYSIS 
 In the past two decades, the physiological and pathophysiological roles of PXR in human 
have been intensively investigated.  The canonical physiology of PXR is to regulate the 
expression of drug metabolizing enzymes and transporters at the transcription level.  In this 
regard, PXR is defined as a master regulator of the hepatic detoxification pathway.  From the 
pathophysiological perspective, PXR-induced drug metabolizing enzymes could increase the 
incidence of adverse drug-drug interaction by accelerating drug turnover or antagonizing the co-
administrated drugs(1,2).  Constitutive activation of PXR results in accumulation of drug 
metabolites, which is considered a driving force of hepatic steatosis(3).  Moreover, PXR-induced 
MDR1 expression is the leading cause of drug resistance in numerous cancer types(4).  The other 
aspect of PXR physiology is to transrepress the inflammatory response specifically in the liver 
and intestines.  Multiple lines of evidence indicate PXR agonists significantly suppress the 
inflammatory response in mice and human, which suggest a potential application of the gut-
specific PXR agonist, antibiotic drug Rifaximin (trade name as Xifaxan), in treating the 
inflammation-related bowel disease (IBD) (5,6).  Despite the abundant evidence that indicates 
PXR governs the crosstalk between the xenobiotic response signaling and the inflammatory 
response signaling, the molecular mechanism regarding regulation of PXR is still ambiguous. 
 Post-translational modifications (PTMs) have emerged as a fundamental mechanism in 
the regulation of NRs in the past few years.  Previous studies in our lab have shown that PXR is 
a molecular target of phosphorylation, ubiquitination, and SUMOylation.  Ding and Lichti-




response(7,8).  Hu et.al have demonstrated that SUMOylation of PXR suppresses the 
inflammatory response(9).  Moreover, results generated from Dr. Mani’s group showed that PXR 
is acetylated in its basal repression state(10).  Based on all of these discoveries, we proposed a 
hypothesis that PTMs fine-tune the PXR-mediated trans-repression of the inflammatory response 
in the liver (Figure 1-2). 
 A working model in which SUMOylation cooperating with ubiquitination to regulate 
PXR biological activity in a context-specific fashion was first described in Chapter 2.  
SUMOylation is a recently well-accepted universal mechanism for NR-mediated trans-repression 
activity recently(11-17).  Our results showed that both a ligand (rifampicin) and an inflammatory 
stimulus (TNFα) promoted PXR SUMOylation in primary mouse hepatocytes.  We identified the 
E3 ligases (PIAS1 and PIASy) for PXR SUMOylation and SENPs (SENP2, 3 and 6) for PXR 
deSUMOylation.  PIAS1-mediated SUMOylation of PXR repressed TNFα-induced expression 
of inflammatory genes while further increased rifampicin-induced gene expression of Cyp3a11 
in primary mouse hepatocytes.  This context-specific difference lends confidence for future 
application of small molecule drugs that targeting PXR SUMOylation for the treatment of 
inflammation-related diseases in the liver and intestines.  Further investigations suggested that 
SUMO(1)ylation facilitates PXR-mediated trans-repression, whereas SUMO(3)ylation promotes 
the ubiquitination-initiated PXR degradation through proteasomes.  A growing body of evidence 
has revealed the existence of SUMO-targeted ubiquitin ligase (STUbL).  Ring finger protein 4 
(RNF4) is the typical STUbL enzyme that conserves the SUMO interacting motif (SIM).  This 
SIM on the RNF4 enzyme permits its preferential binding to the poly-SUMOylation chain and 
promotes the subsequent ubiquitination-mediated protein degradation(18).  It is well known that 




model, we suggest that STUbL initiates the ubiquitination of stress-induced PXR SUMOylation 
and thereby accelerates PXR protein turnover in response to xenobiotic or inflammatory stimuli.  
We have identified multiple ubiquitination sites on PXR protein using a proteomic approach.  
Unfortunately, we were unable to locate the site(s) of SUMOylation on PXR using the 
established proteomic approach due to the extremely low stoichiometry of SUMOylation.  We 
utilized an alternative site-directed mutagenesis approach to identify the SUMOylation sites of 
PXR.  Our results revealed that K108 is the primary site for both PXR SUMO(1)ylation and 
SUMO(3)ylation, and K128 is the second site for PXR SUMO(3)ylation.  Collectively, we 
demonstrated SUMOylation and ubiquitination coordinately regulate PXR biological function in 
the liver in response to xenobiotic or inflammatory stress. 
 Subsequently, the interface between SUMOylation and acetylation in the context of PXR 
biology was discussed in Chapter 3.  Acetylation contributes to the regulation of protein stability, 
functional activity, as well as capability to interact with other regulatory proteins(19).  
Lysine/histone acetyltransferase proteins (HATs) and lysine/histone deacetylase proteins 
(HDACs) coordinately regulate the protein acetylation.  The histone deacetylase (HDAC) 
proteins are known to target a wide variety of non-histone proteins that are involved in the 
regulation of cell proliferation and apoptosis.  Among all of the HDAC family members, 
HDAC3, in particular, regulates metabolism through many signaling pathways in the liver(20).  
Representative substrate proteins of HDACs are comprised of NRs, chaperone proteins, as well 
as cytoskeletal proteins(21).  In the past decade, inhibition of HDACs has been an attractive 
therapeutic strategy for various human diseases.  Therapeutic applications of HDAC inhibitors 
range from psychiatric disorders, neurodegenerative diseases, inflammatory diseases, to many 




SUMOylation is critical for the regulation of the substrate protein.  For instance, Blakeslee 
reported that inhibition of class I HDACs increases cardiac protein SUMOylation(22).  Kim 
reported that acetylation of FXR disrupts its SUMOylation while inducing the inflammatory 
response.  Thus we sought to examine the regulatory networking among acetylation, 
SUMOylation, and ubiquitination at the level of PXR in primary hepatocytes.  Our results 
showed that PXR is acetylated at the transcriptional silent state and ligand-activation decreases 
the acetylation of PXR.  Inhibition of class I/II HDACs by TSA treatment suppresses the ligand-
mediated activation of Cyp3a11 gene in mouse hepatocytes.  This finding indicates that 
acetylation inhibits the PXR-mediated transcriptional activation, which is in line with previous 
discovery(10).  Further investigations showed that HDAC3/SMRT corepressor protein complex 
diminished the SUMOylation of PXR while TSA treatment reversed such outcome.  
Furthermore, SUMOylation sufficiently disrupted the association of PXR and HDAC3/SMRT 
protein complex.  Taken together, our results suggest that SUMOylation and acetylation exerts a 
synergistic effect on PXR-mediated trans-repression.  These findings provide new insights on 
targeting HDACs in the treatment of inflammation-related liver diseases. 
 Finally, the site-specific phosphorylation in the regulation of PXR biology in the liver 
was discussed in Chapter 4.  Phosphorylation is often considered a regulatory event towards 
PXR, which suppresses the PXR-originated trans-activation through multiple actions.  
Phosphorylation affects the heterodimerization of PXR-RXRα, modulates the coregulator 
exchange, and alters the subcellular localization of PXR(7,8,23,24).  In the current study, we 
have identified two novel phosphorylation sites of PXR at threonine 135 (T135) and serine 221 
(S221), respectively.  Phosphorylation at either site suppresses the ligand-induced trans-




transcriptional repression on CYP3A4 reporter gene may through site-specific mechanisms.  
Precisely, S221 phosphorylation inhibits the ligand-induced PXR trans-activation capacity by 1) 
inhibiting the heterodimerization with RXR, 2) increasing the interaction with corepressor 
protein, and 3) decreasing the interaction with coactivator proteins.  However, T135 
phosphorylation-mediated trans-repression may involve additional mechanisms such as crosstalk 
with other PTMs at the level of PXR.  Yet the kinase that phosphorylates PXR at identified sites 
is still unknown at the current stage.  Reported kinases for PXR phosphorylation include 
cytokine-activated PKC, glycogen and lipid metabolism-activated PKA, and cell cycle regulator 
CDKs.  These serine/threonine protein kinases are commonly activated by cellular stress.  
Therefore, PXR phosphorylation is a potential mechanism to reduce cellular stress through 
balancing the activation of the xenobiotic response and the inhibition of inflammatory response.  
Future efforts should focus on discovering the protein kinase that phosphorylates PXR at T135 
and S221 for a better understanding of the physiological and pathophysiological functions of 
PXR phosphorylation. 
 In summary, PTMs are involved in the regulation of many aspects of PXR biology in the 
liver.  They coordinately interact with each other to fine-tune the PXR-mediated transcription 
events in a signal-specific manner.  A summary diagram is shown in Figure 5-1.  In the silent 
state, PXR is acetylated and associated with corepressor complex.  Upon ligand (rifampicin) 
binding, PXR is deacetylated and detached from the corepressor complex while recruiting the 
coactivator complex.  Liganded PXR forms a heterodimer with its partner RXRα and binds to the 
DNA response element to regulate the transcription activation of genes encoding drug-
metabolizing enzymes.  In response to inflammatory stimulus (TNFα), a portion of PXR protein 




particular scenario, SUMOylation disrupts PXR association to HDAC3/SMRT corepressor 
protein complex and dominantly suppresses the inflammatory gene expression.  Another portion 
of PXR protein is phosphorylated to suppress the expression of genes encoding drug-
metabolizing enzymes.  At the end of the PXR-mediated transcription events, SUMO(3)ylation 
and ubiquitination coordinately regulate the degradation of PXR.  Specifically, liganded PXR or 
SUMO(1)ylated PXR is first targeted by the SUMO(3)ylation.  The STUbL enzyme RNF4 
recognizes the poly- SUMO(3)ylation chain and accelerates the ubiquitination of PXR.  
Ubiquitin primarily forms a K48-linked poly-ubiquitination chain on PXR then escorts PXR to 
the proteasome for degradation.  This diagram suggests that the well-known PXR-mediated 
mutual repression between the xenobiotic response signaling and the inflammatory response 







Figure 5-1. Concluding diagram of PTMs in the regulation of PXR biology in the liver.  
(1) PXR is acetylated and associated with corepressor proteins in the silent state.  Upon ligand 
(rifampicin) binding, activated PXR forms a heterodimer with RXR to induce the expression of 
the cytochrome P450 genes.  This transcriptional activation is regulated by dissociation from 
corepressor protein complex and recruitment of coactivator protein complex.  (2) Inflammation 
stimulus TNFα promotes the SUMO(1)ylation of PXR to transrepress the NFκB-mediated 
activation of the inflammatory response.  (3) Both rifampicin and TNFα increase the 
SUMO(3)ylation of PXR. STUbL enzymes recognize the SUMO3-mediated poly-SUMOylation 
on PXR and accelerate the ubiquitination-mediated proteasomal degradation of PXR protein.  (4) 
Inflammation stimulus likely induces the phosphorylation of PXR at S221.  Phosphorylation 
suppresses the PXR-mediated transactivation of CYPs through disrupting PXR interacts with 
coactivators while enhancing PXR association with corepressors.  Moreover, phosphorylation 





5.2 FUTURE OUTLOOK 
5.2.1 Targeting PXR SUMOylation to Suppress Inflammation 
 Recently, targeting the SUMOylation signaling has been an attractive strategy for the 
treatment of many human diseases, which include cardiovascular diseases, neurodegenerative 
diseases, and cancer.  In the context of PXR, we showed that SUMO1-modification is the critical 
step for PXR to facilitate trans-repression on inflammatory genes.  Moreover, our data indicates 
that PIAS1-mediated SUMOylation of PXR suppresses the expression of inflammatory genes 
without affecting the expression of canonical PXR target genes.  Therefore, targeting the 
SUMOylation of PXR could selectively suppress inflammation while maintaining normal 
physiology in the regulation of xenobiotic response. Furthermore, we have determined that PXR 
is SUMOylated at lysine 108 (K108).  Future studies could focus on examining the therapeutic 
potential of manipulating PXR SUMOylation in the treatment of inflammation-related diseases.  
A gene knock-in mouse model that expresses the SUMO-deficient PXR (PXR-K108R) should be 
generated and employed for the phenotype characterization regarding PXR-mediated repression 
of inflammation.  The model of PXR-K108R knock-in mouse is expected to lose its ability to 
transrepress the inflammatory response in the liver.  The E3 ligases that promote PXR 
SUMOylation include PIAS1 and PIASy, whereas SENP2 possesses the most efficient 
deSUMOylation activity on PXR.  Small molecule compounds that specifically inhibit the 
SENP2 enzymatic activities, or promote PIAS1 enzymatic activities should be screened for 
decreasing PXR SUMOylation in the liver.  Finally, the ideal small-molecule drug should either 
selectively decrease the deSUMOylation of PXR or selectively increase the SUMOylation of 





5.2.2 Targeting the SUMOylation-Ubiquitination Circuitry to Conquer Drug Resistance 
in Chemotherapy 
 Our results revealed a novel SUMO(3)ylation-promoted ubiquitination in primary mouse 
hepatocytes.  MDR1-mediated drug resistance is primarily due to the chemotherapeutic agents-
caused constitutive activation of PXR in specific tissues.  Therefore, targeting the 
SUMO(3)ylation of PXR to accelerate its degradation could be a novel strategy to reduce 
MDR1-mediated drug resistance in chemotherapy.  Our data showed that SENP3 and SNEP6 
sufficiently remove the poly-SUMOylation chains that attached to PXR.  Inhibition of SENP3 
and SNEP6 by small molecule drugs is expected to retain the SUMOylation chain on PXR, 
which results in eventual ubiquitination-mediated proteasomal degradation of PXR.  An 
alternative approach to modulate PXR stability could be promoting the expression or enzymatic 
activity of RNF4.  While PXR activation increases the drug resistance in prostate cancer, it 
prevents the progression of breast cancer.  Therefore, inhibition of RNF4-mediated PXR 
degradation could exert beneficial effects in the treatment of breast cancer. 
5.2.3 Targeting PXR Phosphorylation To Enhance Xenobiotic Metabolism in 
Inflammation-Related Liver Diseases 
 In the United States, the incidence of the inflammation-related liver disease is 
dramatically growing in the recent years.  These inflammation-related liver diseases, include 
non-alcohol fatty liver disease, non-alcoholic steatohepatitis, and chronic hepatitis B/C infection, 
are considered the driving forces of hepatocellular carcinoma.  Accumulating evidence indicates 
PXR as the master regulator of hepatic detoxification pathway contributes to the pathogenesis of 
the inflammation-related liver diseases.  Our results demonstrate that site-specific 




impaired xenobiotic response increases the cytotoxicity, inhibition of PXR S221 phosphorylation 
should reduce the cytotoxicity in the inflamed liver by improving the hepatic detoxification 
pathway.  In this regard, small molecule inhibitors that selectively target the kinase, which 
phosphorylates PXR at S221, would be a novel therapeutic strategy for the inflammation-related 
liver diseases. 
5.2.4 Concluding Remarks 
 The physiological functions of PXR have been intensively studied in the past twenty 
years.  It is a well-accepted notion that PXR is not only a master regulator of the xenobiotic 
response but also a negative regulator of the inflammatory response in the liver and intestines.  
The mutual repression between the xenobiotic detoxification signaling and the inflammatory 
signaling in the liver is the foundation of this dissertation research.  The data presented here 
revealed potential molecular mechanisms regarding PXR-mediated regulation of both signaling 
pathways in the liver.  The knowledge we obtained from this study provides a new perspective to 
develop novel therapeutic strategies to target the PTMs at the level of PXR for the treatment of 
inflammation-related diseases in liver and intestines. 
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Appendix: Increased SUMO-Signaling Attenuates Interaction Between Heat 
Shock Protein 70 (HSP70) and Bcl2-Associated Athanogene 3 (BAG3) 
 
ABSTRACT 
 Covalent modification of protein substrates by the SUMO is an important regulator of 
pivotal biochemical processes.  Using novel expression tools in primary cultures of hepatocytes 
coupled with a mass spectrometry-based proteomic approach we identified the SUMOylation 
pattern of a heat-shock protein (HSP) 70-associated protein called Bcl2-associated athanogene 3 
(BAG3).  The BAG3 protein functions as a co-chaperone with HSP70 to regulate major 
physiological and pathophysiological processes.  Our data reveal for the first time that the BAG3 
is the molecular target of the SUMO-signaling pathway in hepatocytes, and identify enzymes 
capable of both SUMOylating and de-SUMOylating this key regulator of HSP70 biology.  Our 
data further reveal that one likely outcome of increased SUMO-signaling with respect to BAG3 
function is to attenuate its interaction with HSP70.  Collectively, these data provide a new 
understanding and innovative framework that may provide novel strategies to develop new drugs 




 The SUMO post-translational modification is known to regulate fundamental biological 
processes including DNA repair and cell division(1).  SUMOylation is a highly regulated three-
step enzymatic process that responds to cellular stimuli or pathogenic challenges, whereas de-




note, the SUMO-signaling pathway is tightly associated with carcinogenesis such as cell growth, 
differentiation, senescence, oxidative stress, and apoptosis.  In general, activation of the SUMO-
signaling pathway is thought of as a pro-survival signal that cells adopt under stress.  Another 
pro-survival signal used by cells is the heat shock response. 
 The BAG family of proteins performs diverse functions in normal cells and in cancerous 
cells in diverse tissue types. BAG family members are distinguished by an evolutionarily 
conserved region known as the BAG domain.  This approximately 45 amino acid domain is 
exclusively found in this family of key protein modulators of HSP70(3).  BAG proteins 
cooperate and interact with HSP70 and other molecular co-chaperones to mediate the proper 
folding of proteins, as well as the re-folding of certain protein aggregates.  The BAG family 
members also help in mediating the degradation of protein aggregates through either lysosomal- 
or proteasomal- degradation pathways.  The signal-dependent lysosomal-mediated degradation 
pathway process is called macroautophagy.  Entry into the macroautophagy pathway is largely 
mediated through the HSP70-BAG3 protein-protein interaction module.  This pathway is 
induced in numerous physiological conditions including the regulation of energy homeostasis, 
neuronal survival, and transcription.  The macroautophagy pathway also operates in many 
pathophysiological conditions including in the development of certain neurodegenerative 
diseases and in the development and progression of many types of cancer. 
 While enrichment strategies for SUMOylated peptides have been developed for 
immortalized cell lines, usually stably transfected HeLa cells(4,5); there has been no survey of 
the protein targets of SUMOylation in cultured primary cells.  This is primarily due to the lack of 
a facile method for readily detecting this post-translational modification in its target substrate 




SUMO(3)ylated peptides from complex cellular proteomes following enrichment from total cell 
extracts isolated from cultured primary cell types.  Our method utilizes two adenoviral 
expression vectors.  One vector drives the expression of the SUMO E3 ligase enzyme PIAS1 
(Ad-PIAS1), while the other vector drives the expression of a genetically modified form of 
SUMO3 we call Ad-SUMO3(Q87R). 
 Using primary cultures of hepatocytes and our adenoviral-based LC-MS/MS 
experimental approach, we identify the SUMOylation of a subset of biochemically linked 
SUMO-substrate proteins.  Five of the twelve potential SUMOylation substrate proteins 
identified in our screening function to coordinately regulate the macroautophagy pathway.  
Using cell-based and biochemical methods, we further characterize and validate the 
SUMOylation of the BAG3 co-chaperone protein in primary cultured hepatocytes and a 
hepatoma-derived cell line.  We define the specific enzymes involved in generating the 
SUMOylation pattern of BAG3, and provide a working hypothesis of the mechanistic outcome 
of SUMO-modified BAG3-HSP70 protein-protein interaction. 
 
MATERIALS AND METHODS 
 Chemicals and antibodies.  N-Ethylmaleimide was purchased from Sigma-Aldrich 
(E1271).  TALON® Metal Affinity Resin (Cobalt beads) was purchased from Clontech 
(635502).  The antibodies that used in this study are: monoclonal anti-Xpress antibody (Thermo 
Fisher Scientific, R910-25), polyclonal anti-BAG3 antibody (Abcam, 47124), polyclonal anti-
SUMO1 antibody (Cell signaling, C9H1), polyclonal anti-SUMO2/3 (Cell Signaling, 18H8), 
monoclonal anti-β-actin antibody (Chemicon, 1501), monoclonal anti-GFP antibody (Clontech, 




HRP (sc-2032), goat anti-mouse IgG-HRP (sc-2005), and goat anti-rabbit IgG-HRP (sc-2004) 
were all purchased from Santa Cruz. 
 Plasmids.  The expression vector encoding human BAG3 (pcDNA3-BAG3) was a 
generous gift from Dr. Michael Sherman(6).  To construct the FLAG-tagged human BAG3 
expression vector, the cDNA encoding human BAG3 was excised from the pcDNA3-BAG3 
expression vector using BamHI and XhoI restriction enzyme recognition sites and inserted into 
pCMV-Tag2B (Agilent) using BamHI and XhoI sites.  The RFP-BAG3 expression vector was 
constructed by using BamHI and XhoI sites to excise the cDNA encoding human BAG3 and 
inserted into pmCherry-C1 expression vector using BglII and SalI sites.  The expression vector 
encoding (His)6-tagged SUMO3 was a generous gift from Dr. Ronald T. Hay(7).  Expression 
vectors encoding PIAS proteins were kind gifts from Dr. Ke Shuai(8) and obtained from 
Addgene (plasmid #: FLAG-PIAS1, 15206; FLAG-PIASxα, 15209; FLAG-PIASxβ, 15210; 
FLAG-PIAS3, 15207; FLAG-PIASy, 15208).  The expression vectors encoding the SENPs and 
the catalytically deficient mutant SENP2 were kind gifts from Dr. Ed Yeh(9) and obtained from 
Addgene (plasmid #: FLAG-SENP1, 17357; FLAG-SENP2, 18047; FLAG-SEMP2m, 18713; 
RGS-SENP3, 18048; RGS-SENP5, 18053; FLAG-SENP6, 18065; 3xFLAG-SENP7, 42886).  
Expression vector encoding pEGFP-hsp70 was a kind gift from Dr. Lois Greene (Zeng et al., 
2004, PubMed 15367583) and obtained from Addgene (plasmid # 15215). 
 Isolation and culturing primary hepatocytes.  Primary hepatocytes were isolated from 
either C57Bl6 mouse (aged 6-10 weeks) or Sprague Dawley rats (purchased from Charles River, 
aged 6 weeks) following a standard collagenase perfusion protocol as described previously(10).  




detecting potential sex differences.  Identical results were obtained from both sexes.  The 
representative results were acquired from male mice/rats. 
 Liquid chromatography tandem mass spectrometry (LC-MS/MS) analysis.  LC-MS/MS 
analysis was carried out as described previously(11).  The modification of lysine by QQTGG 
(+454, this molecular weight was calculated based on the cyclization of N-terminal glutamine, Q 
to pyroE), a tryptic remnant of SUMO(Q87R) attachment to lysine, was included in the 
searching parameters. 
 Immunoprecipitation assay.  Generally, the immunoprecipitation assay was performed 
as previously described(10).  For detecting SUMOylated BAG3 in primary mouse hepatocytes, a 
condensed immunoprecipitation assay was utilized.  Briefly, primary culture of mouse 
hepatocytes were harvested in 1 mL of lysis buffer, which contains150 mM NaCl, 50 mM Tris-
Cl (pH 8.0), 1% Triton X-100, 20 mM NEM, and 1% Halt™ protease and phosphatase inhibitor 
cocktail (Thermo Scientific). Cells were disrupted through sonication and subsequently 
centrifuged at 18,000 ×g for 10 min to remove the insoluble substances. A fraction of the 
supernatant (5%) was saved as a loading control for Western blotting, while the rest of sample 
was subjected to pre-clearing with 5% protein A/G sepharose beads at 4 °C.  The pre-cleared cell 
lysates were separated from beads through centrifugation.  Subsequently, pre-cleared cell lysates 
were incubated with the mixture of 5 vol.% of protein A/G sepharose beads and 4 μg polyclonal 
anti-BAG3 antibody for immunoprecipitation of BAG3 protein for 4 hours at 4 °C with rotating. 
 Immobilized metal affinity chromatography (IMAC).  SUMO-modified ((His)6-tagged) 
proteins were enriched and purified with cobalt affinity beads as described previously(10). 





 Subcellular co-localization analysis.  The subcellular co-localization of BAG3 and 
HSP70 were detected using fluorescent microscopy.  Primary cultures of mouse hepatocytes 
were transfected using Lipofectamine 2000 (Invitrogen) and maintained in William’s E Media 
prior to image analysis. Twenty-four hours post-transfection, hepatocytes were washed once with 
1x PBS and then stained with Hoechst 33432 for an additional 30 minutes.  For fluorescent 
protein imaging, mouse hepatocytes were washed three times with 1x PBS and subsequently 
maintained in Opti-MEM® I Reduced Serum Media. Fluorescent proteins were imaged using an 
Olympus IX81 inverted epifluorescence microscope with 40x air objective, and excited at either 
485 nm (GFP) or 561 nm (RFP).  The co-localization of two proteins in fluorescent images was 
measured by using Slidebook 6 software, and Pearson’s co-efficient (r) was measured as 
described previously(12). 
 Statistical analysis.  The statistical analysis was performed wherever appropriate. 
Statistical differences between experimental groups were examined using paired two-sample 
Student’s t test. 
 
RESULTS 
Strategy for Identification of PIAS1-Inducible SUMO-Substrate Proteins.   
 The experimental strategy we developed for use in primary cultures is shown in Figure 
A1-A.  The addition of a hexa-histidine (His)6-tag followed by the Xpress epitope (Invitrogen) at 
the N-terminus of SUMO3 supports the convenient purification and detection of SUMO-
substrate proteins using an immobilized metal affinity chromatography (IMAC) strategy and 
Western blotting approach.  The substitution of the glutamine at position 87 in SUMO3 with an 




allowing for detection of branched SUMO-substrate peptides post-trypsin digestion by liquid 
chromatography tandem mass spectrometry (LC-MS/MS).  This modified form of SUMO2/3 has 
previously been shown to incorporate into endogenous protein substrates when expressed stably 
in HeLa cells similar to that observed with the wild type form of SUMO2/3(5).  The co-
transduction of an empirically defined mixture of these two adenoviral expression vectors 
facilitated the efficient SUMOylation of substrates by SUMO3(Q87R) in primary cultures of rat 













Figure A1. Validation of the Use of the Adenoviral-mediated Experimental Approach to 
Drive SUMOylation in Primary Hepatocytes.  (A) Scheme depicting the adenoviral expression 
constructs (inset) and the steps used (flow chart) to identify PIAS1-driven SUMO-substrate 
proteins in primary hepatocytes.  (B) Three fifteen centimeter plates per experimental group of 
primary hepatocytes were used to enrich total protein extracts using IMAC as described in 
Materials and Methods.  The three experimental groups were blank adenovirus (Ø), Ad-(His)6-
SUMO3(Q87)R (S3), and Ad-(His)6-SUMO3(Q87)R together with Ad-PIAS1 (S3 + P1).  
Following resolution of captured proteins using SDS-PAGE, three identical gels were applied to 
either silver-staining method (left panel) or Western blot analysis using antibodies that detect the 





IMAC Methods Capture Functionally Linked SUMO-Substrate Proteins. 
 Parallel mass spectrometry analysis of in-gel trypsin digests of protein isolates was 
performed following resolution of IMAC-captured proteins using conventional SDS-PAGE.  
Three experimental groups included in this analysis isolated from primary hepatocytes were (1) 
blank virus-transduced, (2) Ad-SUMO3(Q87R) (Ad-S3) transduced, and (3) Ad-PIAS1 (Ad-
P1)/Ad-S3 co-transduced cell extracts.  This analysis identified twelve proteins that were 
exclusive to the Ad-P1/Ad-S3 co-transduced samples and are listed in Table A1.  Five 
previously reported SUMO-substrate proteins were identified in our analysis including 
RanGap(13,14), the two histone proteins H2B and H4(15,16), the transcriptional intermediary 
factor 1-β(17), and importantly, the SUMO3 protein itself(12).  Additional enzymes involved in 
the SUMOylation pathway were identified including PIAS1 and the ubiquitin-like 1-activating 
enzyme E1B, also known as SAE2 or UBA2(18).  Several important heat shock proteins known 
to regulate the response to environmental stress including HSP105, HSP40, and HSP70 were 
also identified exclusively in our experimental group.  Two proteins that interface with the heat 
shock response to regulate the macroautophagy pathway were identified including BAG3, and 
sequestersome-1, also known as p62.  BAG3 is a well-known master regulator of HSP70 biology 














RanGap1 N.A. Yes Lys 526 
Histone H2B Lys 12 Yes N.A. 
Histone H4 N.A. Yes Lys 14 
Transcription intermediary 
factor 1 beta (TIF1β) N.A. Yes Lys 750, 779 
SUMO3 Lys 11 Yes Lys 11 
PIAS1 Lys 152, 315 No N.A. 
Uba2 N.A. No N.A. 
BAG3 N.A. No N.A. 
HSP70 N.A. No N.A. 
HSP105 N.A. No N.A. 
DnaJ (HSP40)  N.A. No N.A. 
Sequestosome1 (p62) N.A. No N.A. 
 
Table A1. Identification of PIAS1-inducible SUMO-substrate Proteins in Primary 
Hepatocytes.  IMAC was performed under strong denaturing conditions using primary rat 
hepatocytes as described in Materials and Methods.  Briefly, forty-eight hours prior to 
generating protein isolates, hepatocytes were transduced with either an empty adenovirus alone 
as a control group, or co-transduced with Ad-S3 and Ad-P1 as experimental group as shown in 
Figure A1.  The protein isolates were subsequently eluted from beads with SDS-sample buffer 
and were then resolved on a 10% SDS-PAGE gel.  In-gel digested tryptic peptides of a total of 
ten gel-slices ranging in size from 30 kDa to the top of the gel were subjected to LC-MS/MS 
analysis followed by a MASCOT database search to identify potential SUMO-substrate proteins.  
Reported here are the unambiguously identified proteins that appeared exclusively in the 
experimental group.  The white-shaded proteins represent previously identified SUMO-substrate 
protein.  The light orange-highlighted proteins including SUMO3, PIAS1, and Uba2 are the 
proteins involved in SUMOylation pathway.  The deep orange-highlighted proteins BAG3, 
HSP70, HSP105, HSP40, and p62 are all associated with the regulation of the heat shock 





The Endogenous BAG3 Protein is the Target of the SUMO-Signaling Pathway. 
 To determine whether endogenous BAG3 is the target of the SUMO-signaling pathway, 
we performed immunoprecipitation experiments.  Equal amounts of whole cell extract isolated 
from six independent primary cultures of mouse hepatocytes were subjected to immuno-
enrichment with an antibody that recognizes BAG3 (Figure A2-A).  A non-immune IgG was 
used as a negative control.  Subsequent Western blot analysis with α-BAG3, α-SUMO1, and α-
SUMO2/3 antibodies was used to examine the potential for SUMO-modified forms of BAG3 
(Figure A2-B).  The BAG antibody detects an approximately 80 kDa un-modified form of 
BAG3 (arrow) as well as lower immuno-reactive levels of an approximately 100 kDa modified 
form of BAG3 (asterisk).  Western blotting of identical electrophoretic transfers with either 
SUMO1- or SUMO2/3-specific antibodies reveals that the endogenous BAG3 protein indeed 
exists in a SUMO-modified form in primary cultured hepatocytes at approximately 100 kDa in 
size.  It is worth noting here that the overall level and immunoreactivity of the SUMO-modified 
form of the BAG3 protein is relatively low when compared with the non-modified form, a well-









Figure A2. BAG3 Is Expressed in Primary Hepatocytes and Exists in a SUMOylation 
Form.  (A) Primary hepatocytes were isolated from C57Bl/6 mice (n=6).  The extent of 
equivalence of the total protein levels were determined by resolving an aliquot of total protein on 
an SDS-PAGE gel followed by Western blot analysis to detect expression of BAG3 and β-actin.  
(B) The BAG3 protein was immunoprecipitated from cell extracts using a polyclonal antibody 
(Abcam, ab47124) as described in Materials and Methods.  A non-immune antibody was also 
used as a negative control (IgG).  The immunoprecipitates were resolved using SDS-PAGE gel 
and Western blot analysis was performed with antibodies that recognize BAG3, SUMO1, and 
SUMO2/3, respectively (n=3).  The unmodified BAG3 (arrow) and SUMO-modified forms of 




Identification of the Molecular Machinery that Regulates SUMOylation of BAG3. 
 To further examine the molecular machinery that drives the SUMOylation of BAG3 in 
cells, we constructed a FLAG-tagged form of BAG3 for plasmid-based co-expression 
experiments using the Hepa1-6 mouse hepatoma-derived cell line (Figure A3).  Co-transfection 
of BAG3 together with the (His)6-tagged form of SUMO3 and the respective members of the 
PIAS family allows for IMAC-enrichment of SUMO-modified BAG3.  The PIAS1 and PIASxα 
SUMO E3-ligase proteins catalyzed high levels of SUMO3ylated BAG3 protein (Figure A3-A).  
A much lower but detectable level of SUMO-modified BAG3 was detected when PIASxβ, 
PIAS3, and PIASy were used. 
 We next examined which members of the SENP family of de-SUMOylation enzymes 
could catalyze the removal of SUMO3 from BAG3.  The SENP1 and SENP2 de-SUMOylating 
enzymes catalyze the most efficient removal of SUMO3, while SENP3, SENP5, SENP6, and 
SENP7 do not function as effectively by comparison (Figure A3-B).  The catalytically deficient 
form of SENP2 (mutSENP2) was used to further confirm that the immunoreactivity detected 
using the BAG3 antibody represents a SUMO-modified form of the BAG3 protein.  Indeed, the 















Figure A3. The PIAS Family of E3 SUMO Ligase and Sentrin Protease Enzymes 
Differentially Mediate the SUMO-Modification of the BAG3 Protein.  As indicated in the 
figure, Hepa1-6 cells were transfected with plasmid-based expression vectors encoding (A) 
individual PIAS family members, (B) the individual SENP de-SUMOylation enzymes, and (C) 
the catalytically deficient mutant SENP2 (R577L, K578M) together with (His)6-tagged SUMO3 
and PIAS1.  SUMOylated proteins were captured using IMAC and the extent of BAG3 





Increased SUMO-Signaling Attenuates the HSP70-BAG3 Protein-Protein Interaction. 
 Much of the biology of BAG3 is mediated through its interaction with the heat shock 
response, and specifically through its interaction with HSP70.  We next sought to examine the 
extent to which increased SUMO-signaling could alter the HSP70-BAG3 interaction in cultured 
cells.  Triplicate cultures were transfected as indicated with expression vectors encoding the 
GFP-tagged form of HSP70 (GFP-HSP70) and the FLAG-tagged form of BAG3.  
Immunoprecipitation of either BAG3 or HSP70 was accomplished using FLAG or GFP immuno-
reactive antibodies, respectively (Figure A4-A and A4-C).  The subsequent level of HSP70-
BAG3 interaction was analyzed using either FLAG or GFP antibodies in parallel Western 
blotting experiments.  A non-immune IgG was used as a negative control in parallel experiments.  
Densitometry image analysis of triplicate experiments reveals that co-expression of SUMO3 and 
PIAS1 significantly decreases the level of HSP70-BAG3 interaction (Figure A4-B and A4-D).  
These data suggest that SUMO-modification of BAG3 likely interferes with or diminishes the 
HSP70-BAG3 protein-protein interaction. 
 We next examined the potential alteration of the sub-cellular location of BAG3 and 
HSP70 in primary cultures of mouse hepatocytes using the GFP-HSP70 and RFP-BAG3.  Co-
transfection of these expression vectors allows the quantitative examination of co-localization 
using biological microscopy(12).  Healthy cultures (Hoechst staining) of GFP-HSP70 and RFP-
BAG3 co-transfected mouse hepatocytes were visualized analyzed using Slidebook 6 software, 
and Pearson’s co-efficient (r) was measured (Figure A5).  High levels of HSP70 and BAG3 
were detected visually (Figure A5-A) and were highly co-localized with a correlation coefficient 
of approximately 0.65 (Figure A5-B).  In contrast, co-expression of SUMO3 and PIAS1 reduced 




(Figure A5-D).  These data support the notion that increased SUMO-modification of BAG3 




















Figure A4. Increased SUMO Signaling Interferes with BAG3-HSP70 Protein-Protein 
Interaction.  Hepa1-6 cells were transfected with the indicated plasmid-based expression vectors 
encoding SUMO3, PIAS1, GFP-HSP70, and FLAG-BAG3.  (A and C) The relative equivalence 
of total protein input and the expression levels of transiently transfected plasmids were 
confirmed through Western blot analysis using antibodies that recognize GFP-HSP70 
(ClonTech, anti-GFP, 632569), FLAG-BAG3 (Sigma-Aldrich, anti-FLAG M2, F3165), and β-
actin (left panel).  Immunoprecipitates from total cell lysates were gathered using either the anti-
FLAG antibody to enrich for the BAG3 protein, or the anti-GFP to enrich for the HSP70 protein.  
A non-immune antibody (IgG) was used as a negative control.  These samples were subsequently 
analyzed for the presence of HSP70 and BAG3 using western blotting methods.  (B and D) 
Western blot images were quantitated by densitometric scanning of the X-ray films and analyzed 
by the ImageJ Software.  The numbers represent the relative densitometric image intensity of the 
immunoprecipitated protein divided by the intensity of he transfected protein input levels.  Data 
are subsequently normalized to β-actin expression.  The non-SUMO-PIAS1 transfected result 
was set to equal 1.  Asterisk indicates a statistical difference from non-SUMO-PIAS1 transfected 

























Figure A5.  Primary Hepatocytes with Increased SUMO Signaling Exhibit Reduced 
BAG3-HSP70 Co-localization.  Primary cultures of mouse hepatocytes were transfected with 
the indicated plasmid-based expression vectors encoding SUMO3, PIAS1, GFP-HSP70, and 
RFP-BAG3.  (A and C) Fluorescent proteins were imaged using an Olympus IX81 inverted 
epifluorescence microscope with 40x air objective.  Cells were excited at either 485nm (GFP) or 
561nm (RFP).  (B and D) The co-localization of two proteins in fluorescent images was 






 The SUMO-signaling pathway enables the stress-inducible cellular regulation of 
biomedical processes such as targeted protein turnover, the repair of damaged DNA, as well as 
the appropriate response to heat shock, oxidative stress, and chemical insult(1,2,21).  The precise 
and differential role of the four specific PIAS-family members is a current focus of intense 
investigation.  Among the other OUAS protein family members, PIAS1-mediated SUMOylation 
is particularly essential for DNA repair, and elevated PIAS1 expression has been associated with 
cancer initiation in diverse tissue types(8,20,22-25). 
 Technical improvements in utilizing an LC-MS/MS-based approach to examine the 
global dynamics of protein phosphorylation have provided a wealth of new understanding into 
the formation of cellular signal transduction networks(13,14).  While similar methods for 
examining SUMO-modification have been experimentally challenging, recent improvement have 
made it possible to detect SUMO-substrates and sites of SUMO-modification on a global 
scale(18,26-28).  However, these analyses have typically been performed using HeLa cells or in 
vitro experimental model systems.  To our knowledge, current studies and methods used to 
examine global SUMO-signaling networks in primary cell lines have yet to be described. 
 Our novel experimental strategy overcomes the problem of the extremely low 
stoichiometry of SUMOylation by increasing the PIAS1-dependent SUMOylation of specific 
protein substrates in primary hepatocytes (Figure A1-B).  Given the broad infectivity profile of 
the adenoviral system, we believe that these tools should be applied to other primary cultures 
systems.  For example, our adenoviral approach could be used together with neuronal or enteric 
primary cultures to aid in the identification of SUMO-substrate proteins in those cell types.  The 




RanGap1, select histone proteins, and a prominent transcriptional corepressor protein lends 
confidence to the validity of our novel adenoviral-mediated methods.  The isolation of the 
biochemically linked SUMO-substrate HSP70, Sequestosome 1, DnaJ, HSP105, and BAG3 
provides evidence of a likely widespread biochemical interface between PIAS1-mediated 
SUMO-signaling in the regulation of macroautophagy and the biology of HSP70.  Our novel 
methodology enables us to identify endogenous SUMO-substrate proteins purified directly from 
primary cells and has yielded important insight into the likely role of PIAS1-mediated increases 
in SUMO-signaling in regulating the formation of the HSP70-BAG3 protein-protein interaction 
module in hepatocytes. 
 The six BAG family members (BAG1-BAG6) all share the conserved BAG protein 
domain from which the family name arises.  All six BAG proteins bind to HSP70 through this 
domain, thereby acting as co-chaperones that regulate the activity of this key heat shock protein 
under divergent cellular conditions.  Collectively, the BAG family proteins have both a pro-
survival and an anti-apoptotic function.  The interaction between HSP70 and the different BAG 
proteins play both overlapping and distinctive roles in regulating cellular protein 
homeostasis(7,29,30).  Under normal physiological conditions, protein turnover via proteasomal 
degradation is driven by the HSP70-BAG1 protein-protein interaction(7,29).   Importantly, in 
response to conditions of heat shock, oxidative stress, or cell aging the expression of BAG3 is 
highly induced and the resulting HSP70-BAG3 protein-protein interaction enables the 
macroautophagy pathway(31-33).  This functional switch from BAG1-mediated proteasomal 
degradation to BAG3-induced macroautophagy has been characterized as an adaptive response 




 Recent investigations suggest the BAG3 protein likely plays a critical role in driving 
tumorigenesis, cancer metastases, cardiac and skeletal muscle myopathies, and 
neurodegenerative diseases(6,35-37).  A key observation is that elevated BAG3 expression is 
detected in many primary tumors and tumorigenic cell types including leukemia(38), thyroid 
tumors(39), neuroblastoma(40), prostate carcinomas(41,42), pancreatic tumors(43,44), ovarian 
cancer(45), glioblastoma(46,47), and aggressive forms of liver cancer(48).  The BAG3 protein is 
comprised of a series of modular protein domains that allow the formation of diverse interactions 
with other signaling proteins.  At the molecular level, the HSP70-BAG3 protein module is a 
broad-acting regulator of cancer cell signaling which functions by modulating the activity of 
transcription factors NF-κB, forkhead box M1 (FoxM1), hypoxia inducible factor 1 alpha 
(HIF1α), the translation regulator HuR, the cell cycle regulators p21, surviving, and Src 
signaling(6,36).  Because the HSP70-BAG3 protein-protein interaction plays a prominent role in 
regulating macroautophagy and apoptosis, this signaling module has recently emerged as an 
attractive and viable drug target(6,36,37,49).  Recent efforts have focused on the identification of 
small molecule inhibitors of the HSP70-BAG3 module to provide a novel means to selectively 
target the function of this cancer-associated molecular chaperone complex(6,36,37). 
 Liver cancer, or hepatocellular carcinoma (HCC), is a highly vascular and invasive 
tumor.  HCC is the third leading cause of cancer deaths worldwide and the second leading cause 
of cancer deaths in China(50).  Elevated expression of PIAS1 protein has been associated with 
non-responding chronic hepatitis C patients, who have a much greater risk of developing 
HCC(19).  The primary driver of HCC formation and progression is un-checked inflammation in 
liver cells.  Important for this study, the levels of BAG3(48), HSP70(51), and the enzymes 




HCC.  Overall, our results provide novel insights into the negative regulatory role of SUMO-
signaling in HSP70-BAG3 signaling complex, and may offer another appealing biochemical 
target in HSP70-BAG3-driven cancers. 
 Our experimental approach, which demonstrates unequivocally that the endogenous 
BAG3 protein is a SUMO-substrate, is presented in Figure A2.  This approach utilizes primary 
hepatocytes and immuno-enrichment (IP with anti-BAG3 antibodies) followed by immuno-
detection (anti-SUMO antibodies).  Merely using Western blotting for BAG3 using whole cell 
extracts consistently fails to detect the SUMO-modified form, or indeed any modified form of 
BAG3 (Figure A2-A, top panel).  Similarly, in Figure A3, we used a transfected cell line and a 
(His)6-tagged form of SUMO3 followed by IMAC to specifically enrich the SUMO-modified 
form of BAG3.  In each case, some sort of an enrichment step is required to visualize SUMO-
modified BAG3.  This is due to the extremely low stoichiometry of the SUMO-modification in 
cells.  It is therefore not currently clear if the SUMOylation event is disrupting the HSP70-BAG3 
interaction directly, or alternatively, the SUMOylation of BAG3 is a signal that delivers itself to 
the macroautophagy pathway.  Deciphering between these mechanisms represent interesting 
issues for the future.  The BAG3 protein was analyzed for the presence of the consensus 
SUMOylation sequence as defined by an online SUMOplot server 
(http://www.abgent.com/tools/SUMOplot).  This type of bioinformatic analysis identifies nine 
potential sites for SUMOylation, three of which are predicted as “high probability” 
SUMOylation sites and six others that are predicted as “low probability” SUMOylation sites 
(Figure A6).  The highest probability consensus SUMOylation sites lie within the N-terminal 
WW domain and C-terminal BAG domain, respectively.  When analyzed using the Clustal 




residue within its ABG domain at that position, while the other family members do not.  We 
therefore feel that it is likely that BAG3 is modified by SUMO potentially at several positions.  
Additional site-direct mutagenesis and in vitro mapping approaches should address the effect of 
increased BAG3 SUMOylation on interaction with HSP70 and other proteins that are known to 
bind to BAG3 through its WW and PxxP domains. 
 Taken together, our data suggest that modulation of the HSP70-BAG3-SUMO3-PIAS1 
interaction may be involved in sustaining HCC formation, and likely plays a role in driving 
tumor migration and invasion.  The methods described here should yield further insight into the 
specific function of the PIAS1 SUMO E3 ligase enzyme in driving HCC.  Future efforts should 
also be focused on determining the extent to which the SUMOylation of BAG3 alters its anti-
apoptotic activity in cancerous cells.  Additionally, future studies should examine the crosstalk 
between acetylation, phosphorylation and SUMO-signaling pathways that likely converge at the 







Figure A6. Bioinformatic Characterization of the Potential SUMOylation Sites within 
the BAG3 protein.  The human BAG3 protein was analyzed for the presence of the consensus 
SUMOylation sequence as defined by an online SUMOPlot server 
(http://www.abgent.com/tools/SUMOPlot).  This type of bioinformatic analysis identifies three 
potential “high probability” sites for SUMOylation and six others that are predicted as “low 
probability” SUMOylation sites.  To provide additional context, a diagram depicts the high 
probability sites within the context of the whole protein amino acid sequence, while a linear 
cartoon depicts the presence of the three “high probability” sites.  A Clustal analysis of the BAG 
domains within BAG1-BAG6 shows that BAG4 possesses a conserved lysine residue within a 
weak SUMOylation consensus site at that location as well, while the other BAG family members 
do not.  Of note, a “high probability” consensus SUMOylation site (K29) occurs within the WW 
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